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CHAPTER I 
 
INTRODUCTION 
 
Overview 
Since its discovery two decades ago, the Eph family of receptor tyrosine kinases has been 
implicated in an accumulating number of physiological and pathological processes in 
many cell types and various organs. Members of the Eph family of RTKs have recently 
received lots of attention, given the important roles for their bidirectional signals in 
multiple aspects of cancer development and progression. Substantial advances have been 
made in understanding the key roles of Eph in the signaling pathways that govern 
fundamental cellular processes in cancer, such as proliferation, survival, migration and 
invasion, as well as those that regulate intercellular communication during tumorigenesis. 
Common themes and controversies of Eph-ephrin interactions in cancer biology have 
been gleaned from intensive research efforts in the field, and continue to be uncovered. 
As part of them, our current results, presented herein, primarily explore the role of EphA 
receptor signaling in breast and lung cancer progression, which has not been elucidated 
systematically and comprehensively. We show pro-tumorigenic effects of EphA2 
receptor in breast cancer by crosstalk with HER2 signaling, and anti-tumorigenic effects 
of EphA3 receptor in lung cancer by inhibiting the mTOR pathway. Our increased 
understanding of the genetic, molecular, and biological characteristics of the Eph-ephrin 
system is essential for the rational development of novel anti-cancer therapies. 
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The Eph receptors and ephrin ligands 
The Eph receptors with 15 members constitute the largest family of receptor tyrosine 
kinases (RTK) that are discovered in human genome [1]. Their ligands, the ephrins, are 
divided into two subclasses: the A-subclass (ephrinA1-ephrinA6), which is tethered to the 
cell membrane by a glycosylphosphatidlinositol (GPI) anchor, and the B-subclass 
(ephrinB1-ephrinB3), which contains a transmembrane domain followed by a short 
cytoplasmic region (Figure 1.1). On the basis of extracellular sequence similarity and 
ligand-binding affinity, the Eph receptors are also grouped into the A-subclass (EphA1-
EphA10) and the B-subclass (EphB1-EphB4, EphB6). 
 
The extracellular portion of Eph receptors contains a highly conserved N-terminal ephrin-
binding domain, a cysteine-rich region (including an epidermal growth factor-like motif) 
and two fibronectin type-III repeats. The Eph receptor cytoplasmic side is composed of a 
juxtamembrane segment, a classical protein tyrosine kinase domain, a sterile-α-motif 
(SAM) domain and a PSD95/Dlg/ZO1 (PDZ)-binding motif (Figure 1.1). 
 
Recent structural and biophysical studies of Eph receptors and ephrin ligands have 
provided molecular insights into how Eph-ephrin complexes assemble to initiate 
signaling (Table 1). The first step is the monovalent interaction between an Eph receptor 
and an ephrin ligand on juxtaposed cell surfaces [2]. Upon binding, the N-terminal 
ephrin-binding domain of the Eph receptor forms an interaction surface complementary 
to a protruding hydrophobic loop from the ephrin. Both Eph receptor and ephrin ligand 
undergo structural rearrangements to induce the interaction. Interestingly, the A-class 
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Figure 1.1. Eph receptors and ephrin ligands. 
 
A schematic diagram of Eph receptors and ephrin ligands, which shows an ephrin-
expressing cell (top) interacting with an Eph-expressing cell (bottom).
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Eph/ephrin interactions involve smaller rearrangements in the interacting partners, better 
described by a "lock-and-key" mechanism, in contrast to the "induced fit" mechanism 
defining the B-class molecules [3]. 
 
In addition to the high-affinity interface, the Eph receptor and ephrin ligand contain a 
second, lower-affinity interface on the opposite side, which can mediate the dimerization 
of two Eph-ephrin heterodimers into a tetramer that comprises two Eph receptors and two 
ephrin ligands [2]. The Eph-ephrin tetramer complexes can further progressively 
aggregate into larger clusters, dependent on the densities of Eph and ephrin molecules on 
the cell surface. Several protein-protein interaction domains can potentially mediate this 
process including the juxtamembrane segment of the ephrinB cytoplasmic tail, the 
ephrin-binding domain, cysteine-rich region and cytoplasmic SAM domain of Eph 
receptors [4]. 
 
On ligand engagement, each Eph receptor of the Eph-ephrin complexes 
autophosphorylates tyrosine residues that are located in the partner Eph receptors. The 
activation of the protein kinase domain of Eph receptors is regulated via autorepression 
by their juxtamembrane region, which contains two autophosphorylation sites [5, 6]. 
When these tyrosine residues are phosphorylated, the juxtamembrane domain is 
uncoupled from the interaction with the kinase domain, which allows the kinase domain 
to convert into its active state. This conformational change also releases the 
phosphorylated juxtamembrane domain to bind to phosphotyrosine-binding proteins [1].
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Table 1. Structure analysis of Eph receptors and ephrin ligands 
 
 
Eph/ephrins  Species Domain/Complex              Reference 
 
EphB2   Murine Ligand binding domain   [7] 
EphB2   Murine Juxtamembrane and kinase domains  [5] 
EphB2   Murine Kinase domain    [8] 
EphB2   Human Sterile alpha motif (SAM)   [9] 
ephrinB1  Murine Ectodomain     [10] 
ephrinB2  Human Ectodomain     [11] 
EphA2   Human Kinase domain    [12] 
EphA4   Murine Sterile alpha motif (SAM)   [13] 
EphA4   Murine Juxtamembrane and kinase domains  [8] 
     with Y604/610F, Y750A 
EphA3   Human Kinase domain with and without  [6] 
     juxtamembrane region 
EphA1   Human Transmembrane domain   [14] 
ephrinA5  Human Ectodomain     [15] 
 
EphB2-ephrinB2 Murine Ligand binding domain of EphB2 in  [2] 
     complex with ectodomain of ephrinB2 
EphB4-ephrinB2 Human Ligand binding domain of EphB4 in  [16] 
     complex with ectodomain of ephrinB2 
EphB2-ephrinA5 Murine Ligand binding domain of EphB2 in   [17] 
   Human complex with ectodomain of ephrinA5 
EphA2-ephrinA1 Human Ligand binding domain of EphA2 in  [3]  
     complex with ectodomain of ephrinA1 
EphA4-ephrinA2 Human Ligand binding domain of EphA4 in  [18]  
     complex with ectodomain of ephrinA2 
EphA4-ephrinB2 Human Ligand binding domain of EphA4 in  [19]  
     complex with ectodomain of ephrinB2 
EphA2-SHIP2  Human Heterotypic SAM-SAM domain association [20] 
 
EphB4-peptide Human Ligand bind domain of EphB4 in  [21] 
     complex with TNYL-RAW peptide 
EphB2-peptide Human Ligand binding domain of EphB2 in  [22] 
     complex with SNEW peptide 
EphA4-  Human Ligand binding domain of EphA4 in  [23] 
small inhibitors   complex with small molecule antagonists 
ephrinB2-  Human Ectodomain of ephrinB2  in complex with  [24] 
NiV-G or HeV-G   Nipah or Hendra viral G proteins 
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Signaling mechanisms of Eph-ephrin system 
Eph receptors and ephrin ligands activate a variety of signal transduction pathways via 
binding many cytoplasmic proteins. Eph-ephrin system participates in a wide spectrum of 
developmental processes and diseases, and the complexity of its signaling networks 
underlies the diverse functions of Eph-ephrin in human. Compared with other RTK 
families, Eph-ephrin signaling displays several distinctive and intriguing features, which 
are just now beginning to be uncovered. 
 
Forward versus reverse signaling 
A unique characteristic of Eph-ephrin complexes is their ability to transduce bidirectional 
signals that affect both the Eph-expressing and ephrin-expressing cells [25]. Eph receptor 
“forward” signaling depends on the tyrosine kinase domain, which mediates 
autophosphorylation as well as phosphorylation of other proteins, and on the association 
of the receptor with various adaptor molecules. A growing number of signaling pathways 
has been identified downstream of Eph receptors, including Rho family of GTPases, PI3K-
Akt, Abl-Crk, and Ras-Raf-MAPK pathways [26, 27], which have been shown to affect 
numerous cell behaviors (Figure 1.2).  
 
EphrinB “reverse” signaling is dependent on tyrosine phosphorylation of the cytoplasmic 
region mediated by Src family kinases or other receptor tyrosine kinases, and on 
associated effector proteins [28]. EphrinA ligands can also mediate their own signaling 
cascades [29, 30]. However, the mechanisms of reverse signaling for ephrinA are less 
understood since they are GPI-linked proteins without cytoplasmic domain. Presumably, 
EphrinA-mediated reverse signaling requires the association of a transmembrane 
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Figure 1.2. Simplified diagram of Eph signaling. 
 
Eph receptors interact with ephrin ligands on adjacent cell membrane. Activated Eph 
transduce both tumor promoting and inhibiting pathways depending on ligand stimulation, 
signaling cross-talk, or other contextual factors. A growing number of signaling pathways 
has been identified to be downstream of Eph receptors, including Rho family of GTPases, 
PI3K-Akt, Abl-Crk, Ras-Raf-MAPK pathways and many others. LBD, ligand binding 
domain; FN3, fibronectin-type III repeats; PTK, protein tyrosine kinase domain; SAM, sterile 
α-motif. 
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signaling partner. The p75 neurotrophin receptor was recently shown to serve this role 
during retinotopic mapping and p75 may be a candidate co-receptor for ephrinAs [31]. 
 
Ligand-dependent versus ligand-independent signaling 
The complexity of Eph-ephrin signaling also lies in that both ligand-dependent and 
ligand-independent signaling pathways exist. The most studied activity of Eph receptors 
and ephrin ligands is in the establishment of topographically organized neuronal 
connections in many regions of the developing nervous system by Eph-mediated 
repulsive responses at excessive ephrin concentration [32]. This was one of the first clues 
that ephrin-dependent Eph signaling may be detrimental to cell functions. Indeed, ligand 
stimulation of Eph receptors inhibits the Abl-Crk pathway [33], Ras-Raf-MAPK cascade 
[34], PI3K-Akt activity [35], integrin signaling [36] and Rac GTPase activation [37], 
which are correlated with inhibition of cell proliferation and migration. Consistently, the 
Eph receptors appear to be ubiquitously expressed but poorly activated in many human 
cancers [25, 38]. Forcing Eph activation with exogenous ephrin ligands inhibits tumor 
cell proliferation, survival, migration and invasion in cell culture and several mouse 
models [33, 39, 40]. 
 
There is now mounting evidence that this classical RTK activation does not account for 
all Eph/ephrin signalling and indeed that ligand-independent signalling processes can 
occur [27]. Ephrin independent function has been demonstrated in C. elegans [41], 
suggesting that this mechanism is evolutionally conserved. A hypothesis for ligand-
independent Eph function is that high levels of Eph receptors may function in concert 
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with other cell-surface communication systems (Table 2). For example, recent studies 
have proposed that the EGF receptor can cooperate with EphA2 as an effector to promote 
cell motility independent of ephrin stimulation [42]. Other studies have reported a direct 
interaction and synergistic responses of fibroblast growth factor receptor (FGFR) and 
EphA4 [43, 44]. Using genetic mouse models and in vitro biochemical analyses, we 
discovered the crosstalk between EphA2 and human epidermal growth factor receptor 2 
(HER2), which is required for breast tumor initiation and metastatic progression. These 
data are presented in Chapter III. 
 
An emerging theme is that ligand-dependent and ligand-independent Eph signaling 
pathways often include common intracellular effectors with opposite effects. This 
partially explains why differences in cellular and oncogenic context can dramatically 
alter the outcome of Eph receptors in tumorigenesis. Miao et al. demonstrated that EphA2 
receptor associates in a ligand-independent manner with focal adhesion kinase (FAK). 
Activation of EphA2 with ephrinA1 results in recruitment of the protein tyrosine 
phosphatase SHP-2, which dephosphorylates and inactivates FAK [36]. Another example 
is the recently discovered reciprocal regulatory loop between EphA2 and Akt, a 
serine/threonine kinase frequently activated in cancer cells [35]. While activation of 
EphA2 with its ligand ephrinA1 suppresses Akt activation and inhibits chemotactic 
migration of glioma and prostate cancer cells, EphA2 overexpression promotes migration 
in a ligand-independent manner. The latter effects require phosphorylation of EphA2 on 
serine 897 by Akt. Thus, EphA2 is both an upstream negative regulator and a 
downstream effector of Akt, dependent on the presence or absence of ephrin ligands.
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Table 2. Crosstalk between Eph and other receptors 
 
 
Eph receptor  Other receptors Signaling outcome   Reference 
 
EphA2   EGF receptor  modulate cell motility  [42] 
EphA4   FGF receptors  MAPK activation  [43] 
EphA   CXCR4 receptor Cdc42 inhibition  [45] 
EphB2, EphB4 CXCR4 receptor Akt activation   [46] 
EphA2   integrins  FAK inhibition  [36] 
EphA4   integrins  integrin activation  [47] 
EphA8   integrins  PI3K activation  [48] 
EphA   integrins  Rac1 inhibition  [49] 
EphA2   claudin-4  claudin-4 phosphorylation [50] 
EphA2   E-cadherin  EphA2 activation  [51] 
EphB   E-cadherin  E-cadherin redistribution [52] 
EphB2   Syndecan-2  Syndecan-2 phosphorylation [53] 
EphB2   L1   L1 phosphorylation  [54] 
EphB2, EphB3 Ryk receptor  unknown   [55] 
EphB   NMDA receptor NMDAR activation  [56] 
EphB6   T cell receptor  T cell activation  [57] 
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Enzymatic cleavage versus transendocytosis 
The Eph receptors and ephrin ligands were initially described as modulators of neuronal 
repulsion and only later were discovered that they can also promote cell adhesion in 
certain circumstances [58-60]. The cell-cell repulsive response following Eph-ephrin 
contact is particularly important for axon guidance and sorting of Eph-expressing cells 
from ephrin-expressing cells during development. Cell separation is not a trivial issue as 
the Eph-ephrin interaction has a very high affinity and these molecules are abundant at 
the cell surface, making dissociation of the Eph-ephrin complexes difficult [1, 61]. Two 
general mechanisms have been proposed to allow the separation of two cell surfaces that 
adhere to each other through Eph-ephrin contacts.  
 
One strategy involves regulated proteolytic cleavage of the ephrin by transmembrane 
proteases. The first evidence for proteolytic ephrin regulation identified ephrinB3 as a 
substrate for the rhomboid transmembrane protease RHBDL2 [62]. Flanagan and 
colleagues documented that interaction of ephrinA2 with EphA3 activates 
metalloprotease ADAM10 (a disintegrin and metalloprotease 10), which cleaves the 
extracellular domain of the ephrin [63]. It remains to be determined whether Eph receptor 
ectodomains might also be cleaved. Interestingly, similar regulatory mechanism also 
exists in glioblastoma multiforme (GBM) and breast adenocarcinoma cells, which could 
cleave and release soluble monomeric ephrinA1 detected in conditioned media [64]. 
 
The other strategy utilizes rapid trans-endocytosis which removes the adhesive Eph-
ephrin complexes from the cell surfaces, allowing the cells to disengage. Two parallel 
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studies showed that the internalized vesicles contain intact EphB4-ephrinB2 complexes 
and both of their surrounding plasma membranes [65, 66]. Importantly, it was found that 
EphB4-ephrinB2 endocytosis requires cytoskeletal rearrangement and Rac1 activity. We 
identified a lipid phosphatase SHIP2 (Src homology 2 domain-containing 
phosphoinositide 5-phosphatase 2), which binds with EphA2 receptor and regulates 
EphA2 endocytosis via inhibiting phosphatidylinositol 3-kinase-dependent Rac1 
activation. These data are presented in Chapter II. 
 
Role of Eph-ephrin in tumor promotion 
The Eph receptors and ephrin ligands have intriguing expression patterns in cancer cells 
and tumor blood vessels, which suggest important roles for Eph signaling in multiple 
aspects of cancer development and progression [67, 68]. The activities of the Eph system 
in cancer are complex in their paradoxical effects. There is good evidence that Eph 
receptors and ephrin ligands can both promote and inhibit tumorigenicity. However, 
multiple Ephs and/or ephrins are present, and often dysregulated, in essentially all types 
of cancer cells and tumor microenvironment, suggestive of their role in tumor promotion. 
 
Eph receptors in tumor progression 
The high abundance of Eph receptors in many human cancers, including various 
carcinomas, melanoma, sarcoma, leukemia, renal and brain tumors, has been very well 
documented [69-71]. In some cases, there is a clear link between this increased 
expression and tumor progression. A number of studies have shown a correlation 
between the degree of tumor malignancy and the levels of Eph receptors. For example, 
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esophageal squamous cell carcinomas that exhibit the highest degree of lymph node 
metastasis have the highest levels of EphA2 expression [72]. In human brain tumors, 
invading glioblastomas have higher EphB2 expression than do low-grade astrocytomas 
[73]. 
 
In addition to dysregulation of Eph expression, many studies have demonstrated a causal 
role of Eph receptors in cancer, which is perhaps best exemplified by EphA2 receptor in 
breast cancer. Experimentally induced overexpression of EphA2 resulted in malignant 
transformation of nontransformed MCF10A breast epithelial cells and enhanced 
malignancy of pancreatic carcinoma cells [74, 75]. Conversely, siRNA-mediated 
inhibition of EphA2 expression impaired malignant progression of pancreatic, ovarian, 
and mesothelioma tumor cell lines, and overexpression of dominant-negative EphA2 
constructs suppressed growth and metastasis of 4T1 metastatic mouse mammary 
adenocarcinoma cells in vivo [75-78]. Similarly, over-expression of EphB4 in the 
mammary epithelium accelerates tumor onset and lung metastasis in MMTV-Neu 
animals [79], while EphB4 knockdown inhibited breast cancer survival, migration, and 
invasion in vitro and tumor growth in a xenograft model in vivo [80]. 
 
The mechanisms by which Eph receptors exhibit oncogenic effects are not entirely clear. 
Highly expressed Eph receptors could be hijacked by other oncogenes, such as EGFR and 
FGFR1 [42, 44], to maximize downstream oncogenic signaling pathways. In certain 
cellular contexts, Eph receptors also activate particular effectors to acquire specific 
oncogenic ability. For example, RRas phosphorylation downstream of EphB2 can 
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enhance glioma cell invasiveness but reduce cell proliferation [81]. Additionally, 
activation of RhoA downstream of EphA2 and EphB4 promotes ameboid-type migration 
of tumor cells and destabilizes epithelial adherens junctions in various cancer cell lines, 
even though RhoA activity inhibits mesenchymal-type cell migration [78, 82, 83]. 
Consistent with these controversial observations, a recent study revealed that EphB2 both 
promotes proliferation and inhibits migration in intestinal cells through distinct pathways 
[84]. Therefore, Eph signaling in tumor progression is extremely dynamic and capable of 
contrasting effects. 
 
Eph receptors in tumor angiogenesis 
Besides being expressed in cancer cells, Eph receptors and ephrin ligands are also present 
in the tumor vasculature [85]. In contrast to the complex effects of Eph signaling in tumor 
cells, Ephs and ephrins have been well characterized to play a vital role to promote 
angiogenesis in tumor vascular endothelial cells [27]. Because tumor associated blood 
vessels are critical for tumor growth and metastatic dissemination, this represents an 
important aspect of the oncogenic effects of Eph-ephrin bidirectional signaling. The main 
roles of Eph-ephrin in tumor angiogenesis have so far been attributed to EphB4-ephrinB2 
reverse signaling and ephrinA1-EphA2 forward signaling based on a series of in vitro and 
in vivo experiments with mouse tumor models. 
 
EphB4 and ephrinB2 play a prominent role in both developmental and tumorigenic 
angiogenesis. During development, they are characteristically expressed in the 
endothelial cells of veins and arteries, respectively, and enable arterial-venous vessel 
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segregation and vascular remodeling [86, 87]. The results of tumor angiogenesis studies 
are consistent with the importance of ephrinB2 reverse signaling, while little is known 
about the role of EphB4 forward signaling. Reverse signaling by ephrinB2 in tumor 
endothelial cells, pericytes and smooth muscle cells is triggered by EphB receptors 
expressed in vascular and/or tumor cells, and has been shown to be crucial for blood 
vessel assembly, maturation and maintenance both in cell culture and in mouse models 
[88-90]. EphrinB2 signaling also promotes the interaction between endothelial cells and 
pericytes or vascular smooth muscle cells [91], suggesting that upregulation of ephrinB2 
may stabilize the vessels of tumors recurring after anti-VEGF therapy. 
 
Extensive evidence, including analysis of tumor growth in EphA2 knockout mice or mice 
systematically treated with inhibitory EphA-Fc fusion proteins, shows that EphA2 
forward signaling promotes tumor angiogenesis [92-95]. In contrast, EphA2 does not 
seem to play a critical role in developmental angiogenesis or in the adult quiescent 
vasculature. Interaction with ephrinA1 in tumor endothelial cells as well as tumor cells is 
responsible for activating endothelial EphA2. Activated EphA2 regulates endothelial cell 
migration and assembly through PI3K-dependent Rac1 GTPase activity [94]. 
Furthermore, a yeast two-hybrid screen identified Vav guanine nucleotide exchange 
factors to be recruited to active EphA2 receptors and subsequently elevate Rac1-GTP 
levels [96]. The upregulation of EphA2 and ephrinA1 observed in late-stage pancreatic 
tumors of mice treated with VEGF inhibitors suggests that EphA2-mediated angiogenesis 
may also contribute to the development of resistance to anti-VEGF therapies [97]. 
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Eph receptors in resistance to anti-cancer therapies 
One arising challenge in cancer therapy is to overcome intrinsic resistance, which leads to 
tumor progression regardless of treatments, and acquired resistance, which is induced by 
therapeutic reagents and results in cancer recurrence after initial response. Because Eph 
receptors are frequently overexpressed in various cancers and exhibit intimate interplay 
with other oncogenic pathways, they are also likely to contribute to regulating drug 
sensitivity to targeted therapeutics. However, characterization of the Eph system in 
resistance to anti-cancer therapies is still at an early stage. Kinch and colleagues reported 
that EphA2 overexpression decreases estrogen dependence as defined by both in vitro 
and in vivo criteria, and impairs the ability of tamoxifen to inhibit breast cancer cell 
growth and tumorigenesis [98]. Therapeutic intervention using EphA2 antibodies can 
resensitize EphA2-overexpressing breast tumor cells to tamoxifen treatment. In another 
study, EphB4 was related to imatinib resistance in Philadelphia chromosome-positive 
acute lymphoblastic leukemia cells [99]. We provide evidence that elevated level of 
EphA2 mediates resistance to trastuzumab therapy and propose strategies to target 
EphA2 as a tactic to reverse trastuzumab resistance. These data are presented in Chapter 
IV. 
 
Eph receptors in cancer prognosis 
Eph expression promises to be a powerful predictor of prognosis. EphA2, for example, 
has been linked to increased malignancy and poor clinical prognosis in breast cancer 
[100], non-small cell lung cancer [101], esophageal squamous cell carcinoma [72], 
cervical squamous cell carcinoma [102], renal cell carcinoma [103], glioblastoma 
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multiforme [104], and endometrial cancer [105]. Overexpression of EphA4 in gastric 
cancer is associated with significantly short overall survival periods [106]. Increased 
expression of EphA7 associates with adverse outcome in primary and recurrent 
glioblastoma multiforme patients [107]. EphB4 overexpression predicts poor overall 
survival in patients with ovarian cancer and head and neck squamous cell carcinoma 
[108-110]. Conversely, colorectal cancer patients with EphB2 expression exhibit 
significantly prolonged overall survival [111]. Therefore, there is a need for a 
comprehensive assessment of Eph expression in large cohorts of human tumors in 
correlation with stages of malignancy and clinical outcome. Carefully validated 
antibodies and quantitative proteomics approaches are necessary to ensure the reliability 
of such studies. 
 
Role of Eph-ephrin in tumor suppression 
Eph-ephrin system does not necessarily aid the tumorigenic process. Tumor suppressor 
activities for Eph signaling have been reported in colorectal, breast, prostate and skin 
cancers both in vitro and in vivo [34, 112, 113]. Accumulating evidence implicates that 
the complexities of the Eph system and dichotomous Eph activities in different tumor 
components partially explain the many confusing and contradictory phenotype. To 
dissect the oncogenic or suppressive role of Eph signaling in tumor pathogenesis and 
advance our understanding of Eph cancer biology, it will be imperative to examine the 
effects of Eph or ephrin deletion, overexpression, and cancer relevant mutations in 
genetically engineered mouse models that mimic the progression of human cancers. Such 
in vivo models are key for studying the Eph system, given its penchant for regulating 
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communication between different cell types, which is difficult to accurately recapitulate 
in vitro. We combine gene knockout mice and transgenic mouse tumor models and 
demonstrate that the role of EphA2 in tumor progression is dependent upon the 
oncogene/tumor suppressor context within which it functions. These data are presented in 
Chapter III. 
 
Inhibition of tumorigenicity by Eph receptors 
EphB receptors have been extensively characterized in suppressing colorectal cancer. In 
normal intestine, EphB receptors and ephrinB ligands are expressed in complementary 
gradients along the crypts under the control of the Wnt/β-catenin/Tcf pathway, which 
upregulates EphB and downregulates ephrinB expression [114]. EphB activities, which 
determine progenitor cell positioning and promote cell proliferation, play an important 
role in intestinal homeostasis [115]. In the transition from normal cells to intestinal 
adenoma, EphB receptors are usually upregulated and ephrinB downregulated by the 
constitutive activation of the β-catenin/Tcf pathway [114]. The EphB proliferative effects 
may have some tumor-promoting ability, which is responsible for about half of the 
proliferation in adenomas [115], but adenoma growth is restricted by repulsion from 
ephrinB in the surrounding differentiated epithelium [52, 112]. Therefore, EphB 
receptors have to be lost in tumor cells, enabling invasiveness as well as tumor expansion. 
This EphB downregulation represents a critical step in the progression to malignant 
stages and correlates with a poor prognosis. 
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Another example is EphA2 in susceptibility to chemically induced keratinocyte 
transformation. Despite the observed upregulation of EphA2 in mouse as well as human 
keratinocyte-derived skin carcinomas, the tumors in EphA2 knockout mice grow faster 
and are more invasive [113]. Similar to the EphB-ephrinB interplay in colorectal cancer, 
ephrinA1 expression in the surrounding skin appears to restrict expansion of the EphA2-
positive tumor cells. Deletion of EphA2 may eliminate EphA2-ephrinA1 interactions, 
which leads to increased tumor susceptibility. 
 
Eph signaling in tumor suppression 
A prominent pathway that may explain these tumor suppressor effects of Eph receptors is 
the Ras-Raf-MAPK signaling cascade. One of the first studies showing the relationship 
between Eph signaling and MAPK activity was performed in several different cell types 
[34]. The study showed ephrinA1 activated EphA signaling inhibits MAPK activation in 
prostate epithelial cells, mouse embryonic fibroblasts, and bovine endothelial cells. This 
effect is likely Ras-dependent, as Ras activity is also decreased and overexpression of 
Ras could compensate for ephrinA-EphA2 induced MAPK inhibition. Recently, a 
conditional feedback loop has been identified, whereby Ras-Raf-MAPK activation 
promotes EphA2 expression, which in turn negatively regulates MAPK activities upon 
ligand stimulation in human breast cancer cell lines [116].  
 
The PI3K-Akt is another signaling cascade involved in the tumor suppression by Eph 
receptors. Phosphorylation by Akt of a single serine site (S897) in EphA2 appears to 
promote cancer cell migration and invasion, an effect independent of catalytic activity of 
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EphA2. Ephrin-A1 stimulation of EphA2 negates Akt activation by growth factors and 
causes EphA2 dephosphorylation on S897. These results identified a reciprocal 
regulatory loop between EphA2 and Akt, with unligated EphA2 functioning as a 
downstream substrate and effector of Akt kinase, but with the ligand-activated EphA2 
functioning as an upstream negative regulator to turn off Akt and cause 
dephosphorylation of EphA2 at the Akt substrate site [35]. 
 
Elegant work by Pasquale and colleagues found that ephrinB2 stimulated EphB4 
signaling results in tyrosine phosphorylation of Crk on Tyr221, which induces a 
conformational change that blocks the ability of Crk to function as an adaptor protein 
[33]. Tyr 221 of Crk is a major target for the Abl family of non-receptor tyrosine kinases, 
and the treatment of breast cancer cells with the Abl inhibitor imatinib or Abl small 
interfering RNA block Crk phosphorylation in response to ephrinB2 stimulation, without 
affecting EphB4 tyrosine phosphorylation. Thus, the Abl–Crk pathway mediates 
inhibition of breast cancer cell proliferation, survival and motility downstream of EphB4. 
 
Silencing of Eph signaling in cancer cells 
In general, ephrin induced Eph receptor forward signaling appears to transduce an 
inhibitory signal that keep cells quiescent and non-invasive. Therefore, cancer cells have 
developed a variety of mechanisms to minimize the tumor suppressor effects of Eph 
signaling. A common phenomenon is the differential expression Eph receptors and ephrin 
ligands in tumors, resulting in low bidirectional signaling [33, 116]. Eph overexpression 
in cancer often is due to oncogenic signaling pathways, hypoxia, or inflammatory 
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cytokines. The Wnt/β-catenin/Tcf pathway promotes EphB expression in colorectal 
cancer cells and the Ras-Raf-MAPK pathway promotes EphA2 expression in breast 
cancer cells. Surprisingly, activation of these two pathways also leads to ephrin 
downregulation and, as a consequence, low Eph receptor activation [114, 116]. 
Chromosomal alterations also regulate Eph and ephrin expression in tumor cells, and a 
number of Eph receptors and ephrin ligands are located in chromosomal regions 
frequently amplified or deleted in human cancers. By analyzing SNP array-based genetic 
maps with gene expression signatures, we found that EphA3 resided in a frequently 
deleted focal locus on chromosome 3p11.2. Interestingly, genes encoding EphA3 ligands, 
ephrinA1, A3, and A5, on chromosome 1q21-q22 are frequently amplified in these 
tumors. These data are presented in Chapter V. 
 
Other mechanisms to keep Eph receptors under-phosphorylated in spite of overexpression 
include disruption of cell-cell contacts in tumor cells and increased activity of 
phosphotyrosine phosphatase. Indeed, loss of E-cadherin or VE-cadherin impairs 
endogenous EphA2-ephrinA1 interactions, which silence their signaling function, in 
malignant breast cancer and melanoma cells, respectively [51, 117]. Phosphotyrosine 
phosphatases could also negatively regulate Eph receptor forward signaling in cancer 
cells [118]. For example, the low molecular weight phosphotyrosine protein phosphatase 
(LMW-PTP) has been implicated in cell transformation through dephosphorylating 
EphA2, thus counteracting ephrin stimulated activation [119]. The protein tyrosine 
phosphatase receptor type O (PTPRO) also dephosphorylates Eph receptors in neurons, 
although it is unknown whether this plays a role in cancer [120]. 
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Somatic mutations in Eph receptors have recently been identified in multiple sequencing 
efforts of tumor specimens to identify cancer genes [121-126], whereas cancer-related 
ephrin mutations have not been reported so far perhaps because most screens have 
focused on the human kinome. These Eph mutations may also contribute to disrupting 
forward signaling by impairing ephrin binding or kinase activity. For instance, the EphA3 
E53K mutation found in a melanoma cell line abrogates ephrin binding [127], and the 
EphB2 G787R mutation found in colorectal cancer impairs kinase activity [128]. We 
systematically investigated the EphA3 mutations identified in non-small cell lung cancer 
and discovered that they are loss-of-function mutations. These data are presented in 
Chapter V. 
 
Eph-based therapeutics in cancer 
Encouraged by recent significant successes of various molecular targeted therapies in 
cancer treatment, as well as a more comprehensive understanding of Eph-ephrin in tumor 
progression as discussed above, Eph receptors and ephrin ligands represent promising 
new therapeutic targets in cancer. A wide range of strategies have been proposed and are 
under evaluation to minimize their tumor-promoting effects and maximize their tumor-
suppressing roles (Table 3). These strategies include directly interfering with Eph-ephrin 
functions, using Eph receptors as delivery vehicles for drugs, and Eph-based 
immunotherapy. 
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Interfering with Eph-ephrin function 
Downregulation of EphA2 or EphB4 with siRNAs or antisense oligonucleotides has been 
shown to inhibit tumor growth in breast cancer, colon cancer, pancreatic cancer and 
ovarian cancer [75, 76, 129, 130]. Ephrin ligands and agonistic Eph antibodies have also 
been successful to inhibit tumor progression, probably by stimulating both forward 
signaling and receptor degradation in the cancer cells [131-134]. Additionally, antibody-
dependent cell-mediated cytotoxicity may also contribute to the anti-cancer effects in 
vivo [135]. Efforts to identify small molecules that target the Eph kinase domain have 
begun to yield some high affinity inhibitors [136-138]. Furthermore, a number of 
inhibitors designed to target other kinases also inhibit Eph receptors. Dasatinib, an Abl 
and Src inhibitor for the treatment of chronic myelogenous leukemia, potently inhibits 
EphA2 [139], and XL647, an EGF and VEGF receptor inhibitor being evaluated in lung 
cancer, also targets EphB4. 
 
Another strategy that shows promise for anti-angiogenic therapy is to inhibit Eph-ephrin 
interactions. The dimeric EphA2 ectodomain fused to Fc, which inhibits Eph forward 
signaling but promotes reverse signaling, and the monomeric EphB4 ectodomain, which 
inhibits both forward and reverse signaling, can both reduce tumor growth by inhibiting 
tumor angiogenesis [95, 140]. Pasquale’s laboratory has developed antagonistic peptides 
by phage display which selectively inhibit specific Eph-ephrin binding [142, 147, 148]. 
imilar strategy is also suitable for chemical compounds to specifically target Eph 
receptors, and two isomeric small molecules that preferentially inhibit ephrin binding to 
EphA2 and EphA4 have been identified [149]. Structural characterization of these 
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Table 3. Eph-ephrin based therapeutics 
 
 
Targets  Molecules   Activity   Reference 
 
EphA2  activating antibodies  Eph activation/degradation [131] 
EphA3  activating antibodies  Eph activation/degradation [141] 
EphA   ephrinA1-Fc   Eph activation/degradation [40] 
EphB4  ephrinB2-Fc   Eph activation/degradation [33] 
EphA2  peptides   Eph activation/degradation [142] 
EphA2  siRNA or oligonucleotides Eph downregulation  [75, 76] 
EphB4  siRNA or oligonucleotides Eph downregulation  [143, 144] 
 
ephrinA  EphA2-Fc, EphA3-Fc  Eph competitor  [95, 145] 
ephrinB  sEphB4   Eph competitor  [140, 146] 
EphA4  peptides   ephrin competitor  [147] 
EphB2  peptides   ephrin competitor  [148] 
EphB4  peptides   ephrin competitor  [148] 
EphA2  small inhibitors  ephrin competitor  [149] 
EphA4  small inhibitors  ephrin competitor  [149] 
EphB2  antibody   ephrin competitor  [132] 
 
EphB4  kinase inhibitors  ATP competitors  [150, 151] 
Eph  kinase inhibitors  ATP competitors  [137, 138] 
 
EphA2  antibody conjugate  internalization of   [152, 153] 
microtubule inhibitors 
EphA2  bispecific antibody  CD3-mediated   [154] 
T cell recruitment 
EphA  ephrinA1-exotoxin A  internalization of  [155] 
      exotoxin A 
EphA  ephrinA1-nanoshells  photothermal ablation  [156] 
of tumor cells 
EphB2  antibody conjugate  internalization of   [132] 
microtubule inhibitors 
 
EphA2  Cu-DOTA-1C1 antibody radioimmunoPET  [157] 
EphA2  peptide-nanoparticles  tumor cell extraction  [158] 
EphA3  111Indium antibody  tumor detection  [141] 
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peptides and small molecules in complex with Eph receptors may assist to optimize the 
specificity and affinity [21-23]. 
 
Targeted delivery of toxins and imaging agents 
Eph functions are redundant in normal tissues, and Eph receptors are often upregulated in 
many tumors, making them attractive targets for the delivery of toxins or imaging agents 
into cancer cells. Several chemotherapeutic toxins conjugated with Eph antibodies or 
ephrin ligands, which cause receptor-mediated drug internalization, appear promising in 
preclinical studies. EphA2 antibodies coupled to the microtubule inhibitor exhibited 
significant antitumor activity in several cancers [152, 153]. Another potential application 
is the targeted delivery of gold-coated nanoshells conjugated to ephrin for photothermal 
destruction of Eph-positive cancer cells [156]. Eph receptors can also be used to deliver 
imaging agents for diagnostic purposes. Promising results have been obtained in animal 
models by using an EphA2 antibody coupled to Cu-DOTA for radioimmunoPET imaging 
and an EphA3 antibody coupled to Indium for gamma camera imaging [141, 157]. 
 
Eph-based immunotherapy 
In addition to the immune cell-mediated cytotoxicity elicited by Eph-targeted antibodies, 
a bispcific single-chain antibody that simultaneously binds both EphA2 on tumor cells 
and the T cell receptor-CD3 complex on T cells causes T cell-mediated destruction of 
EphA2-positive tumor cells in vitro and decreases tumor growth in vivo [154]. 
Furthermore, Eph receptor isoform has been identified as sources of tumor-associated 
peptide antigens that are recognized by effector T cells [159-162]. Eph receptors that are 
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preferentially expressed in tumors compared with normal tissues are also attractive 
targets for cancer vaccines, and vaccination with EphA2 derived epitopes shows promise 
as a strategy to elicit tumor rejection [163-165]. 
 
Summary 
Eph receptors and ephrin ligands form an important cell communication system in cancer 
pathogenesis. Eph-ephrin has a clear role in cancer cell autonomous regulation of 
tumorigenesis, but it also functions in the tumor microenvironment that contributes to the 
progression of the disease. The unique mechanisms of Eph signaling enable it to either 
potentiate the activities of oncogenic signaling networks or repress them, making Eph 
receptors associated with both tumor promotion and suppression. Due to this puzzling 
dichotomy, designing the therapeutic targeting strategy that involves modification of this 
pathway remains a challenge and the balance of pro- versus anti-tumorigenic effects 
should be considered. As an example, EphA2 agonists would be expected to activate 
tumor suppressor signaling pathways and induce receptor degradation in cancer cells, 
which leads to tumor inhibition. Conversely, tumor angiogenesis may be increased by 
EphA2 stimulation in endothelia cells and this could result in subsequent tumor 
progression. Therefore, Eph-targeting agents likely act through a combination of multiple 
effects on cancer cells and tumor microenvironment, and in order to develop optimal 
strategies to interfere with Eph function, we must better understand the differential roles 
of this pathway in the different cellular compartments of specific tumors. 
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Increasing evidence suggests that Eph receptors function as an oncogene. They are 
upregulated in a wide variety of cancers and their expression has been linked to increased 
malignancy and poor clinical outcome. In addition, it is well-documented that Eph 
receptors play a causal role in neoplasia and tumor angiogenesis. Other evidence, 
however, suggests that Eph may function as a tumor suppressor. Ligand-dependent Eph 
signaling is detrimental to several oncogenic pathways including Ras-Raf-MAPK, PI3K-
Akt, and Abl-Crk. One possible reason for this paradox may reside in that the 
experimental systems in vitro may not accurately recapitulate human cancers in vivo. We 
have now integrated genetically engineered mouse models as well as biochemical 
analyses in cell culture, and provided one possible explanation to these controversial 
observations. More importantly, we have used these mouse models for preclinical 
evaluation of new Eph-based therapies. 
 
In addition to dysregulation in Eph expression, Eph gene mutations likely also contribute 
to cancer pathogenesis. Indeed, somatic mutations in Eph receptors have recently been 
identified in multiple sequencing projects of human cancers. Elucidating the effects of the 
mutations will provide important insights into the functional roles of the Eph system in 
cancer. Nevertheless, the significance of these mutations is not yet known. Here, we 
comprehensively analyzed EphA3 mutations discovered in lung adenocarcinoma. These 
information, together with the functional analysis of EphA3 both in vitro and in vivo, has 
expanded our understanding of Eph receptors in cancer biology and paved the way 
for future therapeutic strategies targeting Eph receptors. 
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Eph receptors promise to be a powerful predictor of prognosis and perhaps drug 
sensitivity, which have only started to be appreciated. We have undertaken the approach 
of analyzing clinical cohorts of breast cancer and lung adenocarcinomas, and found that 
EphA2 and EphA3 are associated with patient survival in breast and lung cancers, 
respectively. Additionally, elevated EphA2 expression in breast tumor cells appears to 
mediate resistance to trastuzumab, an approved targeted therapy for women with HER2 
positive breast cancer. Although these findings remain to be clinically validated, they 
undoubtedly hold the promise that Eph receptors can potentially be utilized to predict 
whether and how we should treat cancer patients. 
 
The thesis projects 
Extensive evidence implicates the Eph receptor family of tyrosine kinases in cancer 
development, but it remains incompletely understood how Eph receptors affect cancer 
progression. Both tumor-promoting and tumor-suppressing effects have been described, 
sometimes for the same Eph receptor in the same type of cance. Understanding the 
mechanisms responsible for these divergent activities has potential therapeutic 
implications for targeting Eph receptors. We therefore integrated genetically engineered 
mouse models, biochemical analyses in cell culture and genomic datamining in clinical 
specimens to systematically investigate the functions of Eph receptors in physiological 
contexts. The thesis projects presented here include several significant findings. We 
discovered the crosstalk between EphA2 and human epidermal growth factor receptor 2 
(HER2), which is required for breast tumor initiation and metastatic progression. 
Consequently, elevated levels of EphA2 in a subset of HER2-positive breast cancers 
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mediate resistance to trastuzumab therapy that targets HER2 receptor. One caveat is that 
the oncogenic role of EphA2 in tumor progression is dependent upon the oncogene 
context such as the presence of HER2. On the other hand, EphA3 is frequently deleted, 
downregulated or mutated in non-small cell lung cancer, resulting in the loss of 
suppressive role of EphA3 receptor which inhibits the mTOR pathway. These work 
revealed one possible mechanism responsible for the hitherto conflicting roles attributed 
to Eph receptors in tumorigenesis, and dissociated two modes of Eph signaling for 
development of novel cancer therapies. 
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CHAPTER II 
 
REGULATION OF EPHA2 RECEPTOR ENDOCYTOSIS BY SHIP2 LIPID 
PHOSPHATASE VIA PHOSPHATIDYLINOSITOL 3-KINASE-DEPENDENT RAC1 
ACTIVATION 
 
The work presented in this chapter is published with the same title in the Journal of 
Biological Chemistry, Jan 2007 [166]. 
 
Abstract 
Endocytosis of Eph receptors is critical for a number of biological processes, including 
modulating axon growth cone collapse response and regulating cell surface levels of 
receptor in epithelial cells. In particular, ephrin-A ligand stimulation of tumor cells 
induces EphA2 receptor internalization and degradation, a process that has been explored 
as a means to reduce tumor malignancy. However, the mechanism and regulation of 
ligand-induced Eph receptor internalization are not well understood. Here we show that 
SHIP2 (Src homology 2 domain-containing phosphoinositide 5-phosphatase 2) is 
recruited to activated EphA2 via a heterotypic sterile α motif (SAM)-SAM domain 
interaction, leading to regulation of EphA2 internalization. Overexpression of SHIP2 
inhibits EphA2 receptor endocytosis, whereas suppression of SHIP2 expression by small 
interfering RNA-mediated gene silencing promotes ligand-induced EphA2 internalization 
and degradation. SHIP2 regulates EphA2 endocytosis via phosphatidylinositol 3-kinase-
dependent Rac1 activation. Phosphatidylinositol 3,4,5-trisphosphate levels are 
significantly elevated in SHIP2 knockdown cells, phosphatidylinositol 3-kinase inhibitor 
decreases phosphatidylinositol 3,4,5-trisphosphate levels and suppresses increased 
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EphA2 endocytosis. Ephrin-A1 stimulation activates Rac1 GTPase, and the Rac1-GTP 
levels are further increased in SHIP2 knockdown cells. A dominant negative Rac1 
GTPase effectively inhibited ephrin-A1-induced EphA2 endocytosis. Together, our 
findings provide evidence that recruitment of SHIP2 to EphA2 attenuates a positive 
signal to receptor endocytosis mediated by phosphatidylinositol 3-kinase and Rac1 
GTPase. 
 
Introduction 
The Eph family of receptor tyrosine kinases (Ephs) and their ligands, the ephrins, 
regulate a diverse array of biological responses in development and disease (reviewed in 
Refs. [1, 25, 69]). These receptors represent the largest family of receptor tyrosine 
kinases in the genome, consisting of at least 16 receptors that interact with nine 
membrane-bound ephrin ligands. They can be further divided into two groups, class A 
and class B, based on sequence homology and binding affinity [167]. Class A Eph 
receptors interact with multiple ligands of the ephrin-A family, a group of glycosyl-
phosphatidylinositol-linked membrane proteins, whereas class B Eph receptors bind to 
ephrin-B ligands, a family of transmembrane proteins. Binding of Eph receptors to their 
ligands induces receptor clustering, receptor transphosphorylation, and activation of 
kinase activity, followed by activation of signaling cascades that mediate multiple 
cellular responses [1, 25, 69].  
 
Major advances have been made in recent years to dissect the molecular mechanisms by 
which Ephs/ephrins regulate biological processes. In particular, ligand-induced receptor 
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endocytosis has been studied in a number of biological systems. Upon juxtacrine 
interaction of cell surface ephrin-B ligand and EphB receptor, ligand-receptor complexes 
are internalized bidirectionally [65, 66, 168]. This bidirectional endocytosis of ephrin-B 
and EphB complexes appears to be sufficient to promote cell detachment in axon 
withdrawal during growth cone collapse. Endocytosis of EphA receptor also appears to 
be critical in converting an initial adhesive interaction into a repulsive event in growth 
cone collapse response [169]. Outside of the nervous system, ligand-induced 
phosphorylation of the Eph receptors in tumor cells has been shown to result in receptor 
endocytosis and down-regulation of surface receptors [170, 171]. Enhanced EphA2 
endocytosis and subsequent degradation are associated with decreased malignant cell 
behavior. Activating EphA2 monoclonal antibodies [134], ephrin-mimetic peptides [142], 
or adenovirus-expressing ephrin-A1 ligand [40] have been developed to induce receptor 
endocytosis as a means to reduce EphA2 activity. Despite the important roles that Eph 
receptor endocytosis plays in biological responses, relatively little is known about how 
this pathway is regulated.  
 
We have previously shown that activation of the EphA2 receptor regulates Rac1 GTPase 
activity through a PI3-kinase-dependent pathway [94]. Through a yeast two-hybrid 
screen, we identified two proteins that interact with the activated EphA2 receptor and are 
capable of regulating the level of phosphatidylinositol 3,4,5-trisphosphate (PIP3): the p85 
subunit of PI3-kinase and SHIP2 (SH2-containing phosphoinositide 5-phosphatase 2). 
SHIP2 belongs to the SHIP family of lipid phosphatases that dephosphorylates PIP3 
produced by PI 3-kinase [172]. PIP3 has been shown to interact with pleckstrin homology 
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domain-containing proteins, such as the Ras and Rho family guanine nucleotide exchange 
factors, leading to the membrane recruitment and activation of these proteins [173]. 
Although expression of SHIP1 is restricted to the hematopoietic cell lineage, SHIP2 is 
expressed in many cell types [174]. These data suggest that SHIP2, together with PI 3-
kinase, may function downstream of the EphA2 receptor to regulate Rho family GTPases.  
 
In this study, we investigate the molecular mechanisms that regulate ephrin-Eph 
endocytosis. We show that ligand stimulation induces EphA2 receptor internalization in 
MDA-MB-231 mammary carcinoma cells. In response to ephrin binding to EphA2, 
SHIP2 is recruited to the sterile α motif (SAM) domain of EphA2. Overexpression of 
SHIP2 inhibited ligand-induced receptor endocytosis. Conversely, suppression of SHIP2 
expression by small interfering RNA (siRNA)-mediated gene silencing increased EphA2 
endocytosis and subsequent degradation. The mechanism of regulation of EphA2 
endocytosis by SHIP2 involves down-regulation of cellular PIP3 levels and inhibition of 
Rac1 GTPase activity. These findings suggest that SHIP2 plays a central role in 
regulation of EphA2 receptor endocytosis.  
 
Methods 
 
Yeast two-hybrid screening 
The mouse EphA2 cytoplasmic domain was cloned into pBridge-LexA (BD Biosciences) 
(pSGS2) as a bait to screen a human placenta library consisting of 3.5 × 106 independent 
clones (Clontech) as described [96]. Briefly, yeast strain L40 (MATa his3D200 trp1–901 
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leu2–3112 ade2 LYS2::(4lexAop-HIS3) URA3::(8lexAop-lacZ) GAL4) was transformed 
with pSGS2 and the placenta cDNA library. The resulting transformants were screened 
for histidine prototrophy and expression of LacZ. The His+/LacZ+ clones that did not 
interact with lamin C were subjected to PCR analyses to eliminate duplicate clones. 
Among 14 unique His+/LacZ+ clones, six overlapping clones encompassing the SAM 
domain of the SHIP2 gene were identified.  
 
Antibodies 
Antibodies used for immunoblot or immunocytochemistry include anti-Myc (1:500; BD 
Biosciences), anti-FLAG (1:1000; Sigma), anti-EphA2 (1:1000; Santa Cruz 
Biotechnology), anti-phosphotyrosine (1:400; Santa Cruz Biotechnology), anti-tubulin 
(1:1000; Sigma), anti-Rac1 and anti-Cdc42 antibodies (1:250; Pharmingen), anti-PIP3 
(1:250; Echelon), and anti-EEA1 (1:1000; BD Biosciences). For immunoprecipitation, 
1.5 µg of polyclonal rabbit anti-SHIP2 antibody (Santa Cruz Biotechnology) was used. 
Anti-SHIP2 polyclonal chick antibodies were made by Zymed Laboratories Inc., using 
the purified GST-SAM domain of the SHIP2 protein as antigen, and used in Western blot 
analysis.  
 
In vitro binding assay 
MBP-EphA2-SAM, the fusion of the intracellular portion of mouse EphA2 SAM domain 
and maltose-binding protein, was created from pMAL-c2X (New England Biolabs) and 
purified on amylose resin according to the manufacturer's instructions. Escherichia coli 
lysate containing GST-SHIP2-SAM domains was incubated with amylose-bound MBP-
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EphA2-SAM or control MBP alone. After extensive washing, bound proteins were eluted 
and subjected to Western blot analyses using anti-EphA2 and anti-SHIP2 antibodies.  
 
Co-immunoprecipitation and western blot analyses 
COS7 cells were co-transfected with 1 µg each of FLAG-tagged SHIP2 and EphA2 or 
Myc-tagged EphA2 mutants using Lipofectamine 2000. Cells were lysed in 1% Nonidet 
P-40 buffer (10 mm Tris-HCl, pH 7.5, 150 mm NaCl, 2 mm EDTA, 1% Nonidet P-40 
plus 50 mm protease inhibitors). Anti-FLAG antibody (Sigma) was used to 
immunoprecipitate SHIP2. The resulting proteins were resolved on SDS-PAGE and 
subjected to Western blot using anti-EphA2. 1.5 µg of anti-EphA2 antibody (sc-924; 
Santa Cruz Biotechnology) was also used in immunoprecipitation, and precipitated 
proteins were subjected to SDS-PAGE and Western blot analysis by SHIP2 antibodies. 
For coimmunoprecipitation between SHIP2 and EphA2ΔSAM or SAM domain alone, 
Myc-agarose (Sigma) was used to immunoprecipitate EphA2 mutants.  
 
siRNA-mediated silencing of SHIP2 in MDA-MB-231 cells 
SHIP2 knockdown was achieved by siRNA-mediated stable silencing of SHIP2 via 
retroviral transduction, as described [92]. Briefly, human SHIP2 siRNAs and control 
siRNA were designed using Invitrogen software according to the manufacturer's 
instructions. A 64-base pair oligonucleotide linker containing SHIP2-specific sense and 
corresponding antisense sequences, flanking a 6-base hairpin, was generated, PAGE-
purified, and subcloned into retroviral vector pRS (a gift of R. Agami, The Netherlands 
Cancer Institute, Amsterdam, The Netherlands). pRS SHIP2 siRNA or control siRNA 
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retrovirus were produced in the Phoenix cell packaging line. For siRNA expression, 
MDA-MB-231 cells were infected with pRS SHIP2 or control siRNA retroviruses and 
selected in the presence of 5 µg/ml puromycin. Pooled clones of MDA-MB-231, number 
1, 2, 3, and 4, or single clone 2A expressing either SHIP2 or control siRNAs were 
analyzed. The level of SHIP2 knockdown in pooled clones was assessed by quantifying 
band intensity of SHIP2 over tubulin using Scion Image software.  
 
Confocal microscopy analysis 
Control or SHIP2 knockdown cells were plated on coverslips in 6-well dishes and 
cultured to 50% confluence. Growth medium was replaced with 1 ml of starvation 
medium (Dulbecco's modified Eagle's medium plus 1% bovine serum albumin or Opti-
MEM) per well. For immunofluorescence assays, cells were stimulated with 1 µg/ml 
ephrin-A1 for 30 min and fixed with 4% paraformaldehyde. Following fixation, cells 
were incubated with primary antibodies (anti-EphA2, 1:1000 (Santa Cruz Biotechnology); 
monoclonal anti-EEA1, 1:1000 (BD Biosciences); monoclonal anti-Myc, 1:1000 (Cell 
Signaling); monoclonal anti-FLAG, 1:1000 (Sigma)) for 2 h at 25 °C or overnight at 4 °C, 
followed by secondary antibodies (Alexa594-conjugated goat anti-mouse (1:3000) or 
Alexa 488-conjugated goat anti-rabbit (1:3000) from Molecular Probes). Images were 
recorded by confocal microscopy. Internalization was quantified by drawing an area 
under the cell membrane (within the cell but excluding cell membrane) of each cell on 
the confocal image, and pixels of internalized vesicles within the area were counted. 
Pixel density is calculated as total pixels per cell within the circled area using Metamorph 
computer software. Experiments were repeated three times, and 20–40 cells/experiment 
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were analyzed. Data are presented as mean ± S.D., and statistical significance was 
assessed by a two-tailed, paired Student's t test.  
 
Biotinylation assay for endocytosis 
MDA-MB-231 cells were incubated with 0.5 mg/ml Sulfo-NHS-LC-Biotin (Pierce) for 
30 min at 4 °C followed by washing to quench free biotin. Cells were then incubated in 
normal medium at 37 °C for the indicated times in the presence of ephrin-A1-Fc or 
control IgG. Biotinylated cell surface proteins were removed by 0.01% trypsinization. 
Remaining biotinylated proteins were sequestered inside cells by endocytosis and were 
protected from trypsinization. Cell lysates were immunoprecipitated with streptavidin 
beads, and biotinylated EphA2 proteins were visualized by anti-EphA2 coupled 
chemiluminescence detection using an ECL kit (Amersham Biosciences).  
 
PIP3 ELISA 
Confluent cells were serum-starved overnight and treated with ephrin-A1-Fc or control 
IgG for 10 min. PIP3 was extracted from cells and subjected to ELISA assay using a 
PIP3 mass ELISA kit (Echelon, Salt Lake City, UT). Briefly, lipids were extracted with 
2.25 ml of MeOH, CHCl3,12 m HCl (80:40:1) for 15 min at room temperature and 
partitioned by centrifugation after the addition of 0.75 ml of CHCl3 and 1.35 ml of 0.1 m 
HCl. The lower phase was vacuum-dried and dissolved in PIP3 buffer. Controls, 
standards and samples were incubated with PIP3 detector, secondary detection reagent, 
and 3,3′,5,5′-tetramethylbenzidine (TMB) solution sequentially. The reaction was 
terminated by adding stop solution (0.5 m H2SO4), and the absorbance was measured at 
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450 nm. Experiments were repeated twice, and all controls, standards, and samples were 
run in triplicate per experiment. Data are presented as mean ± S.D., and statistical 
significance was assessed by two-tailed, paired Student's t test.  
 
Guanine nucleotide exchange assays 
For Rac1 and Cdc42 activation assays, cells were serum-starved for 24 h in 1% fetal 
bovine serum followed by stimulation with ephrin-A1 (1 µg/ml). Lysates were prepared 
and incubated with Pak-1 binding domain-GST beads (Upstate Biotechnology, Inc.) as 
described by the manufacturer's protocol to pull down GTP-bound Rac1 and/or Cdc42. 
Activated Rac1 and Cdc42 (or total Rac1 and Cdc42 in lysates) were detected by 
immunoblot using anti-Rac1 or anti-Cdc42 antibodies. Active Rac1-GTP or Cdc42-GTP 
levels were quantified by densitometry (Rac1-GTP/total Rac1) using Scion Image 
software. Experiments were repeated three times, and data are presented as means ± S.D. 
Statistical significance was assessed by a two-tailed, paired Student's t test.  
Previous SectionNext Section 
 
Results 
 
Activated EphA2 receptor interacts with SHIP2 
A yeast two-hybrid screen was used to identify EphA2 receptor-interacting proteins [96]. 
The bait construct consisted of the intracellular portion of mouse EphA2 fused to the 
DNA binding domain of LexA. Upon screening a cDNA library from human placenta, 
we obtained six independent but overlapping interacting clones that contained the SAM  
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Figure 2.1. Activated EphA2 receptor recruits SHIP2 in mammalian cells. A. full-
length EphA2 and FLAG-tagged SHIP2 cDNA expression plasmids or vector alone were 
co-transfected into COS7 cells. Cells were stimulated with ephrin-A1 at the indicated 
times, and cell lysates were immunoprecipitated (IP) with anti-FLAG, followed by 
Western blot analysis with anti-EphA2 antibodies. Blots were stripped and reprobed for 
expression of SHIP2. B. FLAG-tagged SHIP2 or vector were transfected into COS7 cells 
and stimulated in the presence or absence of ephrin-A1 following a time course. 
Endogenous EphA2 receptors were immunoprecipitated by anti-EphA2, followed by 
Western blot analyses with anti-SHIP2. C. MDA-MB-231 cell lysates were added to 
GST-SHIP2 or control GST resin, and bound proteins were eluted and analyzed by 
Western blot analysis using anti-EphA2 antibodies. D. MDA-MB-231 cells were 
stimulated with ephrin-A1 for the indicated time, and cell lysates were 
immunoprecipitated with anti-SHIP2 or control IgG, followed by Western blot analysis 
using anti-EphA2. E, Myc-tagged SHIP2 and EphA2, A3, or A4 receptors were co-
transfected into COS7 cells. SHIP2 was immunoprecipitated with anti-Myc-conjugated 
resins, followed by Western blot analysis (IB) using anti-EphA2, A3, or A4 antibodies. 
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domain of SHIP2. Interestingly, the binding of SHIP2 to the EphA2 receptor is quite 
specific, since it binds to neither EphB1 receptor nor other EphA receptors (data not 
shown). 
 
The observation that the SHIP2 SAM domain interacts with the cytoplasmic domain of 
EphA2 in yeast raised the possibility that SHIP2 and EphA2 interact in mammalian cells. 
To test this hypothesis, we transfected COS7 cells with a FLAG-tagged full-length 
SHIP2 expression construct and immunoprecipitated cell lysates with an anti-FLAG 
antibody. As shown in Fig. 2.1A, the EphA2 was readily detected in anti-FLAG 
immunoprecipitates. The co-immunoprecipitation of EphA2 with the anti-FLAG 
antibody was dependent on the expression of SHIP2 and ephrin-A1 stimulation, since 
EphA2 was undetectable in the unstimulated samples and in immunoprecipitates in which 
a control vector was expressed. In the reverse direction, SHIP2 was easily detected in 
anti-EphA2 immunoprecipitates from cells transfected with SHIP2 and stimulated with 
ephrin-A1 (Fig. 2.1B). However, SHIP2 does not bind to EphA3 or EphA4 (Fig. 2.1E), 
demonstrating the binding specificity of SHIP2 to EphA2.  
 
To determine whether endogenous EphA2 receptor can bind to SHIP2, MDA-MB-231 
cells were stimulated with ephrin-A1, and cell lysates were subjected to a GST-SHIP2-
SAM pulldown assay. As shown in Fig. 2.1C, GST-SHIP2, but not control GST, binds to 
endogenously expressed EphA2 in response to ephrin-A1 ligand stimulation. In addition, 
EphA2 was detected in anti-SHIP2 immunoprecipitates upon ephrin-A1 stimulation in 
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MDA-MB-231 cells (Fig. 2.1D). These findings indicate that SHIP2 is recruited to 
activated EphA2 receptors in breast cancer cells.  
 
Mapping of interaction domains between EphA2 and SHIP2 
To identify the domains within the EphA2 receptor that mediate the interaction with 
SHIP2, a panel of EphA2 constructs was generated in which portions of EphA2 were 
deleted. The resulting EphA2 mutants were expressed at comparable levels in the yeast 
two-hybrid assay and tested for their interaction with SHIP2 (Fig. 2.2A). EphA2 
receptors lacking the juxtamembrane domain, kinase domain, or PDZ binding motif were 
capable of binding with SHIP2 as efficiently as the wild-type receptor. The interaction 
between the two proteins is disrupted in EphA2 mutants with a deletion of the SAM 
domain. The EphA2 SAM domain alone binds to SHIP2 as well as the wild-type receptor, 
indicating that the SAM-SAM interaction is required for binding to SHIP2. The original 
six independent and overlapping yeast two-hybrid interacting clones of SHIP2 all 
contained the SAM domain. As shown in Fig. 2.2B, the SAM domain of SHIP2 alone can 
bind to the EphA2 cytoplasmic domain, whereas the SHIP2 SH2 domain fails to bind to 
EphA2. 
 
The heterotypic interaction between the EphA2 SAM and the SHIP2 SAM domains was 
verified in mammalian cells. As predicted from the yeast two-hybrid assay, binding of 
EphA2 to SHIP2 is independent of EphA2 receptor phosphorylation, since a kinase-dead 
(D738N) mutant or three Tyr to Phe mutations (Y921F, Y929F, and Y959F) in the 
EphA2 SAM domain did not affect binding significantly (Fig. 2.2C); nor did the deletion 
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Figure 2.2. Interaction and domain mapping of EphA2 and SHIP2. A. a SHIP2 
cDNA fragment containing the SAM domain (amino acids 1117–1258) was co-expressed 
in the yeast two-hybrid assay with wild type or various mutants of the EphA2 
cytoplasmic domain. D738N, a kinase dead mutation. B. the EphA2 cytoplasmic domain 
was co-expressed in the yeast two-hybrid assay with wild type or various deletion 
mutants of SHIP2. C–E. wild type and various mutants of EphA2 and SHIP2 were 
transfected into COS7 cells and subjected to coimmunoprecipitation/Western blot 
analysis. F. the maltose-binding protein-EphA2 SAM domain fusion protein (MBP-
EphA2-SAM) and the GST-SHIP2-SAM domain fusion protein were expressed in E. coli. 
Soluble GST-SHIP2-SAM was added to the MBP-EphA2-SAM or control MBP amylose 
column, and bound proteins were eluted and analyzed by SDS-PAGE followed by silver 
staining (top panel). Western blots of eluted fractions are shown in the bottom panels. 
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of the SH2 domain in SHIP2 protein (Fig. 2.2E). In contrast, deletion of the EphA2 SAM 
domain abolished the ability to bind to SHIP2, whereas the EphA2 SAM domain alone 
was capable of interacting with SHIP2 (Fig. 2.2D). Conversely, deletion of the SHIP2 
SAM domain also inhibited binding to the EphA2 receptor (Fig. 2.2E), confirming the 
heterotypic interaction between the two SAM domains.  
 
To test for a direct interaction between EphA2 and SHIP2, the SAM domains of SHIP2 
and EphA2 were expressed as GST and MBP fusion proteins, respectively. As shown in 
Fig. 2.2F, GST-SHIP2-SAM bound to MBP-EphA2-SAM that was linked to amylose 
beads. After extensive washing, only GST-SHIP2-SAM and MBP-EphA2-SAM were 
eluted from the column. Although GST-SHIP2-SAM bound to MBP-EphA2-SAM, it 
failed to interact with MBP alone, indicating that the binding is specific to the EphA2-
SAM in vitro and independent of phosphorylation. Taken together, these results suggest 
that the EphA2 receptor binds to the SHIP2 phosphatase through a SAM-SAM 
heterotypic interaction.  
 
Overexpression of SHIP2 inhibits ligand-induced EphA2 receptor endocytosis 
As a first step to determine the functional link between SHIP2 and EphA2 endocytosis, 
we analyzed the kinetics of ligand-induced EphA2 receptor internalization in MDA-MB-
231 cells by confocal microscopy. As shown in Fig. 2.3A, upon stimulation with soluble 
ephrin-A1, EphA2 receptor (green) clusters rapidly and localizes in large patches, 
followed by internalization of the receptor. These internalized vesicles were costained 
with EEA1 (red), an early endosomal marker [175], suggesting that EphA2 receptor is 
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internalized by endocytosis. Next, we over-expressed wild-type Myc-tagged SHIP2 in 
COS7 cells and examined ephrin-A1-induced receptor endocytosis. Anti-Myc antibodies 
detected cells expressing exogenous SHIP2 (red), whereas subcellular localization of the 
endogenous EphA2 receptor was detected by anti-EphA2 antibodies (green). 
Internalization of EphA2 receptor (green) was significantly inhibited in cells 
overexpressing SHIP2 (red) but not SHIP2ΔSAM (Fig. 2.3, B and C), suggesting that 
SHIP2 regulates ligand-induced EphA2 receptor endocytosis via its SAM domain.  
 
Although SHIP2 can function directly as a phosphoinositide phosphatase, it is interesting 
to note that it also contains multiple functional domains/motifs that may mediate the 
recruitment of other signaling molecules. To determine whether SHIP2 regulates EphA2 
endocytosis via its phosphatase activity or acting as an adaptor protein, we transfected 
COS7 cells with a catalytic-inactive SHIP2 mutant, D607A [176, 177]. As shown in Fig. 
2.3, B and C, the D607A mutant did not inhibit ephrin-A1-induced EphA2 receptor 
internalization, suggesting that the enzymatic activity of SHIP2 is required for regulation 
of EphA2 endocytosis.  
 
Enhanced EphA2 receptor endocytosis in SHIP2 knockdown cells 
To understand the role of SHIP2 in EphA2 receptor endocytosis in breast cancer cells, we 
inhibited the endogenous SHIP2 expression by retrovirus-mediated siRNA knockdown. 
Four siRNA duplexes of sequence specific to SHIP2 were tested in MDA-MB-231 breast 
cancer cells. These siRNAs were stably expressed in MDA-MB-231 cells by retroviral 
transduction. As shown in Fig. 2.4A, MDA-MB-231 cells expressing siRNA2 inhibited 
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Figure 2.3. Overexpression of SHIP2 inhibits ligand-induced EphA2 receptor 
endocytosis. A. kinetics of ligand-induced EphA2 endocytosis. MDA-MB-231 cells were 
stimulated with ephrin-A1 ligand following a time course. EphA2 receptor (green) is 
localized diffusely at the cell border at 0 min. Ephrin-A1 stimulation results in EphA2 
receptor clustering and internalization (see insert) at 2 min. At 15 min, extensive 
internalized EphA2 vesicles were observed, co-localizing with EEA1, an endosomal 
marker. B. EphA2 and a Myc-tagged SHIP2,a SHIP2 mutant with SAM domain deletion 
(SHIP2∆ SAM), or a SHIP2 mutant that lacks phosphatase activity (SHIP2D607A) were 
co-transfected into COS7 cells, and cells were stimulated with ephrin-A1 for 15 min. 
EphA2 and SHIP2 are detected by antibodies against EphA2 (green) and Myc (red), 
respectively. EphA2 endocytosis is significantly inhibited in SHIP2-overexpressing cells 
(p < 0.01) but not in SHIP2ΔSAM or D607A mutant-expressing cells. Arrowhead, 
transfected cells. C. internalized vesicles in each cell were quantified by counting vesicle 
pixel density using Metamorph software. Experiments were repeated three times, and ~30 
cells/experiment were analyzed. Data are presented as mean ± S.D., and statistical 
significance was assessed by a two-tailed, paired Student's t test. WT, wild type. 
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the expression of endogenous SHIP2 to greater than 80%. siRNAs 1, 3, and 4 also 
produced a target protein suppression but to a lesser degree (~50%). A control siRNA 
with two mismatches in sequence 2 was completely inactive.  
 
To investigate whether ephrin-A1-induced EphA2 receptor endocytosis is affected by 
knockdown of SHIP2 in MDA-MB-231 cells, SHIP2 knockdown or control cells were 
treated with ephrin-A1, and EphA2 receptor localization was followed by confocal 
immunofluorescence analysis. As shown in Fig. 2.4B,in SHIP2 knockdown cells, ephrin-
A1 stimulation enhanced the accumulation of internalized EphA2 vesicles, compared 
with parental MDA-MB-231 (data not shown) or control siRNA-expressing cells. 
Quantification of these vesicles revealed that there was an ~2-fold increase in vesicle 
pixel density in SHIP2 knock down cells, compared with control siRNA-expressing cells, 
indicating that SHIP2 negatively regulates EphA2 endocytosis.  
 
Internalization of cell surface EphA2 was also tracked using a surface biotinylation assay 
described by Le et al. [178]. MDA-MB-231 cells were surface-biotinylated at 4 °C and 
then returned to 37 °C following a time course to allow trafficking to resume. Cells were 
incubated briefly with a dilute trypsin solution to remove cell surface proteins. 
Internalized EphA2 was sequestered at 37 °C and therefore protected from trypsin 
digestion. Little if any EphA2 was detected in control cells (Fig. 2.4C, 0 min), confirming 
that under these conditions, biotinylated cell surface proteins were efficiently removed by 
trypsin. In contrast, after 10, 20, and 30 min at 37 °C, a biotinylated pool of EphA2 was 
detected in cells following trypsin treatment (Fig. 2.4C, 10, 20, and 30 min), indicating 
47 
 
that EphA2 was internalized and protected from typsinization. Ephrin-A1 induced EphA2 
internalization in both control and SHIP2 knockdown cells, but the level of internalized 
EphA2 was appreciably higher in SHIP2 knockdown cells compared with that in control 
cells (Fig. 2.4C). We also observed a basal level of EphA2 internalization in the absence 
of ligand stimulation (Fig. 2.4C, right). However, this level is significantly lower than 
that with ephrin-A1 stimulation. These data provide independent evidence that ephrin-A1 
stimulation induces EphA2 internalization, and this process is regulated by SHIP2.  
 
To determine whether increased endocytic vesicles observed in SHIP2 knockdown cells 
affected ligand-induced receptor degradation, we performed Western blot analysis of 
EphA2 following ephrin-A1 treatment. The total level of EphA2 receptor decreased with 
increasing length of ephrin-A1 treatment, and this process was enhanced in SHIP2 
knockdown cells (Fig. 2.4D), indicating that SHIP2 regulates EphA2 degradation.  
 
SHIP2 regulates EphA2 endocytosis through modulation of cellular PIP3 levels 
We next explored the mechanisms by which SHIP2 regulates EphA2 receptor 
endocytosis. As SHIP2 is a phosphoinositide 5-phosphatase, we determined the impact of 
SHIP2 knockdown on phospholipid PIP3 levels. We measured PIP3 levels by ELISA 
using an anti-PIP3 monoclonal antibody that is widely used in many studies [179-182]. 
As shown in Fig. 2.5C, compared with those in control cells, PIP3 levels in SHIP2 
knockdown cells increased ~2-fold, either at resting phase or stimulated by ephrin-A1. 
Because phospholipid PIP3 is a product of PI 3-kinase, we tested whether inhibition of PI 
3-kinase affects EphA2 endocytosis. The PI 3-kinase inhibitor LY294002 (50 µm) 
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Figure 2.4. Inhibition of SHIP2 in cancer cells by siRNA-mediated silencing. A. 
Western blot analysis on SHIP2 siRNA clones. MDA-MB-231 cells were infected with 
retroviruses expressing siRNA 1, 2, 2A, 3, and 4 and a control mutant 2 siRNA. Pooled 
clones were subjected to Western blot analysis using an anti-SHIP2 polyclonal antibody. 
The blot was stripped and reprobed for EphA2 and tubulin for a loading control. B. 
EphA2 endocytosis is documented by confocal imaging analysis and quantified by 
Metamorph analysis as described in the legend to Fig. 3C. MDA-MB-231 cells were co-
stained by anti-EphA2 antibody (green) and endosomal marker EEA1 (red) in SHIP2 
knockdown and control cells. Enhanced endocytosis of EphA2 receptor was observed in 
SHIP2 knockdown cells. C. MDA-MB-231 cells were biotinylated, and surface proteins 
were either removed immediately as indicated by the 0 time point or removed following a 
time course in the presence (left panel) or absence (right panel) of ephrin-A1 stimulation. 
Levels of internalized biotinylated EphA2 were then determined by immunoprecipitation 
with streptavidin beads followed by Western blot analysis using anti-EphA2 antibody. D. 
EphA2 protein level is detected by Western blot analysis following ephrin-A1 stimulation 
in control and SHIP2 knockdown cells. Enhanced EphA2 degradation was observed in 
SHIP2 knockdown cells. 
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significantly inhibited increased PIP3 levels (Fig. 2.5C) as well as ephrin-A1-induced 
EphA2 endocytosis (Fig. 2.5, A and B). Taken together, these data indicate that SHIP2 
regulates EphA2 endocytosis via modulation of cellular PIP3 levels.  
 
SHIP2 regulates EphA2 endocytosis through a Rac1 GTPase-dependent pathway 
Previous studies have shown that Vav family guanine nucleotide exchange factors and 
Rac GTPase activity are required for endocytosis of Eph molecules [66, 169]. Since the 
activation status of guanine nucleotide exchange factors can be regulated by PIP3 levels 
[183, 184] and PIP3 is a major substrate of SHIP2 [172], we investigated whether ephrin-
A1-induced Rac1 GTPase activation is affected in SHIP2 knockdown cells. As shown in 
Fig. 2.6A, upon ephrin-A1 stimulation, we detected a transient activation of Rac1 GTPase, 
with a peak at 2.5–5 min. In SHIP2 knockdown cells, the basal level of GTP-bound Rac1 
is increased, and the Rac1 activity is further enhanced upon ephrin-A1 stimulation. In 
contrast, ephrin-A1 stimulation does not appear to affect Cdc42 activity. The enhanced 
basal and ephrin-A1-induced Rac1-GTP levels in SHIP2 knockdown cells were blocked 
by PI 3-kinase inhibitor, LY294002 (Fig. 2.6A, bottom). These data suggest that, in 
contrast to PI 3-kinase, SHIP2 negatively regulates Rac1 GTPase activity.  
 
To determine the functional relevance of Rac1 in ligand-induced EphA2 endocytosis, we 
expressed a wild-type Rac1, a constitutively active mutant of Rac1 (Rac1 V12), or a 
dominant negative mutant of Rac1 (Rac1 N-17) [185] in COS7 cells. As shown in Fig. 
2.6B, expression of either wild-type Rac1 (green, top) or Rac1 V-12 (red, middle) did not 
affect EphA2 internalization significantly, but expression of Rac1 N-17 (red, bottom) 
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Figure 2.5. SHIP2 regulates EphA2 endocytosis through modulation of cellular PIP3. 
A. SHIP2 knockdown cells were stimulated with ephrin-A1 in the presence of PI 3-kinase 
inhibitor LY294002 (50 µm) or control vehicle for the indicated time, fixed, 
permeabilized, and stained with anti-EphA2 and anti-EEA1 antibodies. LY294002 
inhibits elevated EphA2 endocytosis in SHIP2 knockdown cells. B. quantification of the 
EphA2 endocytosis using Metamorph software as described in the legend to Fig. 3C. C. 
control and SHIP2 knockdown cells were stimulated with ephrin-A1 for the indicated 
time in the presence or absence of PI 3-kinase inhibitor LY294002. The PIP3 levels in 
control and SHIP2 knockdown cells were quantified by ELISA analysis.  
51 
 
markedly impaired EphA2 endocytosis, suggesting that Rac1 GTPase activity is required 
for ligand-induced EphA2 endocytosis.  
 
Discussion 
In this study, we show that when ephrins bind to Ephs the lipid phosphatase SHIP2 is 
recruited to the SAM domain of the activated EphA2 receptor through a heterotypic 
SAM-SAM interaction. We found that overexpression of SHIP2 significantly inhibited 
ligand-induced EphA2 receptor endocytosis. Silencing of SHIP2 via siRNA-mediated 
knockdown enhanced the ephrin-A1 ligand-induced increase in PIP3 levels and Rac1 
GTPase activity as well as ligand-induced EphA2 receptor endocytosis. Taken together, 
our data indicate an important role for SHIP2 in regulating phosphoinositol lipids to 
modulate Eph receptor function in cancer cells.  
 
Recruitment of SHIP2 to the activated EphA2 receptor via a heterotypic SAM-SAM 
domain interaction 
SHIP1 and SHIP2 have been shown to associate with a number of cell surface receptors 
[172]. Both SHIP1 and SHIP2 contain an N-terminal SH2 domain, a lipid phosphatase 
domain, proline-rich regions, and NPXY motifs serving as potential protein-protein 
interaction sites. SHIP2 also possesses a C-terminal SAM domain that is not present in 
SHIP1. In the case of SHIP1, the amino-terminal SH2 domain binds to phosphotyrosine 
residues to mediate the interactions with a number of signal transduction proteins [172, 
186, 187]. However, this is not the case in the interaction between SHIP2 and the EGFR. 
Pesesse et al. [188] reported that the SH2 domain of SHIP2 was unable to precipitate the 
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Figure 2.6. SHIP2 regulates EphA2 endocytosis via Rac1 GTPase. A. active GTP-
bound forms of Rac1 and Cdc42 were analyzed by Pak-1 binding domain pull-down, 
followed by immunoblot in lysates from SHIP2 knockdown or control MDA-MB-231 
cells stimulated with ephrin-A1, in the presence or absence of PI 3-kinase inhibitor 
LY294002 (blots). Total Rac1 and Cdc42 levels within the lysate prior to Pak-1 binding 
domain pull-down were detected by immunoblot. Results from three independent 
experiments were quantified using Scion Image software and expressed as mean ± S.D. 
(graphs). B. a wild-type Rac1, a Myc-tagged constitutively active Rac1 mutant (Rac1 V-
12), or a dominant negative N17 Rac1 expression construct was transfected into COS7 
cells, and ligand-induced EphA2 endocytosis (at 15 min) was analyzed by confocal 
microscopy. Ephrin-A1-induced EphA2 endocytosis is not affected in wild type-or V12 
Rac1-expressing cells but is inhibited in N17 Rac1 expressing cells (red). Arrowhead, 
transfected cells. Internalized vesicles in each cell were quantified by counting vesicle 
pixel density using Metamorph software, as detailed under “Methods”  
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EGFR, whereas a C-terminal truncated form of SHIP2 that lacks the last 366 amino acids 
was able to bind to EGFR in EGF-stimulated cells. These results suggest that neither the 
SH2 nor SAM domain of SHIP2 is capable of binding to the activated EGFR, and a 
specific EGFR binding domain in SHIP2 remains to be identified. Here we show that it is 
the SAM domain of SHIP2, rather than its SH2 domain (Fig. 2.2E), that is required for 
interacting with the activated EphA2 receptor. 
 
SAM domains are protein-protein interaction motifs that can interact homotypically with 
identical SAM domains or heterotypically with other related SAM domains [189]. All 
known Eph proteins contain SAM domains at the C terminus, which are thought to play a 
role in receptor clustering. Crystal and solution structures of the EphA4-SAM domain 
and the EphB2-SAM domain have been resolved [13, 190, 191]. Despite the potential 
role of these SAM domains in promoting receptor oligomerization, homotypic SAM-
SAM self-association in solution is weak (Kd > 1 mm). In light of our data, one major 
function of the EphA2 receptor SAM domain appears to be mediating heterotypic 
protein-protein interactions to transduce signals downstream of the Eph receptor. As the 
EphA2 SAM domain contains three tyrosine residues, one possibility is that the activated 
receptor phosphorylates its own SAM domain, leading to recruitment of SHIP2. However, 
our data do not favor this hypothesis. A kinase-dead (D738N) EphA2 mutant and Tyr to 
Phe mutations in the SAM domain are all still capable of binding to the SHIP2 SAM 
domain (Fig. 2.2, A and C). In addition, an SH2 domain deletion mutant of SHIP2 protein 
retains its ability to interact with the EphA2 receptor (Fig. 2.2E). The more likely model 
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is that ligand stimulation induces conformational changes in the EphA2 receptor, 
allowing SHIP2 to gain access to the EphA2 SAM domain.  
 
SHIP2 and regulation of receptor endocytosis 
Ligand-induced Eph receptor endocytosis has been previously reported [66, 192]. In 
these cases, Rac1 was shown to be required for endocytosis of the plasma membrane and 
reorganization of F-actin. More recently, Vav family proteins were recognized as Rho 
guanine nucleotide exchange factors to activate Rac GTPase in the growth cone collapse 
response [169]. Since Vav proteins can be regulated through tyrosine phosphorylation 
and/or binding to PIP3 via the pleckstrin homology domains, one way to regulate 
receptor endocytosis is to modulate PIP3 levels through PI 3-kinase and/or lipid 
phosphatases. In support of this idea, we found that the phosphorylated EphA2 receptor 
interacts with the p85 subunit of PI 3-kinase (data not shown), a result that is consistent 
with previous findings by Pandey et al. [193]. Activated EphA2 also recruits the SHIP2 
phosphatase, providing negative feedback to reduce PIP3 levels. Indeed, knockdown of 
SHIP2 in MDA-MB-231 cells led to an increase in EphA2 receptor endocytosis and 
degradation. This increased endocytosis of the EphA2 receptor was accompanied by 
increased ephrin-A1-induced PIP3 levels and activation of Rac1. A PI 3-kinase inhibitor, 
LY294002, blocked basal and ligand-induced Rac1 activation and significantly inhibited 
EphA2 endocytosis in SHIP2 knockdown cells. Taken together, these results suggest a 
switch from a phosphotyrosine-dependent to a SAM-dependent signaling mechanism to 
regulate EphA2 endocytosis (Fig. 2.7).  
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Involvement of a phosphoinositide 5-phosphatase in receptor endocytosis has been 
described previously [194]. Irie et al. reported that activation of EphB2 in neurons 
induced tyrosine phosphorylation of synaptojanin 1, a phosphatidylinositol 5-phosphatase 
that is involved in clathrin-mediated endocytosis. Ephrin-induced phosphorylation of 
synaptojanin 1 inhibits both the interaction with endophilin and the 5-phosphatase 
activity of synaptojanin 1, resulting in inhibition of internalized vesicle uncoating and 
blocking entry to endosomes. This mechanism apparently is different from regulation of 
EphA2 endocytosis by SHIP2. Although we also observe increased vesicles in SHIP2 
knockdown cells, the elevated numbers of vesicles co-localize with EEA1, an endosomal 
marker. In addition, EphA2 receptor degradation is enhanced in SHIP2 knockdown cells, 
suggesting that internalized vesicles reach endosomes for protein degradation. Thus, it is 
likely that SHIP2 acts at an early stage of EphA2 endocytosis, through modulation of 
Rac1-dependent cytoskeletal dynamics, to regulate EphA2 trafficking. 
 
Aside from modulating Rac1 GTPase activity, SHIP2 may also regulate EphA2 receptor 
endocytosis via Cbl, a ubiquitinating ligase (E3). Cbl has been recently reported to 
interact with SHIP2 through the SHIP2 SH2 domain [195, 196] as well as several 
receptor tyrosine kinases, including the EphA2 and the EGF receptors [170, 171, 196]. 
Prasad and Decker proposed that SHIP2 may sequester Cbl, preventing it from binding to 
the EGF receptor, thereby inhibiting EGF receptor degradation. If SHIP2 also regulates 
EphA2 via a similar mechanism, the enzymatic activity may not be required for SHIP2 
function. However, a SHIP2 mutation (D607A) that abolishes phosphatase activity did 
not affect EphA2 endocytosis (Fig. 2.3B). Our finding suggests that inhibition of EphA2 
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Figure 2.7. A model for how SHIP2 may regulate ephrin-induced EphA2 
endocytosis. Upon binding to ephrins, the EphA2 receptor is tyrosine-phosphorylated. 
Through the recruitment of the p85 subunit of PI 3-kinase, EphA2 receptor up-regulates 
phospholipid PIP3 levels and activates Rac1 GTPase to transduce signals as well as 
promoting EphA2 receptor endocytosis. EphA2 also recruits SHIP2 through a heterotypic 
SAM-SAM interaction to mediate negative feedback to reduce PIP3 levels. Thus, the 
EphA2 receptor is capable of switching from phosphotyrosine-dependent to SAM-
dependent signaling to regulate EphA2 endocytosis.  
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endocytosis by SHIP2 is unlikely to be due to sequestion of Cbl by SHIP2. Rather, 
SHIP2 may function as a lipid phosphatase to down-regulate PIP3 levels, which inhibits 
Rac1 GTPase activity and EphA2 receptor endocytosis.  
 
Role of SHIP2 in tumor cell malignancy 
SHIP2 belongs to a family of SH2-containing phosphoinositide 5-phosphatases. The 
closest relative to SHIP2 is SHIP1. SHIP1 expression is restricted to hematopoietic cells 
and developing spermatogonia, whereas SHIP2 is more widely expressed in many 
different tissues and cell types [172]. The role of SHIPs in the enzymatic conversion of PI 
3,4,5-trisphosphate to PI 3,4-biphosphate raises the question of whether they can act as 
tumor suppressors like PTEN, which utilizes the same lipid substrate but produces a 
different lipid product, PI 4,5-biphosphate. Loss of SHIP1 in mice resulted in a 
myeloproliferative disease [197]. In addition, SHIP1 expression is reduced in both 
primary cells from leukemic patients and upon induction of BCR-ABL [198]. These data 
suggest that reduced SHIP1 activity may be a prerequisite for the proliferative advantage 
of some chronic and acute myelogenous leukemic clones. It is currently unclear whether 
SHIP2 may also play a tumor suppressor-like role. In an earlier study, loss of both SHIP2 
and Phox2a in mice led to neonatal lethality and increased sensitivity to insulin [199]. 
Neonatal lethality in this strain renders it difficult to study the role of SHIP2 in cancer, 
and deletion of Phox2a would confound the results. More recently, deletion of SHIP2 
alone in mice resulted in resistance to dietary obesity [200]. Since this SHIP2-deficient 
mouse strain is viable, it provides an opportunity to investigate SHIP2 function in 
tumorigenesis and metastatic progression. 
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Our data in malignant breast cancer cells suggest that SHIP2 inhibits EphA2 receptor 
endocytosis. Since EphA2 level is correlated with tumor malignancy, it is possible that 
enhanced EphA2 receptor endocytosis and degradation in SHIP2 knockdown cells may 
reduce tumor malignancy. However, it is important to note that SHIP2 also regulates 
other growth factor receptors, endocytosis of many of which is required for receptor 
signaling. Thus, it is also possible that ablation of SHIP2 globally may enhance receptor 
signaling and cell proliferation/migration, resulting in increased cell malignancy. In vivo 
experiments using relevant animal models are required to resolve this issue.  
 
In summary, our findings reported here implicate a critical role for SHIP2 in regulating 
ligand-induced EphA2 receptor endocytosis. Since EphA2 level is linked to tumor 
malignancy, these studies provide a foundation for investigating EphA2 as a potential 
target for therapeutic intervention.  
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CHAPTER III 
 
THE RECEPTOR TYROSINE KINASE EPHA2 PROMOTES MAMMARY 
ADENOCARCINOMA TUMORIGENESIS AND METASTATIC PROGRESSION IN 
MICE BY AMPLIFYING ERBB2 SIGNALING 
 
The work presented in this chapter is published with the same title in the Journal of 
Clinical Investigation, Jan 2008 [201]. 
 
Abstract 
Overexpression of the receptor tyrosine kinase EPH receptor A2 (EphA2) is commonly 
observed in aggressive breast cancer and correlates with a poor prognosis. However, 
while EphA2 has been reported to enhance tumorigenesis, proliferation, and MAPK 
activation in several model systems, other studies suggest that EphA2 activation 
diminishes these processes and inhibits the activity of MAPK upon ligand stimulation. In 
this study, we eliminated EphA2 expression in 2 transgenic mouse models of mammary 
carcinoma. EphA2 deficiency impaired tumor initiation and metastatic progression in 
mice overexpressing ErbB2 (also known as Neu) in the mammary epithelium (MMTV-
Neu mice), but not in mice overexpressing the polyomavirus middle T antigen in 
mammary epithelium (MMTV–PyV-mT mice). Histologic and ex vivo analyses of 
MMTV-Neu mouse mammary epithelium indicated that EphA2 enhanced tumor 
proliferation and motility. Biochemical analyses revealed that EphA2 formed a complex 
with ErbB2 in human and murine breast carcinoma cells, resulting in enhanced activation 
of Ras-MAPK signaling and RhoA GTPase. Additionally, MMTV-Neu, but not MMTV–
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PyV-mT, tumors were sensitive to therapeutic inhibition of EphA2. These data suggest 
that EphA2 cooperates with ErbB2 to promote tumor progression in mice and may 
provide a novel therapeutic target for ErbB2-dependent tumors in humans. Moreover, 
EphA2 function in tumor progression appeared to depend on oncogene context, an 
important consideration for the application of therapies targeting EphA2. 
 
Introduction 
Malignant progression of solid tumors is a complex process that involves the activation 
of oncogenic signaling and downregulation of tumor suppressor pathways. In addition, 
modulation of the tumor microenvironment, for example through neovascularization, 
enhances tumor cell growth and survival, promoting invasion and metastatic spread 
(reviewed in refs. [202-204]). Oncogenic conversion, amplification, or overexpression of 
protooncogenes, such as those encoding cell surface receptor tyrosine kinases (RTKs) 
like the EGF receptor family member ErbB2, are frequently observed in human cancers 
and contribute to malignancy. Other pathways, such as p53 transcription factor/genome 
surveillance factor, negatively regulate growth, and loss of these pathway components 
also contributes to tumorigenesis (reviewed in refs. [204, 205]). Recent evidence suggests 
that Eph RTKs play multiple roles in neoplastic progression, including regulation of 
processes intrinsic to tumor cells, and in the tumor microenvironment, such as tumor 
neovascularization (reviewed in refs. [69]). 
 
The Eph RTK family is the largest family of RTKs identified in the genome, with at least 
15 receptors and 9 ligands identified in vertebrates (reviewed in refs. [85, 206]). The 
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family is subdivided into class A and class B based on homology and binding affinity for 
2 distinct types of membrane-anchored ephrin ligands. Class B receptors generally bind 
to class B ephrins that are attached to the cell membrane by a transmembrane-spanning 
domain, while A class receptors normally interact with glycosyl-phosphatidylinositol–
linked class A ephrins, although interclass binding does occur among certain family 
members. These molecules function during embryogenesis to regulate angiogenic 
remodeling processes, axon guidance, and tissue boundary formation (reviewed in refs. [1, 
32]). More recently, members of this RTK family, including EPH receptor A2 (EphA2), 
have been linked to tumor progression and neovascularization (reviewed in ref. [85]).  
 
Increasing evidence suggests that EphA2 expression may be causally related to neoplasia. 
EphA2 RTK overexpression has been observed in several models of cancer, including 
primary and transplanted rodent tumors, human tumor xenografts, and primary human 
tumor biopsies (reviewed in refs. [69, 85, 207]). Experimentally induced overexpression 
of EphA2 resulted in malignant transformation of nontransformed MCF10A breast cells 
and enhanced malignancy of pancreatic carcinoma cells [74, 75]. Conversely, siRNA-
mediated inhibition of EphA2 expression impaired malignant progression of pancreatic, 
ovarian, and mesothelioma tumor cell lines, and overexpression of dominant-negative 
EphA2 constructs suppressed growth and metastasis of 4T1 metastatic mouse mammary 
adenocarcinoma cells in vivo [74, 76-78]. EphA-Fc receptor proteins that disrupt 
endogenous receptor activation significantly inhibited growth and neovascularization of 
tumors in vivo [95, 145, 208]. Coupled with the observation that EphA2 signaling 
induces phosphorylation and activation of the pro-proliferative p42/44 MAPK family 
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member Erk in tumor cell lines [209, 210], these data suggest that EphA2 functions as an 
oncogene.  
 
Other evidence, however, suggests that EphA2 may function as a tumor suppressor. 
EphA2–/– gene-trap mice displayed increased susceptibility to chemical carcinogen-
induced skin cancer compared with control littermates, along with increased tumor cell 
proliferation and phosphorylation of Erk [113]. Stimulation of EphA receptors with 
soluble ephrin-A1–Fc ligand reduced Erk phosphorylation in tumor cell lines, fibroblasts, 
and primary aortic endothelial cells and suppressed growth of primary keratinocytes and 
prostate carcinoma cells [34, 113, 116]. Macrae et al. also reported that treatment of 
human breast cancer cell lines with ephrin-A1–Fc, which stimulated EphA2 
phosphorylation, attenuated EGF-mediated phosphorylation of Erk and inhibited 
transformation of NIH3T3 cells expressing v-erbB2 [116]. In addition, EphA2 was 
reported to be a transcriptional target of the tumor suppressor p53 [211-214]. 
Overexpression of EphA2 in lung and breast cancer cell lines negatively regulated 
proliferation and induced apoptosis [211, 214]. These data suggest that EphA2 functions 
as a tumor suppressor.  
 
Given the controversy surrounding the role of EphA2 in tumorigenesis, we investigated 
the consequences of EphA2 deficiency in transgenic mouse models of endogenous 
mammary tumor formation. We chose the MMTV-Neu and MMTV–PyV-mT transgenic 
models, as they each recapitulate the numerous stages of human breast tumor formation 
and progression. In these models, the mouse mammary tumor virus (MMTV) long-
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terminal repeat drives expression of Neu, the rat homolog of ErbB2, or polyoma virus 
middle T (PyV-mT) antigen specifically in mammary gland epithelium. These models 
recapitulate multistage tumor progression in vivo in a similar fashion to that observed in 
human breast cancer, making them excellent models for analysis of endogenous tumor 
progression [215, 216]. Herein, we demonstrate that EphA2 enhanced tumor formation 
and proliferation in the context of Neu, both in vivo and in ex vivo molecular analyses of 
purified tumor cells. Host-derived EphA2 was required for maximal tumor 
vascularization in the MMTV-Neu model. Within MMTV-Neu tumor cells, maximal 
levels of Neu/ErbB2 signaling required EphA2, which promoted both tumor initiation 
and metastatic progression of MMTV-Neu–derived mammary tumors. Therapeutic 
inhibition of EphA2 impaired growth of MMTV-Neu tumors. By contrast, EphA2 
deficiency or inhibition did not affect tumor formation or progression in the MMTV–
PyV-mT model of breast cancer. These results demonstrate that the role of EphA2 in 
tumor progression is dependent upon the oncogene/tumor suppressor context within 
which it functions. Such considerations are likely to be important regarding the 
application of therapies targeting EphA2.  
 
Methods 
 
Reagents  
Antibodies against the following proteins were used: EphA2 (Zymed Laboratories, Santa 
Cruz Biotechnology, and Upstate Biotechnology); EphA4 (Upstate Biotechnology); 
PCNA (BD Biosciences); anti-Erk, anti–phosphothreonine-202/tyrosine-204 Erk, Akt, 
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and phosphoserine-473 Akt (Cell Signaling Technology); anti-tubulin (Sigma-Aldrich); 
ErbB2 (Neomarkers/Lab Vision Corporation); anti–β-actin (Santa Cruz Biotechnology); 
Ras (BD Biosciences); RhoA (Santa Cruz Biotechnology and BD Biosciences); vWF 
(Zymed Laboratories); E-cadherin (BD Biosciences); Ki67 (Vision Biosystems Inc.); and 
normal rabbit IgG (Santa Cruz Biotechnology). Therapeutic anti-EphA2 (1C1) and 
control nonspecific IgG (R347) antibodies were provided by MedImmune Inc. Raf-1 
RBD agarose Ras assay reagent was purchased from Upstate Biotechnology. BrdU was 
purchased from Sigma-Aldrich. BrdU detection and ApopTag Red In situ Apoptosis kits 
were purchased from Zymed Laboratories and Chemicon/Millipore, respectively. Avidin 
peroxidase reagents were from Vector Laboratories, and liquid 3,3′-diaminobenzidine 
tetrahydrochloride (DAB) substrate kit was from Zymed Laboratories. Ephrin-A1–Fc was 
from R&D Systems. Estrogen, progesterone, insulin, and EGF were from Sigma-Aldrich. 
DAPI was purchased from Sigma-Aldrich. TO-PRO-3 iodide nuclear stain, CellTracker 
orange CMTMR, and CellTracker green CMFDA dyes was purchased from Invitrogen. 
Growth factor–reduced Matrigel was purchased from BD Biosciences. AG825 ErbB2 
kinase inhibitor was from Calbiochem (EMD Biosciences). Recombinant adenoviruses 
expressing constitutively active RhoA (Q63L) and Erk-1 were purchased from Cell 
Biolabs and Vector Biolabs, respectively. Control adenoviruses expressing β-gal and 
adenoviruses expressing EphA2 have been previously described [94, 217]. MEK inhibitor 
U0126 was purchased from Calbiochem.  
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Mice and in vivo tumor studies 
All animals were housed under pathogen-free conditions, and experiments were 
performed in accordance with AAALAC guidelines and with Vanderbilt University 
Institutional Animal Care and Use Committee approval. EphA2–/– mice were 
backcrossed with FVB animals for 5–7 generations prior to crossing with MMTV-Neu or 
MMTV–PyV-mT mice on an inbred FVB background (Jackson Laboratories; refs. [215, 
216]). MMTV-Neu– or MMTV–PyV-mT–positive transgenic animals that were 
EphA2+/+, EphA2+/–, or EphA2–/– [94]were identified by PCR analysis of genomic 
DNA from tail biopsy using the following primers: 5′-
GGGTGCCAAAGTAGAACTGCG-3′ (forward), 5′-
GACAGAATAAAACGCACGGGTG-3′ (neo), 5′-
TTCAGCCAAGCCTATGTAGAAAGC-3′ (reverse). The neu and PyV-mT transgenes 
were detected by PCR using primers and conditions recommended by Jackson 
Laboratories. Age-matched littermates were monitored for tumor formation by weekly 
palpation.  
 
Tumors and lungs were collected from 2 cohorts of MMTV-Neu hemizygous EphA2+/+, 
EphA2+/–, and EphA2–/– animals at 8 months and 1 year after birth. Tumors and lungs 
were collected from MMTV–PyV-mT hemizygous EphA1+/+, EphA1+/–, and EphA1–/– 
animals 100 days after birth. Tumors were enumerated, and dimensions were measured 
by caliper. Tumor volume was calculated as l × w2 × 0.52, where l represents length and 
w width [218]. Lungs were fixed and dehydrated, and surface metastases were 
enumerated. For transplantation studies, the left inguinal mammary gland fat pad of 3-
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week-old recipient EphA2+/+ or EphA2–/– FVB female animals was cleared of 
endogenous epithelium as described previously [219]and injected with 106 tumor cells 
derived from MMTV-Neu [220] or MMTV–PyV-mT [221] animals. Resulting tumors 
were harvested 4–5 weeks after injection for analysis. Where indicated, beginning at 2 
weeks after tumor cell injection, recipient mice received intraperitoneal injections of 1C1 
anti-EphA2 antibody or control IgG (10 mg/kg twice weekly for 3 weeks) prior to 
collection and analysis of primary tumors. At least 10 animals per condition were 
analyzed in 2–3 independent experiments. Statistical analysis of tumor development and 
metastasis frequency was assessed by c2 test assuming that 50% of MMTV-Neu female 
mice should develop tumors within 7–8 months after birth, as was originally reported 
[216].  
 
Histologic analyses  
Mammary glands and tumors were harvested at the indicated time points and fixed in 
10% neutral buffered formalin (Fisher Scientific) for 24 hours at 4°C. Whole-mount 
hematoxylin staining of mammary glands and H&E staining of 7-µm mammary gland 
tissue sections was performed as described previously [219]. Immunohistochemical 
staining for EphA2 and PCNA was performed as described previously [95], and 
proliferation was quantified by calculating the average percentage of PCNA+ nuclei 
relative to total nuclei (4 random fields of at least 4 independent mammary and tumor 
samples per genotype; original magnification, ×20). Apoptosis assays were performed 
using the Apoptag red in situ apoptosis detection kit per the manufacturer’s protocol 
(Chemicon International). Apoptosis was calculated as the average percentage TUNEL+ 
67 
 
nuclei relative to total nuclei (4 random fields of at least 4 independent mammary and 
tumor samples per genotype; original magnification, ×20). We detected p-Erk in tissue 
sections using rabbit monoclonal anti–p-Erk antibody clone 20G11 per the 
manufacturer’s protocol (Cell Signaling Technology). Colorimetric 
immunohistochemical staining for vWF was performed by the Vanderbilt University 
Immunohistochemistry Core Facility, and immunofluorescence staining was performed 
as described previously [93]. Microvascular density was determined by counting the 
number of vWF+ vessels in 4 random fields per sample of at least 4 independent tumors 
per genotype (original magnification, ×20). ErbB2 immunohistochemistry was performed 
using 5 µg/ml rabbit anti-ErbB2 antibody (Neomarkers/Lab Vision Corporation).  
 
Cell culture  
PMECs were isolated from mice as described previously [219, 221, 222] and maintained 
in PMEC media (DMEM/F12 media [Mediatech] supplemented with 5 ng/ml estrogen, 5 
ng/ml progesterone, 5 ng/ml EGF, and 5 µg/ml insulin [Sigma-Aldrich]) on growth 
factor–reduced Matrigel–coated (1:20 dilution) tissue culture dishes. Primary tumor cells 
were derived from EphA2+/+ or EphA2–/– MMTV-Neu animals as previously described 
[220]. Enrichment of tumor cells in cultures was verified by expression of the neu 
transgene. The MMTV-Neu tumor-derived cell line [220] and the MMTV–PyV-mT 
tumor-derived cell line [221] used in transplantation and signaling studies were cultured 
in PMEC media. For EphA2 degradation studies, tumor cells were cultured in the 
presence of 1C1 anti-EphA2 antibody or control IgG (MedImmune) at the indicated 
concentrations for 48 hours prior to harvesting lysates for immunoblot analysis. In vitro 
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proliferation and apoptosis analyses were performed as described previously [95, 222] 
using BrdU and TUNEL detection kits described above. For rescue experiments, EphA2–
/– MMTV-Neu primary tumor cells were transduced with 1 × 108 pfu/ml adenovirus 
expressing Erk-1, EphA2, or control β-gal 48 hours prior to BrdU assay. For MEK 
inhibitor studies, cells were treated with 5 and 10 µM U0126 (Calbiochem) or DMSO 
vehicle control for the 12 hours during the BrdU labeling/serum stimulation time frame. 
Transwell migration assays were performed as described previously [94]. For rescue 
experiments, EphA2–/– MMTV-Neu primary tumor cells were transduced with 1 × 108 
pfu/ml adenovirus expressing constitutively active RhoA (Q63L) or control β-gal 48 
hours prior to transwell assay. Tumor-endothelial cell coculture migration assays were 
performed as described previously [92, 93].  
 
siRNA sequences for mouse EphA2 or irrelevant control sequences were cloned into 
pRetroSuper viral vector and used to produce retroviruses for infection of MMTV-Neu 
tumor cells as previously described [92, 223]. The following sequences were used to 
target EphA2: siRNA no. 1, 5′-GCCAAAGTAGAACTGCGTT-3′ (aa 1,140–1,158); 
siRNA no. 2, 5′-GCGCTAGACAAGTTCCTTA-3′ (aa 2,211–2,229); control siRNA, 5′-
GCACCAGTTCAGCAAGACT-3′. We established 3-dimensional spheroid cultures as 
described previously [224]. Cultures were maintained for 8 days prior to 
photodocumentation. Digital images were scored for spheroid culture area in 4 random 
fields, 3 cultures per field, using NIH ImageJ software. For confocal imaging, spheroid 
cultures were fixed in 10% neutral buffered formalin and subjected to 
immunohistochemistry for E-cadherin followed by nuclear staining with TO-PRO-3 as 
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previously described [225]. Tumor cells were transplanted into the cleared fat pads of 
recipient FVB mice as described above. At least 10 animals per condition were analyzed 
in 2–3 independent experiments.  
 
Parental MCF10A and MCF10A cells stably overexpressing HER2 were maintained as 
described previously [226]. We established 3-dimensional spheroid cultures as described 
previously [224]. Cells were transduced with 1 × 108pfu/ml adenovirus expressing 
constitutively EphA2 or control β-gal 48 hours prior to analysis. Staining for confocal 
analysis was performed as described above.  
 
Immunoprecipitation and immunoblot analysis  
Immunoprecipitation and immunoblot of EphA2 was performed as described previously 
[95]. ErbB2 was immunoprecipitated using 1 µg rabbit anti-ErbB2 plus 1 µg mouse anti-
ErbB2 Ab-17 (Neomarkers/Lab Vision Corporation). Where indicated, 2.5 × 105 PMECs 
(for Western analyses) or 2.5 × 106 primary tumor cells (for GTP-Ras and –Rho/Rac 
pulldown assays) were cultured in DMEM:F12 media plus 2% FBS overnight. For 
analysis of EphA2 stability, MMTV-Neu or MMTV–PyV-mT tumor cells (2.5 × 106) 
were treated with EphA2-agonist monoclonal antibody 1C1 or control IgGs at the 
indicated doses and times. Lysates were harvested and used for immunoblot analysis as 
described previously [95]. Densitometric analysis was performed using NIH ImageJ 
software.  
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For Ras and Rho/Rac pulldown assays, tumor tissue was collected, weighed, 
mechanically homogenized in PBS, pelleted, and resuspended in manufacturer-
recommended assay buffer (Upstate Biotechnology). Approximately 500 µg tumor lysate 
was used per assay. Ras assays were performed using Raf-1 Ras-binding domain–GST 
assay reagent (Upstate Biotechnology) per the manufacturer’s protocol. Rho assays were 
performed using Rhotekin-binding domain–GST reagents as previously described [78]. 
For some coimmunoprecipitation assays, COS7 cells were cotransfected with 1 µg each 
of myc-tagged erbB2 (pcDNA3-erbB2) and ephA2 (pcDNA3-EphA2) using 
Lipofectamine 2000 (Invitrogen). Cells were lysed in 1% NP-40 buffer (10 mM Tris-HCl, 
pH 7.5; 150 mM NaCl; 2 mM EDTA; and 1% NP-40 plus 50 mM protease inhibitors). 
Lysates were used for immunoprecipitation with anti-myc (Sigma-Aldrich) or anti-
EphA2 antibodies (catalog no. sc-924; Santa Cruz). Immune complexes were resolved on 
SDS-PAGE and Western blotted using anti-EphA2 or anti-myc antibodies. EphA2 was 
immunoprecipitated from MMTV-Neu cells, followed by treatment of half the samples 
with the 1 mM of the crosslinking agent DTSSP. Immunoprecipitates were subjected to 
Western blot analysis using anti-ErbB2 (1:2,000 dilution; Neomarkers). EphA2 and 
ErbB2 were immunoprecipitated from MCF10A and MCF10A.HER2 cells as described 
above. Where indicated, cells were incubated with 10 µg/ml AG825 ErbB2 kinase 
inhibitor for 24 or 48 hours prior to immunoprecipitation.  
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Statistics  
Statistical differences among groups were determined by single-factor ANOVA, by 2-
tailed, paired Student’s t test; or by χ2 test as indicated in the figure and table legends. A 
P value less than 0.05 was considered significant.  
 
Results 
 
EphA2 deficiency suppresses mammary epithelial hyperplasia, tumorigenesis, and 
metastasis in MMTV-Neu mice  
MMTV-Neu–positive female mice that were EphA2+/+, EphA2+/–, or EphA2–/– were 
generated and monitored for tumor formation. Mammary gland tissue and/or tumors were 
collected from 2 cohorts of animals 8 months and 1 year after birth. Relative to 
EphA2+/+ and EphA2+/– controls, EphA2–/– MMTV-Neu females exhibited a 
significant decrease in epithelial hyperplasias and tumors of the mammary gland with a 
2-to 3-fold reduction in frequency (Table 4). Whole-mount and histologic analysis 
revealed a reduction in mammary epithelial hyperplasia and epithelial cell content for 
EphA2–/– MMTV-Neu glands relative to controls (Figure 3.1B).  
 
To examine premalignant changes within the epithelium of EphA2–/– versus EphA2+/+ 
MMTV-Neu mammary glands, we assessed proliferation and apoptosis in tissue sections 
by staining for proliferating cell nuclear antigen (PCNA) and by TUNEL assay, 
respectively. We observed a 5.5-fold reduction in epithelial cell proliferation in the 
EphA2–/– versus the EphA2+/+ MMTV-Neu mammary epithelium, while levels of 
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Table 4. Incidence of hyperplasia, tumorigenesis, and lung metastasis frequency in mice 
8 months and 1 year after birth 
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Figure 3.1. EphA2 deficiency reduces mammary tumorigenesis, metastasis, 
proliferation, and vascularity in MMTV-Neu mice. 
 
A. Number of surface lung lesions was significantly reduced in EphA2–/– MMTV-Neu 
mice (P < 0.05; single-factor ANOVA). Data are mean ± SEM. B. Top: Whole-mount 
mammary gland preparations (8 mo) revealed diminished hyperplasia in EphA2–/– glands 
relative to controls. Shown are an EphA2+/+ gland with pervasive epithelial hyperplasia 
(left) and an EphA2+/– gland with a small tumor (arrowhead; middle). Asterisks indicate 
inguinal lymph node. Bottom: H&E-stained mammary gland sections (8 mo) reveal 
reduced epithelial cell content in EphA2–/– MMTV-Neu tissue samples relative to 
controls. Scale bar: 250 µm. C. Top: Mammary epithelial proliferation (PCNA+ nuclei; 
arrowheads), was significantly reduced (P < 0.05; 2-tailed, paired Student’s t test). Scale 
bar: 50 µm. Bottom: Mammary epithelial apoptosis (TUNEL+ nuclei; arrowheads) was 
not affected. D. Top: Proliferation of primary mammary epithelial cells from EphA2–/– 
animals (BrdU incorporation; arrowheads) was reduced relative to EphA2+/+ cells (P < 
0.05; 2-tailed, paired Student’s t test). Bottom: Apoptosis (TUNEL+ nuclei; arrowheads) 
was significantly increased in EphA2–/– primary mammary epithelial cells relative to 
controls (P < 0.05; 2-tailed, paired Student’s t test). Scale bar: 20 µm. E. H&E-stained 
tumor sections (1 yr) demonstrate increased cystic degeneration and lumen formation in 
EphA2–/– tumors. Scale bar: 250 µm. F. Decreased tumor cell proliferation (PCNA+ 
nuclei; arrowheads) was observed for EphA2–/– MMTV-Neu tumors compared with 
controls (P < 0.05; single-factor ANOVA). Scale bar: 50 µm. G. Microvascular density 
(CD31+ vessels; arrowheads) was significantly reduced in EphA2–/– MMTV-Neu tumors 
relative to controls (P < 0.05; single-factor ANOVA). Scale bar: 100 µm.  
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apoptosis were unaffected (Figure 3.1C). To determine whether proliferation defects were 
due to EphA2 deficiency in mammary epithelium versus surrounding host tissue, we 
analyzed proliferation and apoptosis in purified primary mammary epithelial cells 
(PMECs) isolated from EphA2+/+ or EphA2–/– animals. Proliferation, as measured by 
incorporation of BrdU, was reduced nearly 3-fold in serum-stimulated EphA2–/– cells 
relative to EphA2+/+ controls (Figure 3.1D), suggesting that EphA2-mediated effects on 
proliferation are, at least in part, intrinsic to the epithelial cell. Interestingly, unlike 
mammary epithelium in situ, we observed a modest yet significant increase in apoptosis 
for EphA2–/– versus EphA2+/+ PMECs (Figure 3.1D). Together, these data indicate that 
loss of EphA2 inhibits ErbB2-initiated mammary epithelial cell hyperplasia.  
 
Among the EphA2–/– animals that actually developed tumors, no significant change in 
time of tumor onset was observed. However, we detected a nearly 3-fold decrease in 
tumor volume in EphA2–/– relative to EphA2+/+ mice (data not shown). In addition, 
EphA2+/+ and EphA2+/– controls displayed a higher overall tumor burden relative to 
EphA2–/– mice, as control animals developed 2 or more tumors 1 year after birth while 
EphA2–/– animals developed single tumors. At 1 year of age, lungs harvested from 
EphA2–/– MMTV-Neu mice displayed a nearly 5-fold reduction in the number of surface 
metastases compared with EphA2+/+ or EphA2+/– controls (Figure 3.1A). Moreover, the 
overall frequency of metastasis was decreased in EphA2–/– animals relative to EphA2+/+ 
and EphA2+/– controls (Table 4).  
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Histologic examination of tumors collected from each genotype 8 months after birth 
disclosed mainly well-circumscribed proliferations of invasive carcinoma with broad 
pushing, rather than infiltrating, borders. More infiltrative-appearing carcinomas were 
seen in animals 1 year after birth. Tumors isolated from EphA2–/– MMTV-Neu mice 
showed more areas of cystic degeneration and occasional lumen formation, suggestive of 
a more differentiated phenotype relative to the dense, solid sheet-like growth patterns 
seen in EphA2+/+ MMTV-Neu tumors (Figure 3.1E). PCNA staining of tumor tissue 
revealed a nearly 2-fold decrease in proliferation in EphA2–/– relative to EphA2+/+ 
MMTV-Neu tumors (Figure 3.1F). The tumor microvasculature was evaluated by 
immunohistochemical staining against vWF, which demonstrated that loss of EphA2 
expression was associated with a significant 2.9-fold reduction in microvascular density 
(Figure 3.1G). Levels of apoptosis were unaltered in EphA2–/– MMTV-Neu tumors 
compared with controls (data not shown). These data suggest that EphA2 is required for 
both mammary tumor initiation and progression.  
 
EphA2 is required in the host microenvironment for vascular recruitment in MMTV-Neu 
tumors 
While the data presented herein suggest that EphA2 deficiency restrains epithelial 
proliferation in MMTV-Neu mammary glands, previously reported data suggest that 
EphA2 may be required for tumor vascularization (reviewed in ref. [85]). Indeed, 
decreased tumor vascularization was observed in EphA2–/– MMTV-Neu tumors (Figure 
3.1G). To determine whether the defects in tumor microvascular density result from 
EphA2 deficiency in host tissue versus tumor cells, we orthotopically transplanted 
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Figure 3.2. Vascular defects observed in MMTV-Neu/EphA2-deficient tumors are 
due in part to loss of EphA2 expression in host endothelium.  
 
A. Tumor cells derived from MMTV-Neu animals were orthotopically transplanted into 
cleared mammary fat pads wild-type or EphA2-deficient FVB host animals. Relative to 
wildtype controls, we observed a significant decrease in tumor volume in tumors 
collected from EphA2-deficient host animals 5 weeks after transplantation (p<0.05; 
single factor ANOVA). B. Consistent with previous studies, we observed significantly 
reduced (p<0.05; ANOVA) microvascular density in tumors isolated from EphA2-
deficient hosts versus wild-type controls based on quantification of vWF 
immunofluorescence (arrowheads indicate vWF+ blood vessels). Scale bar = 100 µm. C. 
To determine if the defects observed in vascular recruitment were due to loss of EphA2 
expression in host endothelium, we performed tumor cell-endothelial cell co-culture 
migration assays (see diagram). Wild-type MMTV-Neu tumor cells labeled with a green 
fluorescent marker were seeded on the lower surface of a Matrigel-coated transwell. 
Endothelial cells derived from wild-type or EphA2-deficient animals were labeled with a 
red fluorescent dye and added to the upper chamber of the transwell and recruitment of 
endothelial cells to the lower surface by tumor-derived signals was measured. After 5 
hours, we observed significantly fewer (p<0.05; 2-tailed, paired student’s T-test) EphA2-
deficient endothelial cells on the lower surface of the transwell than control wild-type 
endothelial cells (arrows indicate endothelial cells that migrated to the lower surface of 
the transwell). 
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EphA2+/+ MMTV-Neu tumor cells into the cleared fat pads of syngeneic EphA2+/+ or 
EphA2–/– FVB host animals. EphA2+/+ tumor cells transplanted into EphA2–/– hosts 
produced significantly smaller tumors than those transplanted into EphA2+/+ hosts 
(Figure 3.2A). We also observed a 7-fold decrease in microvascular density of tumors 
isolated from EphA2–/– versus EphA2+/+ recipients (Figure 3.2B). Consistent with these 
data, microvascular endothelial cells isolated from EphA2–/– animals displayed a 
markedly decreased migratory response to MMTV-Neu tumor cells in coculture assays 
compared with the robust migratory response exhibited by endothelial cells isolated from 
EphA2+/+ mice (Figure 3.2C). Together, these data suggest that EphA2 signaling 
promotes tumorigenesis and progression through distinct processes both in the tumor 
microenvironment, including vascular endothelium, and within tumor cells.  
 
Loss of EphA2 expression impairs tumor formation and invasiveness in MMTV-Neu 
tumor cells  
In addition to analysis of EphA2 function in tumor initiation and progression within 
endogenous MMTV-Neu tumors in which EphA2 deficiency precedes tumorigenesis, we 
examined the effects of diminishing EphA2 expression in established tumor cells. Using 
an RNAi knockdown strategy in an established cell line derived from an MMTV-Neu 
tumor, stable expression of 2 independent siRNA sequences significantly reduced EphA2 
expression in MMTV-Neu cells relative to parental cells and cells expressing control 
siRNA (Figure 3.3A). Pooled populations of cells in which EphA2 expression was 
diminished displayed slower growth rates than parental or control siRNA-expressing cells 
(data not shown). Consistent with the diminished growth rates, inhibition of EphA2 
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Figure 3.3. Loss of EphA2 expression impairs tumor formation and invasiveness in 
MMTV-Neu tumor cells. 
 
A. EphA2 expression was significantly diminished in MMTV-Neu tumor cells 
transduced with retroviruses expressing EphA2 siRNA sequences versus control siRNAs. 
Erk phosphorylation was reduced upon EphA2 knockdown. B. Parental and control 
siRNA tumor cells formed large, irregularly shaped clusters with invasive protrusions 
(arrowheads) when cultured on Matrigel, whereas EphA2 siRNA–expressing cells 
formed smaller clusters with a rounded morphology and few protrusions, indicative of 
reduced invasiveness. Scale bar: 200 µm (top), 50 µm (bottom). We observed a 
significant decrease in colony size, as determined by calculating the average pixel area 
occupied by individual colonies, for cells expressing EphA2 siRNA relative to controls 
(P < 0.05; single-factor ANOVA). C. Cultures stained with TO-PRO-3 iodide nuclear 
stain (blue) and anti–E-cadherin (green) were imaged by confocal microscopy. Control 
tumor cells formed multiacinar structures with invasive protrusions (arrowheads), 
whereas tumor cells expressing EphA2 siRNA sequences formed round, uniform acinar 
structures composed of a single layer of epithelial cells surrounding a central lumen 
(arrows). Scale bar: 20 µm. D. Upon orthotopic transplantation into cleared fat pads of 
FVB recipient female mice, tumor cells expressing control siRNA sequences produced 
tumors of comparable volume to those generated by transplantation of parental cells at 5 
weeks. Tumor cells expressing EphA2 siRNA sequences, however, either failed to form 
tumors or formed very small, nonpalpable tumors in a small fraction of animals (P < 0.05; 
single-factor ANOVA). Data are mean ± SEM.  
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expression by siRNA correlated with diminished levels of p-Erk, a known regulator of 
proliferation in the MMTV-Neu model (reviewed in ref. [227]), in EphA2 siRNA clones 
(Figure 3.3A). Parental MMTV-Neu cells and cells transduced with the control siRNA 
formed large, multiacinar structures and failed to form lumens in 3-dimensional Matrigel 
culture, consistent with previous descriptions of the effects of ErbB2 activity on 3-
dimensional cultures of human MCF10A cells [228]. In contrast, diminished EphA2 
expression impaired the ErbB2/Neu-driven multiacinar phenotype of the MMTV-Neu 
cells in 3-dimensional culture. Instead, these cells primarily formed small, organized 
acini composed of epithelial cells surrounding a single central lumen (Figure 3.3B and C). 
Furthermore, the size of individual 3-dimensional colonies formed by control cells was 3- 
to 4-fold greater than cells with decreased EphA2 expression (Figure 3.3B). While 
MMTV-Neu parental cells or cells expressing control siRNAs formed tumors when 
orthotopically transplanted in the cleared fat pads of FVB recipient female mice, MMTV-
Neu cells with diminished EphA2 expression failed to establish tumors or formed very 
small, nonpalpable tumors in a small percentage of animals (Figure 3.3D). These data 
suggest that EphA2 activity is required for tumor cell–intrinsic growth and invasiveness 
in the context of the ErbB2/Neu oncogene.  
 
Elevated EphA2 expression augments growth and invasiveness of MCF10A cells 
overexpressing human ErbB2 
To determine whether EphA2 enhances ErbB2-mediated growth and invasiveness in 
human cells, we overexpressed EphA2 in both nontransformed MCF10A human 
mammary epithelial cells and in MCF10A cells that stably express the human homolog of 
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Figure 3.4. Elevated EphA2 expression in MCF10A.HER2 cells enhances cell 
proliferation and invasiveness in vitro.  
 
A. Parental MCF10A human breast cells and MCF10A.HER2 cells were transduced with 
adenoviruses (Ad) expressing EphA2 or control β-gal and plated on growth factor–
reduced Matrigel to generate 3-dimensional spheroid cultures. After 10 days in culture, 
parental MCF10A cells and cells expressing Ad–β-gal formed small, round acinar 
structures, while MCF10A.HER2 cells formed larger colonies with irregular, invasive 
protrusions (arrows). Expression of Ad-EphA2 in MCF10A cells resulted in larger, 
irregular colonies, an effect that was amplified in MCF10A.HER2 cells (P < 0.05; single-
factor ANOVA). Scale bar: 25 µm. B. Cultures were stained with TO-PRO-3 iodide 
nuclear stain (red) and anti-Ki67 (green) and imaged by confocal microscopy. Confocal 
analysis revealed that parental and Ad–β-gal–transduced MCF10A formed uniform 
acinar structures composed of a single layer of epithelial cells surrounding a central 
lumen, while MCF10A.HER2 cells formed multiacinar structures with invasive 
protrusions (arrows) and a poorly defined lumen containing several cells. MCF10A cells 
transduced with Ad-EphA2 also formed multiacinar structures with a poorly defined 
lumen. Invasion and lumen filling were enhanced in MCF10A.HER2 cells 
overexpressing EphA2. Scale bar: 20 µm. EphA2 overexpression significantly enhanced 
proliferation (Ki67+ nuclei, arrows) within acinar structures formed by MCF10A and 
MCF10A.HER2 cells (P < 0.05; single-factor ANOVA). C. Expression of adenoviral 
gene products and overexpression of ErbB2/HER2 in MCF10A.HER2 cells was 
confirmed by immunoblot, and uniform loading was verified by immunoblot for actin. 
Expression of p-Erk, total Erk, p-EphA2, and total EphA2 was also assessed by 
immunoblot.  
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ErbB2 (HER2; ref. [226]) by adenoviral transduction. Consistent with previous studies 
[74], overexpression of EphA2 enhanced growth, as we observed increased colony size 
in3-dimensional Matrigel culture (Figure 3.4A). Relative to parental MCF10A, HER2-
overexpressing (MCF10A.HER2) cells formed larger, multiacinar structures that failed to 
form lumens in 3-dimensional Matrigel culture (Figure 3.4A), consistent with previous 
reports [226, 228]. Overexpression of EphA2 by adenoviral transduction in 
MCF10A.HER2 cells led to a 2-fold increase in the size of individual colonies relative to 
untransduced controls or cells transduced with adenovirus expressing β-gal (Figure 3.4A). 
In addition, there was an increase in lumen filling and invasive protrusions in acinar 
structures formed by MCF10A and MCF10A.HER2 cells upon overexpression of EphA2, 
as assessed by confocal microscopy (Figure 3.4B). Quantification of nuclear Ki67 
revealed that overexpression of EphA2 in MCF10A and MCF10A.HER2 cells increases 
proliferation nearly 3-fold compared with levels observed in control cells (Figure 3.4B). 
Overexpression of HER2 in MCF10A.HER2 cells, as well as expression of adenoviral 
gene products, was confirmed by immunoblot (Figure 3.4). Increased p-Erk levels in cells 
overexpressing HER2, and to a greater extent cells overexpressing both HER2 and 
EphA2, correlated with increased levels of proliferation in culture (Figure 3.4C). These 
data suggest that EphA2 enhances mammary epithelial proliferation and invasion and 
augments growth and invasive properties induced by ErbB2/HER2 in human breast 
epithelial cells. 
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Figure 3.5. EphA2 is required for Ras/Erk activation and proliferation in the 
context of Neu/ErbB2-mediated neoplasia. 
 
A. Proliferation of PMTCs isolated from EphA2–/– animals, as assessed by nuclear 
incorporation of BrdU (arrowheads), was reduced relative to EphA2+/+ cells. For rescue 
experiments, PMTCs were transduced with adenoviruses expressing EphA2 or β-gal 48 
hours prior to BrdU incorporation assay. Overexpression of EphA2 significantly elevated 
serum-induced proliferation relative to control (P < 0.05; 2-tailed, paired Student’s t test). 
Scale bar: 20 µm. Expression of adenoviral transgenes was confirmed by immunoblot. B. 
Ras activity in unstimulated cells, as measured by effector pulldown assay of GTP-bound 
Ras by GST-Raf Ras-binding domain, was reduced in EphA2–/– PMTCs relative to 
control, as was Erk phosphorylation. Uniform loading was confirmed by immunoblotting 
for total Ras/Erk and actin. EphA2 deficiency and uniform expression of Neu/ErbB2 was 
confirmed by effector pulldown assay and immunoblotting for EphA2 and ErbB2. EphA2 
was phosphorylated in unstimulated EphA2+/+ tumor cells, and no changes in ErbB2 
phosphorylation were detected in EphA2+/+ versus EphA2–/– PMTCs. C. Diminished Ras 
and Erk activity were confirmed in whole tumor extracts isolated from 3 independent 
EphA2+/+ or EphA2–/– tumors. D. For rescue experiments EphA2–/– PMTCs were 
transduced with adenoviruses expressing Erk-1 or control βgal. Overexpression of Erk-1 
in EphA2–/– PMTCs significantly elevated serum-induced proliferation relative to control 
(P < 0.05, EphA2–/– Ad–β-gal versus EphA2+/+ or EphA2–/– Ad-Erk-1; single-factor 
ANOVA). Expression of adenoviral transgenes was confirmed by immunoblot. E. 
Treatment of EphA2+/+ PMTCs with the MEK inhibitor U0126 for 12 hours significantly 
inhibited serum-induced proliferation relative to vehicle control (P < 0.05, 5- and 10-µM 
U0126 versus vehicle). Inhibition of Erk phosphorylation by U0126 was confirmed by 
immunoblot.  
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EphA2 promotes activation of Ras/MAPK and tumor cell proliferation  
To examine the specific EphA2 signaling events intrinsic to the breast epithelial cells that 
regulate proliferation, we purified MMTV-Neu hyperplastic PMECs and primary 
mammary tumor cells (PMTCs) from EphA2–/– and EphA2+/+ mice. EphA2–/– tumor 
cells expressed no detectable levels of EphA2, but ErbB2 expression or phosphorylation 
was not affected in these cells (Figure 3.5B), suggesting that EphA2 did not regulate 
ErbB2 expression or activity. Both PMECs and PMTCs that were EphA2–/– exhibited a 
decrease in proliferation relative to that in EphA2+/+ cells (Figure 3.5A and Figure 3.1D), 
and the proliferation defect was rescued by restoring EphA2 expression (Figure 3.5A). 
While there were no significant changes in levels of p-src, p-stat5, p–cyclin-D1, or p-
PLCγ (data not shown), levels of p-Erk and active GTP-bound Ras were significantly 
diminished in EphA2–/– relative to EphA2+/+ cells (Figure 3.5B). Similarly, there was a 
substantial reduction in Erk and Ras activity in whole tumor lysates from EphA2–/– 
animals compared with tumors from EphA2+/+ MMTV-Neu mice (Figure 3.5C). 
Overexpression of exogenous Erk-1 rescued proliferation defects in EphA2–/– PMTCs 
relative to cells expressing control β-gal (Figure 3.5D), suggesting that modulation of 
Ras/Erk signaling is a primary mechanism through which EphA2 affects Neu-mediated 
tumor growth. Treatment of EphA2+/+ PMTCs with the MEK inhibitor U0126 
significantly impaired proliferation. As MEK activates Erk in response to activation of 
Ras, these data confirm that Ras/MEK/Erk pathway activation regulates growth in these 
cells (Figure 3.5E). 
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Figure 3.6. EphA2 is required for RhoA activation and tumor cell migration in the 
context of Neu/ErbB2-mediated malignancy. 
 
A. EphA2–/– PMTCs displayed significantly reduced migration in response to growth 
media supplemented with 10% serum compared with EphA2+/+ PMTCs in transwell 
migration assays (P < 0.05; 2-tailed, paired Student’s t test). B. RhoA activity, as 
measured by effector pulldown assay of GTP-bound RhoA in tumor cell lysates and in 
whole tumor extracts by GST-Rhotekin Rho-binding domain, was reduced in EphA2–/– 
PMTCs and intact tumors relative to EphA2+/+ cells and tumors. We also observed a 
decrease in total RhoA protein levels in EphA2–/– MMTV-Neu tumor cells and in whole 
tumor extracts relative to EphA2+/+ controls. We observed no change in GTP-bound, 
activated Rac, or total Rac protein levels in tumor cell lysates from EphA2–/– or EphA2+/+ 
PMTCs. C. For rescue experiments, EphA2–/– MMTV-Neu primary tumor cells were 
transduced with adenoviruses expressing constitutively active RhoA (Q63L) or control β-
gal 48 hours prior to migration assay. Expression of constitutively active RhoA restored 
serum-induced migration of EphA2–/– tumor cells to levels comparable to those observed 
in tumor cells derived from EphA2+/+ animals, while control β-gal had no effect (P < 0.05, 
EphA2–/– Ad–β-gal versus EphA2+/+ and EphA2–/– Ad-Rho; single-factor ANOVA). 
Expression of adenoviral transgenes was confirmed by immunoblot assays.  
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EphA2 promotes tumor cell migration through activation of RhoA GTPase  
To dissect the mechanisms by which EphA2 promotes tumor metastasis, we analyzed 
motility of MMTV-Neu tumor cells in the context of EphA2 deficiency using a transwell 
migration assay. EphA2–/– MMTV-Neu tumor cells displayed a 1.5-fold decrease in 
serum-stimulated migration relative to EphA2+/+ cells (Figure 3.6A). Because 
expression and activity of Rho family small GTPases are integral components of 
signaling pathways that regulate cell migration, we sought to determine whether EphA2 
regulates tumor cell motility through a Rho-dependent mechanism. Diminished levels of 
active GTP-bound RhoA were present in both EphA2–/– tumors and in purified EphA2–
/– PMTCs relative to EphA2+/+ controls (Figure 3.6B). EphA2–/– tumor cells also 
displayed a decrease in total RhoA protein expression. In contrast, there were no 
detectable changes in levels of activated Rac1 under our experimental conditions. To 
determine whether activation of RhoA mediates EphA2-dependent cell migration, we 
expressed a constitutively active RhoA in EphA2–/– MMTV-Neu tumor cells. While 
expression from a control adenovirus expressing β-gal had no effect on migration in 
EphA2–/– PMTCs, expression of exogenous activated RhoA restored migration to levels 
similar to those of EphA2+/+ control cells (Figure 3.6C). These findings suggest that 
RhoA activation contributes to EphA2-mediated tumor cell migration. 
 
While Rho family GTPases, including RhoA, have also been shown to regulate cell cycle 
progression [229, 230], expression of constitutively active RhoA did not rescue 
proliferation in EphA2–/– PMTCs to the levels observed in control cells (data not shown), 
suggesting that RhoA activation specifically contributes to EphA2-mediated tumor cell 
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Figure 3.7. EphA2 physically and functionally interacts with ErbB2. 
 
A. COS7 cells were transfected with plasmids for expression of EphA2 or/and ErbB2. 
EphA2 or ErbB2 was immunoprecipitated from cell lysates, and products were analyzed 
for ErbB2 or/and EphA2. Coexpression of EphA2 and ErbB2 was sufficient to permit 
coimmunoprecipitation. B. Endogenous ErbB2 and EphA2 were coimmunoprecipitated 
with anti-EphA2 or anti-ErbB2 antibodies, respectively, in EphA2+/+ MMTV-Neu tumor 
cells that were untreated or treated with the chemical crosslinker DTSSP. The interaction 
detected was specific: EphA2 and ErbB2 were not immunoprecipitated by control IgG. 
Uniform input was validated by probing lysates for expression of EphA2 and ErbB2. C. 
COS7 cells were transfected with plasmids for expression of EphA2 or ErbB2. EphA2 
was immunoprecipitated from cell lysates, and products were analyzed for EphA2 
expression and tyrosine phosphorylation. Coexpression of ErbB2 and EphA2 was 
sufficient to induce phosphorylation of EphA2 in COS7 cells in the absence of ephrin 
ligand stimulation. D. Interaction between EphA2 and HER2 in MCF10A cells 
overexpressing HER2 was observed, as EphA2 and HER2 were coimmunoprecipitated 
with anti-EphA2 antibodies in HER2-overexpressing cells, but not in parental MCF10A 
cells. Elevated EphA2 phosphorylation was observed in MCF10A cells overexpressing 
HER2 relative to parental MCF10A cells, and treatment with the ErbB2 kinase inhibitor 
AG825 reduced EphA2 phosphorylation as well as ErbB2 phosphorylation in MCF10A 
cells overexpressing HER2.  
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migration rather than growth. Conversely, we did not observe any change in migration of 
EphA2–/– PMTCs upon overexpression of Erk-1 (data not shown). These data suggest 
that proliferation and motility are regulated separately by Erk-1 and Rho, respectively, in 
the context of ErbB2/EphA2-mediated tumor progression.  
 
EphA2 physically and functionally interacts with ErbB2 
To investigate the molecular mechanism(s) by which EphA2 modulates Neu/ErbB2-
mediated proliferation and invasiveness, biochemical studies were performed to assess 
physical interaction between EphA2 and ErbB2 in COS7 cells overexpressing both 
proteins and between endogenous proteins in MMTV-Neu–derived PMTCs. We detected 
the presence of ErbB2 in EphA2 immunoprecipitates, and EphA2 in ErbB2 
immunoprecipitates, in lysates from COS7 cells overexpressing the human isoforms of 
EphA2 and ErbB2 (Figure 3.7A). Coimmunoprecipitation analysis of endogenous 
proteins from PMTCs also confirmed that ErbB2 formed a complex with EphA2 (Figure 
3.7B). In both PMTCs and COS7 cells, EphA2 and ErbB2 were expressed at high levels, 
and the EphA2/ErbB2 interaction occurred constitutively in the absence of ligand 
stimulation (Figure 3.7C). Strikingly, coexpression of ErbB2 and EphA2 in COS7 cells 
was sufficient to induce tyrosine phosphorylation of EphA2 in the absence of ligand or 
serum stimulation (Figure 3.7C). Likewise, elevated EphA2 phosphorylation was 
observed in MCF10A.HER2 cells overexpressing ErbB2 relative to parental MCF10A 
cells (Figure 3.7D). Consistent with coexpression data in COS7 cells, treatment with an 
ErbB2 kinase inhibitor diminished EphA2 phosphorylation as well as HER2 
phosphorylation in MCF10A.HER2 cells (Figure 3.7D). Given evidence for physical 
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interaction between ErbB2 and EphA2 and the functional requirement of EphA2 
expression for maximal activation of signaling pathways downstream of ErbB2, these 
data suggest that that EphA2 participates in ErbB2 signaling.  
 
EphA2 deficiency has no impact on tumor progression, angiogenesis, or metastasis in 
MMTV–PyV-mT transgenic animals 
To assess EphA2 function in an independent endogenous model of mammary 
tumorigenesis that is also dependent upon the Ras/MAPK pathway, we crossed MMTV–
PyV-mT mice with EphA2–/– mice. These animals were used to generate MMTV–PyV-
mT mice that were EphA2+/+, EphA2+/–, or EphA2–/–. Virgin female mice were 
monitored for tumor formation through 100 days. Despite confirmed loss of EphA2 
deficiency in the MMTV–PyV-mT model (Figure 3.8A and C), EphA2 deficiency did not 
affect rate of tumor formation, tumor volume, number of surface lung lesions (data not 
shown), or microvascular density (Figure 3.8B). Additionally, there were no differences 
in levels of total Ras, active GTP-bound Ras, p-Erk, or total Rho in MMTV–PyV-mT 
tumors derived from EphA2+/+ versus EphA2–/– mice (Figure 3.8C). These findings are 
in striking contrast to the effects of EphA2 deficiency observed in the MMTV-Neu model. 
These data suggest that, in marked contrast to the MMTV-Neu model, EphA2 does not 
affect tumor initiation, metastasis, or vascular density in the MMTV–PyV-mT model, nor 
does loss of EphA2 affect the signaling pathways that contribute to these aspects of tumor 
progression in this model. 
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Figure 3.8. EphA2 deficiency does not affect tumorigenesis, microvascular density, 
or growth regulatory signaling pathways in MMTV–PyV-mT tumors. 
 
A. Loss of EphA2 protein expression was confirmed by immunohistochemical staining. 
Scale bar: 50 µm. B. We detected no change in MMTV–PyV-mT tumor microvascular 
density based on vWF staining (arrows indicate vWF+ blood vessels). Scale bar: 100 µm. 
C. We did not observe any change in levels of GTP-bound active Ras or p-Erk in EphA2–
/– MMTV–PyV-mT whole tumor extracts relative to controls, nor did we observe any 
change in levels of RhoA. Uniform loading was confirmed by immunoblotting for total 
Ras, total Erk, and tubulin. D. We observed EphA2 overexpression and elevated 
phosphorylation in MMTV-Neu and MMTV–PyV-mT tumors relative to normal 
mammary tissue isolated from control FVB mice, with the highest levels observed in 
MMTV-Neu tumors. We also observed overexpression of ErbB2 and ephrin-A1 in both 
tumor types, with comparable ephrin-A1 expression in both tumor types and higher 
ErbB2 levels in MMTV-Neu tumors. Uniform loading was confirmed by immunoblot for 
actin. E. We confirmed EphA2 overexpression specifically in epithelium by comparing 
EphA2 levels in PMEC lysates versus PMTCs derived from MMTV-Neu and MMTV–
PyV-mT mice.  
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We next assessed expression and activation of EphA2 in normal mammary tissue isolated 
from FVB female mice, in MMTV-Neu and MMTV–PyV-mT tumor tissue, and in 
PMECs and PMTCs isolated from both MMTV-Neu and MMTV–PyV-mT animals. 
EphA2 was overexpressed and phosphorylated in tumor tissue derived from both 
MMTV-Neu and MMTV–PyV-mT models compared with normal mammary tissue.  
 
Furthermore, expression of ephrin-A1 ligand was elevated in tumor lysates from both 
models compared with normal mammary tissue (Figure 3.8C and D). Levels of ephrin-A1 
were comparable in EphA2+/+ and EphA2–/– tumor lysates (Figure 3.8C and D). 
Notably, however, levels of both total EphA2 and p-EphA2 were higher in MMTV-Neu 
tumors compared with MMTV–PyV-mT tumors (Figure 3.8D). EphA2 overexpression 
was detected specifically in tumor cells and not in non-neoplastic epithelial cells (Figure 
3.8E). While ErbB2 overexpression has been previously reported in MMTV–PyV-mT 
tumors [231] and was also observed in our tumor lysates, MMTV-Neu tumors displayed 
a much higher level of ErbB2 overexpression (Figure 3.8D). The evidence therefore 
suggests that EphA2 augments ErbB2/Neu-mediated signaling and that increased 
expression of EphA2 may be a mechanism by which ErbB2 signaling pathways are 
amplified in tumors.  
 
Anti-EphA2 therapy shows efficacy in the MMTV-Neu tumor model 
To determine whether MMTV-Neu tumors are responsive to targeted anti-EphA2 therapy 
in vivo, we transplanted wild-type MMTV-Neu tumor cells into the cleared fat pads of 
wild-type FVB recipient animals. At 2 weeks after transplantation, animals were injected 
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Figure 3.9. Treatment with an anti-EphA2 antibody inhibits tumor growth in 
MMTV-Neu but not MMTV–PyV-mT tumors. 
 
A. Treatment with anti–murine EphA2 antibody diminished EphA2 protein expression in 
tumor cells derived from MMTV-Neu and MMTV–PyV-mT mice. Tumor cells were 
treated with control IgG (10 µg/ml) or increasing concentrations of anti-EphA2 antibody 
for 48 hours. Uniform loading was confirmed by immunoblot for actin. Blots were 
stripped and reprobed with anti-EphA4 antibodies as a control for antibody specificity. B. 
Cells derived from EphA2+/+ MMTV-Neu mice were orthotopically transplanted into the 
cleared fat pads of female FVB recipient mice. At 2 weeks following transplantation, 
mice were injected intraperitoneally with anti-EphA2 antibody or control IgG (10 mg/kg) 
twice weekly for 3 weeks. We observed a significant reduction in tumor volume in anti-
EphA2–treated animals relative to control IgG–treated mice (P < 0.05; 2-tailed, paired 
Student’s t test). Data are mean ± SEM. C. Tumor cell proliferation was significantly 
impaired in anti-EphA2–treated animals relative to controls (P < 0.05; single-factor 
ANOVA; arrowheads indicate PCNA+ nuclei). Scale bar: 50 µm. D. EphA2 expression 
was significantly diminished in anti-EphA2–treated tumors relative to IgG controls, as 
assessed by immunohistochemistry and immunoblot. Blots were stripped and reprobed 
for actin expression to verify uniform loading. Scale bar: 50 µm. E. We observed 
significantly reduced (P < 0.05; 2-tailed, paired Student’s t test) microvascular density in 
tumors isolated from anti-EphA2–treated mice relative to controls (arrowheads indicate 
vWF+ blood vessels). Scale bar: 100 µm. (F) Cells derived from MMTV–PyV-mT mice 
were orthotopically transplanted in the cleared fat pad of FVB female recipient mice and 
were treated with anti-EphA2 antibody or control IgG as described above. We observed 
no change in tumor volume between animals treated with anti-EphA2 antibody relative to 
control IgG-treated mice.  
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intraperitoneally twice weekly for 3 weeks with either control IgG or an anti-EphA2 
antibody that targets murine EphA2 for degradation (Figure 3.9A). The anti-EphA2 
antibody specifically targeted EphA2, as expression of the related receptor EphA4 was 
unaffected in antibody-treated tumor cells derived from MMTV-Neu and MMTV–PyV-
mT animals (Figure 3.9A). MMTV-Neu tumors harvested from anti-EphA2–treated 
animals displayed a 3-fold reduction in tumor volume relative to tumors isolated from 
IgG-treated mice (Figure 3.9B). In addition, tumor cell proliferation was significantly 
decreased in anti-EphA2–treated animals relative to controls, as determined by 
quantifying nuclear PCNA staining (Figure 3.9C). As predicted, EphA2 protein levels 
were significantly reduced in anti-EphA2–treated tumors relative to control IgG–treated 
tumors, as assessed by immunohistochemistry and immunoblot (Figure 3.9D), although 
downregulation of EphA2 expression did not affect expression of ErbB2 in anti-EphA2–
treated tumors, nor did control IgG treatment affect ErbB2 expression in tumors (data not 
shown). We also observed a significant reduction in microvascular density in tumors 
harvested from anti-EphA2–treated animals relative to those treated with control IgG 
(Figure 3.9E). In contrast to these results, anti-EphA2 treatment had no effect on tumor 
volume (Figure 3.9F) in animals transplanted with MMTV–PyV-mT tumors in spite of 
downregulated levels of EphA2 protein in anti-EphA2-treated tumors. These data suggest 
that the efficacy of anti-EphA2 therapy depends upon the oncogene context in which 
tumor progression occurs, as treatment of MMTV–PyV-mT tumor-bearing animals did 
not affect tumor progression as in MMTV-Neu tumor-bearing mice in spite of EphA2 
overexpression in both tumor models.  
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Discussion 
 
Role of EphA2 in ErbB2-driven mammary tumor initiation and metastatic progression 
The role of EphA2 in breast tumor progression has remained controversial, based on 
discrepancies among individual studies. For example, recent screens of RTK expression 
in tumors revealed that EphA2 RTK is overexpressed in a variety of human epithelial 
cancers, including more than 80% of breast cancer clinical samples [232]. While these 
studies did not discriminate between stromal cell–intrinsic versus tumor cell–intrinsic 
EphA2 expression, they clearly demonstrated a correlation between EphA2 expression 
and breast cancer progression. In contrast, some initial studies suggested that EphA2 does 
not play a role in tumor initiation, including reports indicating that stimulation of tumor 
cells with soluble ephrins does not promote, and may even inhibit, MAPK activation and 
tumor cell proliferation [34, 113, 116]. In addition, the majority of previous in vivo 
studies regarding EphA2 function in tumor progression involved tumor xenograft models 
that do not recapitulate endogenous tumor initiation and progression [74, 76-78] [95, 98, 
208, 233]. To provide a comprehensive examination of the role of EphA2 in the multiple 
stages of mammary tumorigenesis, we generated EphA2–/– MMTV-Neu mice. We chose 
the MMTV-Neu model because the mammary epithelium progresses from hyperplasia to 
carcinoma in situ and to invasive and metastatic carcinoma in a stepwise manner is 
similar to that seen in ErbB2-overexpressing human breast cancers [216]. EphA2–/– 
MMTV-Neu female mice exhibited a reduction in mammary epithelial hyperplasia and 
developed tumors with reduced frequency secondary to a significant reduction in 
epithelial cell proliferation (Figure 3.1), consistent with a role for EphA2 in the earliest 
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stages of breast cancer formation. This proliferation defect was, at least in part, intrinsic 
to epithelial cells, as BrdU incorporation was also reduced in primary mammary 
epithelial cells and tumor cells isolated from EphA2–/– animals relative to controls 
(Figures 3.1 and 3.5). Taken together, these results suggest that EphA2 is required for 
mammary tumor onset and growth.  
 
At later stages of tumor progression, MMTV-Neu mammary tumors progress from 
hyperplasia to metastatic carcinoma through multiple steps, including increased tumor 
cell invasion and migration and sustained angiogenesis. Loss of EphA2 significantly 
inhibited MMTV-Neu tumor metastasis to the lung. While EphA2-dependent tumor cell 
proliferation is intrinsic to the epithelium, EphA2-dependent tumor metastasis can be 
attributed to dual roles for EphA2 in both tumor cells and host microenvironment. Ex 
vivo studies using EphA2–/– MMTV-Neu tumor cells revealed that loss of EphA2 
impaired serum-induced cell migration (Figure 3.6), indicating a tumor cell–intrinsic role 
for EphA2-mediated malignant progression. Additionally, tumor angiogenesis was 
significantly diminished when MMTV-Neu cells were transplanted into EphA2–/– host 
environment (Figure 3.2). These studies underscore the complex nature of EphA2 
signaling.  
 
Oncogene interaction in mammary tumorigenesis and metastatic progression  
A large body of work indicates that tumorigenesis is a multistep process, and different 
oncogenes often cooperate to promote different steps of tumor progression (reviewed in 
refs. [202-204]). Here we demonstrated a physical interaction between EphA2 and ErbB2 
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at the tumor cell surface, inducing phosphorylation of the EphA2 in the absence of ligand 
stimulation. This interaction between ErbB2 and EphA2 amplified Ras/Erk signaling and 
Rho GTPase activation (Figures 3.5 and 3.6), likely contributing to the increased 
proliferation and motility of EphA2-expressing tumor cells. This observation holds 
repercussions regarding how ErbB2-expressing breast cancers are treated, especially 
those that are refractory to anti-ErbB2 therapies. Our findings provide translational 
evidence that anti-EphA2 therapy may be effective against ErbB2-expressing tumors, 
alone or in combination with methods targeting ErbB2.  
 
By contrast, EphA2 deficiency in MMTV–PyV-mT transgenic mice had no effect on 
tumor progression or in observed levels of activated Ras or p-Erk. Because Ras and Erk 
displayed high basal activity in PyV-mT–expressing tumors regardless of EphA2 
expression, these data suggest that PyV-mT antigen activates Ras/MAPK pathway by 
alternate mechanisms, bypassing the requirement for EphA2 function. More importantly, 
this observation demonstrates that EphA2 function in tumor progression depends upon 
the context of other oncogenic/tumor suppressive determinants of malignancy, which 
may underlie some of the controversy regarding the role of EphA2 in tumor progression. 
While ErbB2 and PyV-mT activate many of the same signaling pathways that contribute 
to malignancy, such as those mediated by Ras, PI3K, src-family kinases, and Stat 
transcription factors (reviewed in refs. [234, 235]), our data indicate that modulation of 
EphA2 signaling represents an important molecular distinction between these pathways 
to malignancy.  
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EphA2 RTK: oncogene or tumor suppressor?  
The contradictory observations that EphA2 may promote tumorigenesis under some 
circumstances (e.g., ErbB2-expressing breast tumors) and fail to influence tumor 
progression under others (e.g., PyV-mT–expressing tumors), or may even prevent tumor 
formation (e.g., carcinogen-induced skin cancers; ref. [113]), may be reconciled by the 
following model that we propose. Under physiologic conditions, epithelial cells form 
adherens junction, permitting ephrins to interact with EphA2s on adjacent cells. Ligand 
stimulation induces receptor endocytosis and degradation, keeping EphA2 levels low. 
Upon tumor initiation, EphA2 expression is upregulated. Elevated EphA2 can be 
phosphorylated by other RTKs, such as ErbB2, independent of ligand stimulation, 
leading to enhanced cell proliferation and tumorigenesis. Thus, ligand stimulation may 
play an antitumorigenic role by downregulation of EphA2, while in the absence of ligand, 
EphA2 crosstalk with other receptors may promote tumorigenesis. This model is 
supported by several lines of experimental evidence. First, ligand stimulation has been 
shown to downregulate EphA2 through endocytosis [40, 116, 166] as well as Cbl 
ubiquitin ligase–mediated proteasome degradation [40, 170, 171]. Second, adenoviral 
delivery of ephrin-A1 [40] and EphA2 activating antibodies have been shown to be 
effective in inhibition of malignant cell behavior in vitro and in treating malignant 
ovarian tumors in vivo [131, 134]. Third, we have shown that ErbB-2 interacted with 
EphA2 physically in MMTV-Neu tumor cells and that EphA2 was phosphorylated by 
activated ErbB2. Fourth, ablation of EphA2 by gene targeting inhibited ErbB2-induced 
mammary tumorigenesis. Thus, EphA2 remains an important therapeutic target, and 
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downregulation of EphA2 expression or inhibition of EphA2 signaling could lead to 
tumor inhibition.  
 
EphA2 as a therapeutic target  
Although EphA2 is overexpressed in a wide variety of tumors, including breast 
adenocarcinomas, our data suggest that overexpression in and of itself does not 
necessarily indicate an active role in tumorigenesis. Significant levels of EphA2 
overexpression were documented in tumors arising in both MMTV-Neu and MMTV–
PyV-mT models of mammary carcinogenesis in this study. However, while deletion of 
EphA2 significantly impaired tumor initiation and progression in MMTV-Neu animals, 
there was no effect of EphA2 deficiency on tumor progression in the MMTV–PyV-mT 
model, which expressed only moderate levels of ErbB2. Thus, the functional 
consequences of EphA2 overexpression depend upon the context of coexpressed 
oncogenes. Therefore, effective therapeutic targeting of EphA2 requires an understanding 
of how EphA2 cooperates with and functionally influences coexisting oncogenic 
signaling networks within specific tumor types. For example, while downregulation of 
EphA2 protein levels showed efficacy against human ovarian tumor xenografts [131], an 
independent, similarly designed antibody reagent had no effect on CT26 human colon 
cancer xenografts or human mammary adenocarcinoma xenografts [236]. Interestingly, 
like MMTV–PyV-mT tumor cells, CT26 cells do not overexpress ErbB2/HER2 [237], 
suggesting that EphA2 overexpression enhances malignant transformation and 
progression particularly in the context of ErbB2 overexpression and is therefore an 
appropriate target in such tumors.  
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While EphA2 overexpression has been reported in a variety of human epithelial cancers, 
including more than 80% of breast cancer clinical samples, HER2 overexpression is 
observed in only 30% of human breast cancers [238]. Moreover, no correlation was 
reported between EphA2 and HER2 expression in a recent screen of 134 human breast 
cancer specimens. Our data demonstrated that EphA2 interacted with ErbB2. Other 
EGFR family members, including EGFR/ErbB1 and an EGFR variant (EGFRvIII, a 
constitutively active deletion mutant implicated in carcinogenesis; refs. [239, 240]), have 
also been shown to physically and functionally interact EphA2 [42]. Overexpression of 
EGFR and EGFRvIII has been reported in a broader subset of human breast cancers, with 
as many as 48% of cases analyzed reported to be positive for EGFR expression [241-246]. 
Thus, EphA2 may act in concert with the EGFR family of RTKs in general, and not 
exclusively with ErbB2, to enhance proliferation and malignant progression. Functional 
interaction between EphA2 and EGFR as well as ErbB2 may be required for breast tumor 
growth and progression. Further investigation of the relationship between EphA2 and 
EGFR family members may provide a sound rationale for targeting EphA2 in breast 
cancers that display amplification and/or activation of 1 or more of this family of RTKs.  
 
Conclusions  
Our data suggest that the role of EphA2 RTK in cancer is context dependent, as EphA2 
deficiency impairs tumor progression in MMTV-Neu, but not MMTV–PyV-mT, 
transgenic models of mammary epithelial adenocarcinoma. We provide evidence that 
EphA2 physically and functionally interacts with ErbB2 to amplify Ras/MAPK and 
RhoA signaling in tumor cells. Ras/MAPK contributes to cell proliferation, while 
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activated Rho GTPase is required for tumor cell motility. Together, these results indicate 
that EphA2 cooperates with ErbB2/Neu to promote tumor progression and may be a 
novel target for tumors that are dependent upon ErbB receptor signaling. 
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CHAPTER IV 
 
ELEVATION OF RECEPTOR TYROSINE KINASE EPHA2 MEDIATES 
RESISTANCE TO TRASTUZUMAB THERAPY 
 
The work presented in this chapter is published with the same title in Cancer Research, 
Jan 2010 [247]. 
 
Abstract 
One arising challenge in the treatment of breast cancer is the development of therapeutic 
resistance to trastuzumab, an antibody targeting the human epidermal growth factor 
receptor-2 (HER2), which is frequently amplified in breast cancers. In this study, we 
provide evidence that elevated level of the receptor tyrosine kinase Eph receptor A2 
(EphA2) is an important contributor to trastuzumab resistance. In a screen of a large 
cohort of human breast cancers, we found that EphA2 overexpression correlated with a 
decrease in disease-free and overall survival of HER2-overexpressing patients. 
Trastuzumab-resistant cell lines overexpressed EphA2, whereas inhibiting EphA2 
restored sensitivity to trastuzumab treatment in vivo. Notably, trastuzumab treatment 
could promote EphA2 phosphorylation by activating Src kinase, leading in turn to an 
amplification of phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase 
signaling in resistant cells. Our findings offer mechanistic insights into the basis for 
trastuzumab resistance and rationalize strategies to target EphA2 as a tactic to reverse 
trastuzumab resistance. 
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Introduction 
Recent advances in the development and application of molecularly targeted therapies for 
cancer have generated promising new treatments. One such treatment is the recombinant 
humanized monoclonal anti-HER2 antibody trastuzumab (Herceptin, Genentech). 
Trastuzumab targets the human epidermal growth factor receptor-2 (HER2/ErbB2) 
oncoprotein [248], a member of the epidermal growth factor receptor (EGFR) family of 
receptor tyrosine kinases (RTK). HER2 is overexpressed in 25% to 30% of human breast 
cancers and is associated with poor patient survival [249]. Despite the proven benefit of 
trastuzumab in treating breast cancer [250-252], not all patients with amplified HER2 
respond to trastuzumab. Indeed, only one third of women with newly diagnosed HER2-
positive breast cancer exhibit tumor regression with trastuzumab monotherapy [252]. In 
addition, the majority of patients who achieve an initial response develop trastuzumab 
resistance within 1 year [252, 253]. Therefore, identifying mechanisms that modulate 
trastuzumab response and resistance is vital to improving the therapeutic index of this 
agent.  
 
Eph receptor A2 (EphA2), an Eph-family RTK, has been recently linked to breast tumor 
initiation and metastatic progression [25, 26, 254]. Experimentally induced 
overexpression of EphA2 resulted in malignant transformation of nontransformed 
MCF10A breast epithelial cells and enhanced malignancy of pancreatic carcinoma cells 
[74, 75]. Conversely, small interfering RNA (siRNA)–mediated inhibition of EphA2 
expression impaired the malignant progression of pancreatic, ovarian, and mesothelioma 
human tumor cell lines, and overexpression of dominant-negative EphA2 constructs 
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suppressed the growth and metastasis of 4T1 mouse mammary adenocarcinoma cells in 
vivo [75-78]. EphA2-mediated oncogenesis seems to be ligand independent, and EphA2 
often signals through cross talk with other cell surface receptors [27, 42]. We recently 
reported that loss of EphA2 receptor impaired tumor initiation and metastatic progression 
in mouse mammary tumor virus (MMTV)-Neu mice [201]. In human and murine breast 
carcinoma cells, EphA2 forms a complex with HER2, resulting in enhanced activation of 
Ras-mitogen-activated protein kinase (MAPK) and RhoA GTPase and increased cell 
proliferation and motility. These data indicate that EphA2 promotes breast tumor 
formation and metastatic progression by amplifying HER2 signaling.  
 
In this report, we investigated the role of EphA2 in regulation of breast cancer sensitivity 
to trastuzumab. We found that high EphA2 levels enhanced both intrinsic and acquired 
trastuzumab resistance. Elevated EphA2 in resistant cells seems to be activated by 
trastuzumab treatment–induced Src kinase, and activated EphA2 amplifies signaling 
through the phosphoinositide 3-kinase (PI3K)/Akt and MAPK pathways in resistant cells. 
In addition, microarray analysis of a large cohort of human breast cancer specimens 
revealed that high levels of EphA2 expression in HER2-positive patients predict poor 
prognosis. Thus, these results provide new mechanistic insights into the molecular basis 
of anti-HER2 resistance, and targeting EphA2 could represent an appealing therapeutic 
strategy to increase the efficacy of HER2-based treatments in breast cancer. 
 
 
 
110 
 
Methods 
 
Survival analysis 
The van der Vijver database, with microarray profiles of 295 human breast tumors and 
associated clinical data, was obtained from Rosetta Inpharmatics.8 The first 25% patients 
that exhibit higher HER2 expression were defined as HER2 positive, as described [255-
257]. The HER2-positive patients were further stratified into two groups based on the 
expression levels of EphA2. Kaplan-Meier analyses were computed using R survival 
package. Statistical differences were determined by log-rank tests.  
 
Cell culture 
The MMTV-Neu tumor–derived cell line [220], parental MCF10A cells, and MCF10A 
cells stably overexpressing HER2 were maintained as described previously [201]. 
Parental and trastuzumab-resistant SK-BR-3 and BT-474 cells were generously provided 
by Francisco Esteva (The University of Texas M.D. Anderson Cancer Center, Houston, 
TX; ref. [258]) and Carlos Arteaga (Vanderbilt University, Nashville, TN; ref. [259]), 
respectively. Three-dimensional spheroid cultures were established on Matrigel as 
described [224]. Cultures were maintained for 8 d before photodocumentation. Digital 
images were analyzed and the percentage of Ki67-positive cells was quantified using 
LSM Image Browser (Zeiss) software. Results were derived from 10 colonies in two 
independent experiments. Statistical differences among groups were determined by 
Student's t test.  
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Mice and in vivo tumor studies 
Athymic nude female mice, 3 to 4 wk old, were implanted with 1.5-mg, 60-d-release 17β-
estradiol pellets s.c. The next day, trastuzumab-resistant BT-474 cells (1.5 x 107; HR5) 
were resuspended in 100 µL PBS/100 µL growth factor–reduced Matrigel and injected 
into the number 4 inguinal mammary gland fat pad as previously described [259]. Tumor 
engraftment and growth was verified by palpation and tumor volume was measured by a 
caliper. Two weeks after transplantation, the mice were treated with control IgG (10 
mg/kg; clone R347, MedImmune, LLC), anti-EphA2 antibody (10 mg/kg; clone 3F2-3M, 
MedImmune, LLC), trastuzumab (20 mg/kg), or the combination of anti-EphA2 antibody 
and trastuzumab by twice-weekly i.p. injections. Tumors were harvested 2 wk after 
treatment and data were derived from 10 independent animals per treatment group in two 
independent experiments.  
 
Histologic analyses 
Tumors were sectioned by the Vanderbilt University Immunohistochemistry Core 
Facility. Immunohistochemical staining for EphA2, proliferating cell nuclear antigen 
(PCNA), and CD31 was done as described previously [93]. Proliferation or apoptosis was 
quantified by calculating the average percentage of PCNA- or terminal 
deoxyribonucleotidyl transferase–mediated dUTP nick end labeling (TUNEL)–positive 
nuclei relative to total nuclei (four random fields of at least four independent tumor 
samples).  
 
112 
 
Fluorescence resonance energy transfer analysis of Src biosensor 
The MCF7 cells expressing HER2 were transfected with Src biosensor (generously 
provided by Yingxiao Wang, University of Illinois, Urbana-Champaign, IL) and serum 
starved for 48 h before being treated with trastuzumab (10 µg/mL). Imaging and 
fluorescence resonance energy transfer (FRET) analysis were done on an LSM 510 
META confocal microscope (Zeiss) using a 40x/1.3 NAPlan-Neofluar objective lens and 
458-nm laser excitation for cyan fluorescent protein (CFP) and FRET. Emission from 
CFP versus yellow fluorescent protein (YFP)/FRET was discriminated using appropriate 
bandpass emission filters (BP 475-525 for CFP and LP560 for YFP/FRET). The 
fluorescence intensities of CFP and YFP images were measured using the Zeiss Image 
Examiner software before being quantified and analyzed by Prism 5 (GraphPad). 
Quantification was based on 20 cells per time point in two independent experiments. 
Statistical differences were analyzed using Student's t test. 
 
Results 
 
Overexpression of EphA2 in HER2-positive patients predicts poor prognosis 
Because our previous investigations in mouse models suggest that cooperation between 
HER2 and EphA2 may promote mammary tumor formation, we sought to determine if 
EphA2 could be an effective therapeutic target for HER2-positive breast cancer patients. 
To analyze the effect of EphA2 overexpression on the prognosis of HER2-positive breast 
cancer patients, we examined previously published microarray data for a panel of 295 
breast cancer samples [260]. Seventy-four HER2-positive samples were examined for 
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Figure 4.1. Overexpression of EphA2 in HER2-positive patients predicts poor 
prognosis. 
 
A previously published microarray data set from the fresh-frozen tissue bank of the 
Netherlands Cancer Institute for a panel of 295 breast cancer samples was analyzed. The 
resulting Kaplan-Meier kinetic analyses of survival data revealed that high levels of 
EphA2 mRNA expression correlated with a decrease in overall survival (A; P = 0.009) 
and recurrence-free survival (B; P = 0.019). 
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EphA2 mRNA expression. The resulting Kaplan-Meier analysis of survival data revealed 
that high levels of EphA2 expression correlated with a decrease in overall (Fig. 4.1A) and 
recurrence-free survival (Fig. 4.1B) in HER2-positive breast cancer patients. These data 
indicate that EphA2 overexpression in HER2-positive patients may predict poor 
prognosis, and elevated EphA2 may enable breast cancer cells to resist anti-HER2 
treatment. 
 
EphA2 overexpression confers cellular intrinsic resistance to trastuzumab 
To investigate whether EphA2 overexpression is sufficient to confer resistance to 
trastuzumab, we transduced a constitutively activated (CA-EphA2) or a kinase-dead 
(KD-EphA2) form of human EphA2 into MCF10A.HER2 cells [261]. MCF10A.HER2 
cells formed large acinar-like structure with a filled lumen and were sensitive to 
trastuzumab treatment (Fig. 2A; ref. [228]). Introduction of CA-EphA2 into in 
MCF10A.HER2 cells further enhanced cell proliferation, but this increased cell growth in 
MCF10A.HER2 cells expressing CA-EphA2 was refractory to trastuzumab (Fig. 4.2A 
and B). In contrast, expression of catalytically inactive KD-EphA2 in MCF10A.HER2 
cells decreased the basal rates of proliferation, which were further decreased on treatment 
with trastuzumab (Fig. 4.2A and B). These data are consistent with previous data 
showing cooperation between HER2 and EphA2 to drive cellular proliferation [201], and 
further suggest that EphA2 kinase activity is able to promote trastuzumab resistance in 
HER2-overexpressing breast cells. 
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Figure 4.2. EphA2 overexpression confers cellular intrinsic resistance to 
trastuzumab.  
 
A. constitutively activated (CA-EphA2) or kinase-dead (KD-EphA2) EphA2 receptor 
were introduced into MCF10A or MCF10A.HER2 cells by retroviral transduction. tras, 
trastuzumab. Pooled G418-resistant cell populations were cultured in three-dimensional 
Matrigel and stained for Ki67 (green) to assess proliferation and counterstained for To-
Pro-3 (red) to visualize nuclei. Overexpression of CA-EphA2, but not KD-EphA2, 
desensitizes MCF10A.HER2 cells to trastuzumab. Cell proliferation was quantified in B. 
*, P < 0.01, Student's t test. C. MCF10A or MCF10A.HER2 cells were cultured in three-
dimensional Matrigel and treated with antibodies as indicated. Anti-EphA2 antibody 
inhibited cell growth in MCF10A.HER2 cells. Cell proliferation in C is qualified in D. *, 
P < 0.01; **, P < 0.05, Student's t test.
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Interestingly, MCF10A.HER2 cells express elevated levels of EphA2 protein relative to 
those in parental MCF10A cells (data not shown). To determine if inhibition of EphA2 
increases innate sensitivity to trastuzumab, MCF10A.HER2 cells were treated with an 
antihuman EphA2 antibody, a ligand-mimetic activating antibody that specifically binds 
to EphA2 and induces receptor internalization and degradation. Whereas the anti-EphA2 
antibody had no effect on nontransformed MCF10A cells that express low levels of 
EphA2, the antibody significantly inhibited cell growth in MCF10A.HER2 cells. More 
importantly, the combination of anti-EphA2 antibody and trastuzumab inhibited cell 
growth with greater potency than either antibody alone (Fig. 4.2C and D). Taken together, 
these data suggest that EphA2 overexpression is one mechanism of intrinsic resistance to 
trastuzumab.  
 
As an independent approach to determine whether EphA2 expression levels correlate 
with trastuzumab resistance, we overexpressed HER2 in a panel of human breast cancer 
cell lines that express EphA2 protein at low or high levels (Fig. 4.3A). BT-474 and SK-
BR-3 cells that express high levels of endogenous HER2 but low levels of EphA2 were 
growth inhibited in response to trastuzumab, and so were MCF7 and T47D that 
overexpress HER2 (Fig. 4.3B). In contrast, HBL100, MDA-468, MDA-231, and BT-549 
expressed high levels of EphA2 and were resistant to the growth inhibitory effects of 
trastuzumab. These data are consistent with a correlation between EphA2 expression and 
trastuzumab response in HER2-overexpressing human breast cancer cells.
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Figure 4.3. EphA2 expression levels correlate with trastuzumab resistance.  
 
A. Human breast cancer cell lines expressing low or high levels of EphA2 were 
transduced with pBABE retrovirus expressing HER2. Expression of EphA2 and 
overexpression of HER2 in these cell lines were confirmed by western blot. B. The effect 
of trastuzumab on cell growth of above human breast cancer cell lines was determined by 
CellTiter-Glo luminescent cell viability assay. * P<0.05; Student’s t test. 
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EphA2 elevation contributes to acquired trastuzumab resistance 
Genome-wide profiling of gene expression showed that EphA2 and HER2 are not always 
coexpressed in human breast cancer. We reasoned that on prolonged trastuzumab 
treatment, a subset of HER2-positive tumors that initially express low levels of EphA2 
and respond to trastuzumab may increase EphA2 expression, leading to a decrease in 
trastuzumab sensitivity. To test this possibility, we analyzed EphA2 expression in two 
independent trastuzumab-resistant human breast cancer cell lines, SK-BR-3 and BT-474, 
which were derived from in vitro or in vivo selection for acquired resistance to 
trastuzumab, respectively [258, 259]. As shown in Fig. 4.4A, EphA2 levels were 
considerably higher in two independently derived trastuzumab-resistant clones from each 
cell line relative to their trastuzumab-sensitive parental cells. To test whether this EphA2 
overexpression is required to maintain trastuzumab resistance, we treated the parental and 
the trastuzumab-resistant cells with anti-EphA2 antibody in the presence or absence of 
trastuzumab. As expected, sensitive SK-BR-3 and BT-474 cells were growth inhibited by 
trastuzumab whereas resistant cells were not. Anti-EphA2 antibody alone did not 
significantly affect cell growth in SK-BR-3 or BT-474 cells. However, EphA2 inhibition 
restored cellular sensitivity to trastuzumab in each resistant cell line, as shown in both 
two-dimensional cell culture (Fig. 4.4B) and three-dimensional Matrigel culture (Fig. 
4.4C). These data suggest that EphA2 is upregulated in treatment-induced, trastuzumab-
resistant cells and that high levels of EphA2 in resistant cells contribute to acquired 
trastuzumab resistance. 
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Figure 4.4. EphA2 elevation contributes to acquired trastuzumab resistance.  
 
A. trastuzumab-sensitive (WT) or trastuzumab-resistant (HR) SK-BR-3 or BT-474 cells 
were subjected to Western blot analysis to assess EphA2 expression levels. B. sensitive 
or resistant SK-BR-3 or BT-474 cells were treated with IgG control, anti-EphA2, 
trastuzumab, or the combination of anti-EphA2 antibody and trastuzumab. Anti-EphA2 
antibody restores cellular sensitivity to trastuzumab. C. sensitive or resistant SK-BR-3 or 
BT-474 cells were cultured in three-dimensional Matrigel. Colonies were photographed 
at day 7 and colony size was quantified. *, P < 0.01, Student's t test. 
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Targeting EphA2 inhibits trastuzumab-resistant tumor growth in vivo 
Having shown the combinatorial activity of anti-EphA2 antibody and trastuzumab for 
growth inhibition of trastuzumab-resistant cells in vitro, we next investigated the 
therapeutic potential of an anti-EphA2 antibody for the treatment of trastuzumab-resistant 
tumor growth in vivo in an orthotopic xenograft model. Trastuzumab-resistant BT-474 
cells were injected into the mammary fat pad of female athymic nude mice. Two weeks 
after transplantation, when tumor volume reached 200 mm3, mice were treated with 
either control IgG or antihuman EphA2 antibody (10 mg/kg) in the presence or absence 
of trastuzumab (20 mg/kg). Consistent with a prior report [259], resistant BT-474 tumors 
did not respond to trastuzumab treatment as compared with IgG-treated tumors. Anti-
EphA2 antibody treatment moderately reduced tumor size relative to controls. In contrast, 
coadministration of anti-EphA2 antibody with trastuzumab markedly reduced tumor 
volume (Fig. 4.5A and B). 
 
To examine cellular changes within treated tumors, we analyzed cell proliferation and 
apoptosis in tissue sections by staining for PCNA and by TUNEL assay, respectively. 
Quantitation of PCNA-positive nuclei revealed a nearly 2-fold decrease in PCNA 
staining in tumors treated with the combination of anti-EphA2 antibody versus tumors 
treated with control IgG (P < 0.05; Fig. 4.5C). In contrast, treatment with anti-EphA2 
antibody alone or with trastuzumab alone did not significantly alter the proportion of 
PCNA-positive cells as compared with IgG-treated tumors. Similarly, apoptosis was 
increased 6-fold in tumors treated with the combination of anti-EphA2 antibody and 
trastuzumab (P < 0.01; Fig. 4.5C) but was unaltered in tumors treated with either 
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Figure 4.5. Targeting EphA2 inhibits trastuzumab-resistant tumor growth.  
 
A. trastuzumab-resistant BT-474 cells were orthotopically transplanted into the mammary 
glands of nude female mice. Two weeks after transplantation, tumors were treated with 
control IgG, anti-EphA2 antibody (10 mg/kg), trastuzumab (20 mg/kg), or the 
combination of anti-EphA2 antibody and trastuzumab twice weekly via i.p. injection. 
Points, mean of 10 mice per treatment group from two independent experiments; bars, 
SEM. B. tumors were harvested and photographed. C. cell proliferation and apoptosis in 
tumor sections were evaluated by PCNA immunohistochemistry and TUNEL assay, 
respectively. *, P < 0.01. Arrowheads, PCNA- or TUNEL-positive nuclei. 
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antibody alone. Taken together, these data suggest that targeting EphA2 may be effective 
for the suppression of trastuzumab-resistant breast tumor growth. 
 
EphA2 regulates breast cancer cell sensitivity to trastuzumab by modulation of Akt and 
MAPK activities 
Breast cancer resistance to HER2 inhibitors could arise through multiple mechanisms, 
including activation of alternative growth factor receptors or enhancing downstream 
signaling pathways. We investigated potential mechanisms by which EphA2 contributes 
to trastuzumab resistance in HER2-overexpressing breast cancer. We found that 
elimination of EphA2 by siRNA knockdown or anti-EphA2 antibody reduced phospho-
Akt and phospho-extracellular signal-regulated kinase (Erk) levels in trastuzumab-
resistant cells (Fig. 4.6A and B), suggesting that EphA2 expression and activity are 
required to maintain signaling through the PI3K-Akt and MAPK signaling pathways.  
 
To determine whether the PI3K-Akt and Ras-MAPK signaling pathways play a causal 
role in trastuzumab resistance, we treated SK-BR-3 cells with a PI3K inhibitor, 
LY294002 (Fig. 4.6C), or a mitogen-activated protein/Erk kinase (MEK) inhibitor, 
U0126 (Fig. 4.6D), and analyzed cell growth in the presence or absence of trastuzumab. 
In sensitive cells, cell growth is inhibited by trastuzumab, and addition of LY294002 or 
U0126 did not further affect cell growth significantly. However, although resistant cells 
do not respond to trastuzumab, they are exquisitely sensitive to the MEK inhibitor (Fig. 
4.6D). In fact, resistant cells are more sensitive to U0126 than trastuzumab-sensitive cells, 
suggesting that trastuzumab-resistant cells are dependent on MAPK signaling. In addition, 
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Figure 4.6. EphA2 regulates breast cancer sensitivity to trastuzumab by modulation 
of Akt and MAPK activity.  
 
A. EphA2 was knocked down by siRNA in either parental or trastuzumab-resistant (HR1) 
SK-BR-3 cells. EphA2, phosphor-Akt, and phospho-Erk levels were assessed by Western 
blot analysis. The ratio of phospho-protein/total protein was determined by densitometry 
and expressed in arbitrary units. B. trastuzumab-sensitive or trastuzumab-resistant cells 
were treated with control, trastuzumab, anti-EphA2 antibody, or the combination of 
trastuzumab and anti-EphA2 antibody in the presence of 10% serum. Quantification of 
phospho-protein/total protein was determined as above. C. and D. trastuzumab-sensitive 
or trastuzumab-resistant (HR1) SK-BR-3 cells were treated with increasing dose of either 
PI3K inhibitor LY294002 or MEK inhibitor U0126 for 3 d and cell viability was 
determined. 
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either PI3K inhibitor or MEK inhibitor significantly restored trastuzumab sensitivity in 
resistant cells. Together, our data suggest that anti-EphA2 antibody therapy reverses 
trastuzumab resistance by inhibiting the activation of both Akt and MAPK.  
 
Chronic trastuzumab treatment activates EphA2 through Src kinase 
To investigate how EphA2 is activated in trastuzumab-resistant cells, we examined the 
involvement of Src kinase because prior studies showed that Src directly interacts with 
HER2 and is activated in HER2-overexpressing cancer cells [262, 263]. Coexpression of 
HER2 and EphA2 in COS7 cells was sufficient to induce tyrosine phosphorylation of 
EphA2, and this process was inhibited by a Src inhibitor, PP2. In addition, constitutively 
activated v-Src induced phosphorylation of EphA2 independently of HER2 (Fig. 4.7A), 
suggesting that HER2 may modulate EphA2 activity through Src. We next investigated 
whether Src can be activated by trastuzumab. A previous study suggested that short 
exposure to trastuzumab rapidly inhibits Src kinase activity [264]. However, we found 
that longer treatment of SK-BR-3 cells with trastuzumab increased Src phosphorylation 
at Y416, an indicator of Src activation (Fig. 4.7B). To further determine whether 
prolonged trastuzumab treatment can activate Src kinase, we used a Src biosensor that 
enables the visualization of Src activity in live cells with high spatiotemporal resolution 
by FRET technology [265, 266]. Trastuzumab induced a 15% to 25% reduction in Src 
activity within 1 hour in MCF7.HER2 cells transfected with the Src biosensor, but the 
decrease in Src activity gradually recovered with prolonged trastuzumab incubation (Fig. 
4.8A). After 24 hours of treatment, Src activity increased by 35% in MCF7.HER2 
relative to control cells (Fig. 4.8B), whereas EphA2 levels were not changed (data not 
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Figure 4.7. Chronic trastuzumab treatment activates EphA2 through Src kinase. 
 
A. COS7 cells were transiently transfected with EphA2 alone or in combination with 
HER2 or v-Src. EphA2 immunoprecipitate was subjected to western blot analysis to 
assess EphA2 phosphorylation. Phosphorylation of EphA2 is increased in the presence of 
HER2 or v-Src. Src inhibitor, PP2, inhibited EphA2 phosphorylation induced by either 
HER2 or v-Src. B. Activation of Src and EphA2 in SK-BR-3 cells with long-term 
trastuzumab treatment was assessed by western blot analysis. C. EphA2 levels in MCF7 
cells with trastuzumab treatment were assessed by western blot analysis. 
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shown). These data support the existence of a switch from trastuzumab-induced Src 
inhibition to activation, which could modulate EphA2 activity in resistant cells. Indeed, 
EphA2 and Src were highly phosphorylated in trastuzumab-resistant cells. Src inhibitors, 
PP2 (Fig. 4.8C) or dasatinib (data not shown), inhibited the activities of both Src and 
EphA2. 
 
To determine whether Src kinase contributes to trastuzumab resistance, we treated SK-
BR-3 cells with trastuzumab, dasatinib, or their combination and assessed cell viability. 
Dasatinib inhibited cell growth in both sensitive and resistant cells. Whereas resistant 
cells did not respond to trastuzumab, dasatinib partially restored trastuzumab sensitivity 
in resistant cells (Fig. 4.8D). Together, these results provide a clear link between 
activation of Src and EphA2 in trastuzumab resistance. 
 
Discussion 
In this report, we described a novel mechanism by which HER2-positive breast cancers 
acquire resistance to trastuzumab. The RTK EphA2 was found to correlate with a poor 
prognosis in patients with HER2-overexpressing breast cancers and had a greater 
negative impact on patient survival in HER2-overexpressing breast cancers as compared 
with other breast cancers. We found that overexpression of EphA2 in HER2-positive 
breast cancer cells was sufficient to confer innate resistance to trastuzumab. Furthermore, 
antibody-mediated EphA2 inhibition enhanced tumor response to trastuzumab both in 
cell culture and in vivo. These data suggest that therapeutic inhibition of EphA2 may 
represent a strategy for improving the clinical response of trastuzumab. 
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Figure 4.8. Trastuzumab treatment activates EphA2 through Src kinase.  
 
A. MCF7.HER2 cells expressing Src reporter were treated with trastuzumab over a time 
course. The normalized CFP/YFP emission ratio of the Src biosensor over time in 
response to trastuzumab is shown. B. MCF7.HER2 cells expressing Src reporter were 
treated with trastuzumab for 0, 1, and 24 h. Changes in CFP/YFP emission ratio were 
quantified in 20 cells per experimental group at given time point. *, P < 0.01. C. sensitive 
(WT) or resistant (HR) SK-BR-3 cells were treated with Src inhibitor PP2 or vehicle 
control. Phospho-Src and phospho-EphA2 levels were assessed by immunoprecipitation 
and Western blot analysis. D. trastuzumab-sensitive or trastuzumab-resistant SK-BR-3 
cells were treated with control, dasatinib, trastuzumab, or the combination of dasatinib 
and trastuzumab for 3 d. Cell growth was determined by luminescent cell viability assay. 
*, P < 0.05, Student's t test. 
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What is the mechanism by which elevated EphA2 confers tumor cell resistance to 
trastuzumab?  
Resistance to anti-HER2/ErbB2 agents could arise through multiple mechanisms, 
including altered receptor-antibody interaction, activation of alternative growth factor 
receptor signaling pathways, and deregulation of downstream signaling pathways [267, 
268]. The most common downstream signaling pathway that contributes to trastuzumab 
resistance is the PI3K-Akt pathway. Persistent activation of PI3K-Akt signaling in 
resistant cells could result from multiple mechanisms such as oncogenic mutations of 
PI3K [269], loss of PTEN [264], or upregulation of insulin-like growth factor-I receptor 
and EGFR activity [259, 270]. In this case, targeting EphA2 inhibited the PI3K-Akt 
pathway in trastuzumab resistant cells (Fig. 4.6). In addition to regulating Akt activity, 
we discovered that EphA2 also modulates phospho-Erk levels in resistant cells. Increased 
EphA2 expression in resistant cells enhanced phospho-Erk levels, and targeting EphA2 
with siRNA or anti-EphA2 antibody inhibited Erk activity (Fig. 4.6). These data, together 
with reports from other laboratories [271, 272], suggest that the development of 
trastuzumab resistance may involve simultaneous activation of multiple parallel signaling 
cascades including the PI3K-Akt and MAPK pathways [273-275]. Indeed, a MEK 
inhibitor that suppresses phospho-Erk significantly decreased the viability of resistant 
cells (Fig. 4.6D). Suppression of MAPK activity by EphA2 antibody was also observed 
in MCF10A three-dimensional culture (data not shown), as well as in MMTV-Neu cells 
(Fig. 4.9A), where Erk phosphorylation recovered after prolonged treatment with 
gefitinib, a dual inhibitor of EGFR and ErbB2/Neu [276]. The combination of anti-
EphA2 antibody and gefitinib completely abrogated MAPK activity and inhibited tumor 
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growth in vivo (Fig. 4.9B). Together, these data suggest that modulation of both Akt and 
MAPK signaling is a primary mechanism through which EphA2 contributes to 
trastuzumab resistance.  
 
How is EphA2 receptor activated in trastuzumab-resistant cells?  
We have previously shown that EphA2 forms a complex with HER2/ErbB2 and can be 
phosphorylated in the presence of HER2/ErbB2 [201]. However, we failed to detect 
direct EphA2 tyrosine phosphorylation by HER2 in an in vitro kinase assay (data not 
shown), indicating the possibility of involvement of another kinase. One candidate is the 
non-RTK Src because Src directly interacts with HER2 and is activated in HER2-
overexpressing cancer cells [262, 263]. Indeed, Src is sufficient to activate EphA2 and is 
required for the phosphorylation of EphA2 by HER2 (Fig. 4.7A). Although trastuzumab 
reportedly inhibits Src activity within a short time frame [264], we observed increased 
Src activity in cells on prolonged exposure to trastuzumab (Fig. 4.7B). Using a FRET-
based Src reporter to monitor Src activity in live cells, we found that short-term exposure 
to trastuzumab inhibits Src kinase activity, consistent with a previous report [264]. 
However, prolonged treatment resulted in increased Src activity (Fig. 4.8A and B). These 
results were supported by biochemical studies, in which Src phosphorylation at Y416 was 
increased with prolonged trastuzumab treatment. The mechanism of switch between 
trastuzumab-induced Src inhibition and activation is unclear. We speculate that 
continuous exposure to trastuzumab may cluster HER2 at the plasma membrane and 
recruit Src into the HER2/EphA2 complex, resulting in activation of Src and 
phosphorylation of EphA2 receptor. 
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Figure 4.9. Suppression of MAPK activity by EphA2 antibody in MMTV-Neu cells. 
  
A. MMTV-Neu cells were treated with 1µM gefitinib (Iressa) following a time course as 
indicated, in the presence or absence of anti-EphA2 (10µg/ ml). Phospho-Erk and 
phospho-Akt levels were determined by western blot analysis. pErk re-emerges after 
prolonged gefitinib treatment. The addition of anti-EphA2 completely abrogated MAPK 
activity. B. One million of MMTV-Neu cells were injected into the cleared mammary 
gland fat pad of recipient FVB female mice. Two weeks after transplantation, mice were 
treated with vehicle control (0.1% Tween 80) or gefitinib (50mg/ kg) by daily orogastric 
gavage, as well as with control IgG or anti-EphA2 (10mg/ kg) by twice weekly 
intraperitoneal injection. Tumors were harvested after two weeks treatment and tumor 
volume was calculated. * P<0.05, ** P<0.01; Student’s t test. 
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Our findings that EphA2 coexpresses with HER2 and confers trastuzumab resistance in 
HER2-positive breast cancers could directly affect the clinical management of these 
patients. We propose that individuals with EphA2 and HER2-positive breast cancer might 
benefit from pharmacologic inhibition of EphA2 in combination with anti-HER2 
therapies. EphA2 expression may also be used as a prognostic marker to predict 
trastuzumab resistance and treatment outcome. In patients who initially are negative for 
EphA2 but subsequently develop resistance to trastuzumab, elevated EphA2 could be one 
of the mechanisms that confer tumor resistance to HER2 inhibitors. Targeting EphA2 
may represent a novel strategy to overcome trastuzumab resistance. In summary, our 
studies provide new mechanistic insights into the molecular basis of trastuzumab 
resistance. These studies provide a basis for rational design of combination therapies to 
overcome tumor resistance to trastuzumab. 
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CHAPTER V 
 
GENOMIC AND MUTATION ANALYSES IDENTIFY EPHA3 RECEPTOR 
TYROSINE KINASE AS A TUMOR SUPPRESSOR IN NON-SMALL CELL LUNG 
CANCER 
 
Abstract 
Somatic mutations of Eph receptors in lung cancer have been recently identified in 
multiple systematic mutational screens. However, because Eph receptors can function in 
both tumor promotion and tumor suppression, the oncogenic potential of these mutations 
in lung cancer remains undefined. In this study, we analyzed copy numbers and 
expression levels of Eph receptors in large cohorts of both cell lines and primary lung 
cancer samples. We found that EphA3 is often deleted and/or under-expressed in human 
lung cancer. Further mutational analysis revealed that EphA3 somatic mutations 
identified in lung adenocarcinoma are loss-of-function mutation. Surprisingly, many 
EphA3 mutations can act dominant negatively to block wild-type EphA3 receptor 
tyrosine phosphorylation and kinase activity. Overexpression of wild-type, but not mutant, 
EphA3 inhibits tumor growth in vivo. EphA3 appears to promote cell apoptosis by 
negatively regulating mTOR complex 1 activity via activation of AMP-activated protein 
kinase. Expression of EphA3 in both tumor cell lines and lung cancer clinical specimens 
are negatively correlated with activities of S6K1 and S6, and higher EphA3 expression in 
tumor cell lines correlates with relative lower responsiveness to rapamycin. These 
findings identify EphA3 receptor tyrosine kinase as a tumor suppressor in non-small cell 
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lung cancer, and suggest that therapeutic intervention to diminish mTOR function may 
benefit patients with EphA3 deletion or mutation. 
 
Introduction 
Lung cancer is a leading cause of cancer-related deaths in the United States. Non-small 
cell lung cancer (NSCLC) accounts for 85% of all lung cancers and the overall five-year 
survival of NSCLC is approximately between 15-16% (NCI SEER Cancer Statistics 
Review, 2008). Although molecular targeted therapies such as EGFR kinase inhibitors 
have been developed, these agents often only target small percentage of patients, and the 
effectiveness is limited by the development of drug resistance. Recent gene sequencing 
studies in large cohorts of human lung cancer samples have identified a set of key 
mutations associated with NSCLC [122-125]. In one such sequencing effort, of 26 
frequently mutated genes, Eph receptor tyrosine kinase (RTK) genes, notably EphA3, are 
mutated at significantly high frequencies and are predicted to be involved in tumor 
development [122]. However, due to the dichotomies of Eph receptor signaling in both 
tumor promotion and tumor suppression, the oncogenic potential of these mutations in 
lung cancer remains unknown. 
 
EphA3 belongs to the largest family of RTKs, the Eph family, that mediate cell-cell 
communication. Since discovery in the 90s, Eph molecules have been increasingly 
recognized as key regulators both in development and disease [1, 25]. In cancer, the Eph 
receptors and their ligands, ephrins, regulate many processes that are essential for tumor 
initiation and progression, including proliferation, invasion/motility, angiogenesis and 
134 
 
metastasis [26, 27, 207]. Paradoxically, there is good evidence that Eph receptors could 
either promote or inhibit tumor, depending on ligand stimulation, signaling cross-talk, or 
other contextual factors. For example, EphA2 is overexpressed in a variety of human 
cancers and is associated with poor survival in breast, prostate, and lung cancer, as well 
as in glioblastoma multiform [78, 100, 101, 104, 247, 277-280]. In several studies, 
overexpression of EphA2 induces ligand-independent signaling, resulting in increased 
tumor cell malignancy in vitro and accelerated tumor growth and metastasis in vivo [74, 
75]. Conversely, EphA2 knockdown or targeted gene deletion inhibited tumor initiation 
and metastatic progression [75, 76, 201]. However, ligand-dependent and kinase-
dependent signaling of EphA2 in both breast cancer cells or glioblastoma lines inhibited 
tumor cell malignant behavior in vitro and tumor growth in vivo [35, 201].  Despite high 
frequency of EphA3 mutations discovered in a variety of tumor types, EphA3 is less well 
investigated in cancer.  Early studies reported that ligand-dependent EphA3 signaling in 
melanoma cells induces cell de-adhesion through a CrkII and Rho-mediated mechanism 
[281].  However, ligand-induced EphA3 kinase-independent signaling in leukemia cells 
stimulated cell adhesion [118]. Together, these studies highlighted the complexity of Eph 
molecules in human cancer and the necessity of careful studies in each tumor type. 
 
In this report, we analyzed copy numbers and expression levels of Eph receptors in 
NSCLC by a combination of SNP analysis and data mining of gene expression profiles in 
large cohorts of both cell lines and primary lung cancer samples.  We found that EphA3 
is often deleted and/or under-expressed in human lung cancer. Further mutational 
analysis revealed that EphA3 somatic mutations identified in lung adenocarcinoma are 
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loss-of-function mutation, but can act dominant negatively to block wild-type EphA3 
receptor function.  Overexpression of EphA3 suppressed tumor growth in vivo by 
regulating the mTOR signaling pathway.  These findings uncovered a previously 
unknown mechanism by which EphA3 receptor inhibits lung tumor malignancy and 
demonstrated the power of an integrative approach to understand the complexities of Eph 
receptors in cancer. 
 
Methods 
 
Antibodies and reagents 
Antibodies against the following proteins were used: EphA2 (Upstate Biotechnology); 
EphA3 (Santa Cruz Biotechnology for western, Sigma-Aldrich for IHC, and Millipore 
Corporation for IP); S6 ribosomal protein, phosphoserine-235/236 S6, p70 S6 kinase, 
phosphothreonine-389 p70 S6 kinase, Erk, phosphothreonine-202/serine-204 Erk, Akt, 
phosphoserine-473 Akt, AMPK, phosphothreonine-172 AMPK (Cell Signaling 
Technology); β-tubulin (Sigma-Aldrich); Actin, phosphotyrosine pY20 and pY99 (Santa 
Cruz Biotechnology); Ki67 (Zymed Laboratories); paxillin (BD Biosciences).   
 
cDNA arrays containing paired normal lung tissues and NSCLC tumor samples or 
different stages of tumor specimens were purchased from Origene Inc. NSCLC cell lines 
and paired lung tissue and tumor sections were provided by Vanderbilt Lung SPORE 
program (Vanderbilt University, TN).  Avidin peroxidase reagents were from Vector 
Laboratories, and liquid 3,3′-diaminobenzidine tetrahydrochloride (DAB) substrate kit 
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was from Zymed Laboratories. TO-PRO-3 iodide nuclear stain was purchased from 
Invitrogen. Rapamycin was purchased from Calbiochem. EphA3 TaqMan gene 
expression assay was from Applied Biosystems. EnzyLight ATP assay kit was purchased 
from Bioassay Systems. 
 
Analysis of SNP array 
The detailed descriptions of SNP arrays were published previously [282]. Affymetrix 
U133 microarray data (Gene Logic, Inc.) from NCI-60 cells were downloaded on DTP 
website (http://dtp.nci.nih.gov). SNP arrays were processed using the dChip software 
[283]. Both CentHind and CentXba SNP data were combined and filtered to reduce 
invariant SNPs. Filtered SNPs were subjected to unsupervised hierarchical clustering 
using the Pearson coefficient and average linkage method. Processed SNP data files were 
viewed in GenePattern software package [284].  SNP analyses of processed data from 84 
human NSCLC lines and 371 clinical specimens were performed using published datasets 
[285, 286]. Analyses were based on the copy number thresholds: copy number 2.14 
(amplifications) and 1.87 (deletions). 
 
Cell viability and apoptosis assay 
Cell viability was determined by CellTiter-Glo luminescent cell viability assay kit 
(Promega), based on quantitation of the amount of ATP in metabolically active cells.   
Two thousand and five hundred cells were seeded each well in 96-well plates in 
quadruplicates.  Following a time course, cells were lysed and luminescence was 
measured by a luminometer according to manufacturer's instruction. For study of cellular 
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sensitivity to rapamycin, cells were plated at the density of 2,500/well in the presence or 
absence of 1µM rapamycin. Cells were harvested after 72h and viability determined as 
described above. Rapamycin resistance index was calculated as rapamycin-treated 
units/control units. 
 
To determine the extent of apoptosis, histone-associated DNA fragments were quantified 
using the Cell Death Detection ELISA (Roche) according to the manufacturer's 
instructions. Briefly, cells (5,000) in 96-well plates were serum starved for 5 days or 
treated with GST-TRAIL (5ug/ml) for 24 hours. Free nucleosomes were detected by 
immobilized anti-histone antibody and anti-DNA peroxidase immunoreagents. The 
amount of peroxidase retained in the immunocomplex was determined with ABTS (2,2’-
azino-di-[3-ethylbenzthiazoline sulfonate]) as substrates. The absorbance was measured 
on a microplate reader (Bio-Tek) at a wavelength of 405/490 nm. 
 
Immunoprecipitation and immunoblot analyses 
Immunoprecipitation and immunoblot were performed as described previously [166]. 
Briefly, Cells were lysed in 1% Nonidet P-40 buffer with protease and phosphatase 
inhibitors. For co-immunoprecipitation HA-tagged wild-type and Myc-tagged mutant 
EphA3, receptor complexes were sequentially precipitated with anti-HA and anti-Myc 
agarose, resolved on SDS-PAGE and subjected to Western blot with desired antibodies. 
For kinase assay, precipitated protein complexes were resuspended in 25µl kinase buffer 
(20mM HEPES pH=7.6, 20mM β-glycerophosphate, 0.1mM sodium orthovanadate, 
10mM MgCl2, 50mM NaCl, 1mM DTT, 200mM ATP, and 20µCi γ-32P ATP), 
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incubated at 30°C for 30 mins, resolved on a 8% SDS-polyacrylamide gel, and 
transferred to nylon membrane for autoradiography.  
 
Tumor studies 
NSCLC tumor cells (5 x 106) were resuspended in 100µl Matrigel (BD Biosciences) and 
subcutaneously injected into the nude mice. Tumors were harvested three weeks after 
injection and dimensions measured by digital caliper. Tumor volume was calculated 
using the following formula: volume = length x width2 x 0.52. The tumor tissue was then 
fixed in 4% paraformaldehyde (Sigma-Aldrich) and processed for immunohistochemistry 
analyses of Ki-67 and cleaved-caspase 3 to determine proliferation and apoptosis in 
tumor tissue. Data were derived from 8-10 animals/group in two independent 
experiments. 
 
ATP measurements 
Cellular ATP levels were determined using a bioluminescence ATP assay kit according 
to the manufacturer's instructions (EnzyLight ATP assay kit; BioAssay Systems, 
Hayward, CA, USA). Briefly, cells were plated on 96-well in serum-free medium. After 
24 hours, cells were stimulated with 10% FBS and lysed with 90µl assay buffer 
containing substrate D-luciferin and luciferase.  The luminescence signal was measured 
within 20min by a luminometer. 
 
 
 
139 
 
Analysis of lung tissue microarray 
Two tissue microarrays (TMA) containing 104 lung tumor samples and 26 normal lung 
tissues were provided by the Vanderbilt Lung SPORE program. Antigen retrival of TMA 
sections were performed by boiling in citrus butter. Two adjacent TMA sections were 
stained by anti-EphA3 (Sigma) or anti-phosphoS6 (abcam), and subsequently scanned 
and analyzed using the Ariol® SL-50 platform. The samples were scored as positive or 
negative for EphA3 and 0, 1, 2, 3 for pS6 according to the percentage and intensity of 
positive color (brown) in the sections, followed by visual verification, as shown in 
Supplemental Figure 6. To determine the statistical significance, Fisher's exact test and 
Chi-square test were performed in normal lung tissues and lung tumor samples, 
respectively. 
 
Expression Array Analyses 
Two independent EphA3-associated gene expression signatures were generated in a 
training dataset [122], and queried in a large testing dataset containing 444 gene 
expression profiles and associated clinical outcome data [287], using EXALT system as 
previously described [288]. EphA3 mutation signature (MutSig) was selected based on 
differentially expressed genes in patients carrying EphA3 mutation relative to those 
carrying the wild-type EphA3 gene. EphA3 co-expression signature (ExpSig) includes a 
cluster of genes with expression patterns correlated with EphA3 defined by Pearson 
correlation coefficient. Kaplan-Meier analyses were computed using R survival package. 
Statistical differences were determined by log-rank tests. 
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Figure 5.1. SNP array analysis of EphA3 gene copy number in NCI-60 tumor cell 
lines. 
 
A. Hierarchical clustering of raw copy-number data from NCI60 cell lines showed cell 
line subclusters and chromosome-specific SNP clusters. Chromosome 3 is often deleted 
in NSCLC lines. Red indicates gain, blue indicates loss, and white indicates no change. B. 
Colorgrams of SNP copy number at chromosome 3p11.2. C. Microarray-based gene 
expression profiling showed loss of copy number of EphA3 and reduced EphA3 
expression in 7 out of 9 NSCLC lines.
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Results 
 
Loss of copy number and expression of EphA3 gene in human NSCLC 
To analyze expression and function of Eph receptors in cancer systematically, we initially 
performed SNP analysis in NCI-60 human tumor cell lines [282].  Hierarchical clustering 
of copy number analysis revealed that regions in chromosome 3 are often deleted in 
NSCLC lines (Figure 5.1A). Further examination of Eph receptors in chromosome 
3p11.2 showed loss of copy number of EphA3 (Figure 5.1B) and reduced EphA3 
expression in 7 out of 9 NSCLC lines in the NCI-60 panel (Figure 5.1C). SNP analysis on 
a larger cohort of 84 NSCLC lines [286] supported the finding that EphA3 is frequently 
deleted (44 out of 84), with median copy number below 1.87 (Figure 5.2). To assess the 
relevance of EphA3 in human lung cancer, copy number of EphA3 gene on chromosome 
3p were examined in a large dataset of 371 lung adenocarcinoma [285]. Consistent with 
the cell line data, EphA3 gene is often deleted in primary tumors (Figure 5.2D). 
Interestingly, genes encoding EphA3 ligands, ephrin-A1, -A3, and -A4, on chromosome 
1q21-q22 are frequently amplified in these tumors (data not shown). 
 
To determine whether EphA3 represents a target of 3p11 loss, we first asked whether 
EphA3 expression was downregulated in lung tumor samples relative to paired normal 
tissues. By quantitative RT-PCR, approximately 80% of samples (19 out of 24) showed 
2- to 45-fold reduction of EphA3 mRNA in tumors relative to normal tissues (note of 
log2 scale on Y axis in Figure 5.3A). Next, we compared EphA3 expression in a panel of 
85 NSCLC clinic specimens with different stages of tumor progression. EphA3 
expression is significantly lower in all stages of tumors, compared to control normal 
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Figure 5.2. SNP array analysis of EphA3 gene copy number in 84 NSCLC lines and 
371 lung tumor samples.  
 
A. Chromosomal copy number of EphA3 was analyzed in 84 NSCLC lines and listed 
from lowest (blue) to highest (red). B. Raw copy number data (y axis) for HCC95 cell 
line are plotted according to chromosome 3 position (x axis). Genomic position of EphA3 
is labeled along the x axis. C. Of 84 NSCLC lines, 44 lines showed copy number loss 
(below 1.87), compared to 20 lines showed copy number gain (above 2.14). D. Copy 
numbers of EphA3 on chromosome 3p are shown in 371 lung adenocarcinomas.  
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tissue (p<0.001, Figure 5.3B). Western blot analysis of 28 NSCLC lines revealed low or 
undetectable levels of EphA3, relative to high expression level of EphA2 receptor (Figure 
5.3C). EphA3 protein expression was also analyzed in 9 paired NSCLC tumor samples 
and adjacent normal lung tissue by immunohistochemistry. While 8 normal tissues 
express EphA3, only 2 of the tumor samples express detectable levels of EphA3 (p<0.05, 
Figure 5.3D). Taken together, both copy number analysis and expression data indicate 
that EphA3 gene is frequently deleted and its expression is significantly downregulated in 
human lung cancer.  
 
Overexpression of EphA3 in tumor cells promotes cell apoptosis 
To determine the function of EphA3 in lung cancer cells, we overexpressed EphA3 in 
three lung cancer cell lines, A549, H1975, and H1299, via retroviral transduction (Figure 
5.4A). To test the effects of EphA3 on cell growth, we initially measured clonal growth 
by colony formation assay. Tumor cells overexpressing EphA3 displayed 30%-50% 
reduction of numbers of colonies on tissue culture dish, although the size of colonies did 
not differ significantly between tumor cells overexpressing EphA3 and vector control 
cells (Figure 5.4B), indicating an equal growth rate but reduced plating efficiency. These 
results were confirmed by an MTT cell viability assay, in which tumor cells 
overexpressing EphA3 were less viable over a time course (Figure 5.4C). To determine 
whether reduced cell viability is due to decreased proliferation or increased apoptosis, we 
measured cellular incorporation of BrdU for proliferating cells and performed an ELISA-
based apoptosis assay (see Methods). As shown in Figure 5.4D, there was no significant 
change in tumor cell proliferation between control and cells expressing EphA3. In  
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Figure 5.3. EphA3 expression is downregulated in NSCLC.  
 
A. EphA3 mRNA levels were assessed by quantitative RT-PCR in paired normal tissues 
and lung tumor samples. 19 out of 24 tumors express lower levels of EphA3 compared to 
normal controls. B. EphA3 mRNA levels were quantified in different stages of NSCLC 
tumor samples. EphA3 is downregulated in all tumor stages relative to normal tissues (*, 
P < 0.01). C. Western blot analysis of 28 NSCLC lines revealed low or undetectable 
levels of EphA3 protein in tumor cell lines. D. Immunohistochemistry staining of 9 
paired normal lung tissues and tumor samples (3 pairs were shown) revealed reduced 
EphA3 expression in tumor sections, compared to adjacent normal lung tissues. 
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Figure 5.4. Overexpression of EphA3 in tumor cells promotes apoptosis.  
 
A. Three NSCLC lines, A549, H1975, and H1299, were transduced with retroviruses 
carrying wild-type EphA3 or vector control. EphA3 overexpression in these lines was 
confirmed by Western blot analysis. B. Colony formation assay indicates that EphA3 
overexpression decreases cell viability, which is confirmed by MTT assay shown in C. D. 
BrdU incorporation assay. E. Cells were serum starved for 5 days and subjected to 
apoptosis assay by Cell Death Detection ELISA kit. Overexpression of EphA3 increased 
apoptosis level. *, P < 0.01, Student's t test.
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contrast, cells expressing of EphA3 displayed markedly enhanced cellular apoptosis 
(Figure 5.4E). Together, these results indicate that increased apoptosis, rather than 
decreased cell proliferation, was responsible for the reduction in colony numbers. 
 
EphA3 mutations exhibit impaired ligand-binding or kinase activities and can function 
dominant negatively to suppress wild-type EphA3 receptor function 
Somatic mutations in Eph receptors in lung cancer have been recently identified in 
multiple systematic mutational screens [122-125]. In one such gene sequencing effort, 
Eph mutations were discovered in 16% of primary lung adenocarcinoma, among which 
EphA3 was the most significantly mutated gene. Eleven mutations were identified in 
EphA3, with 8 mutations in extracellular domain and 3 in the kinase domain [123]. 
Additional EphA3 mutations were also identified by other studies (Table 5). These 
studies highlight the relevance of Eph family in lung cancer.  
 
The majority of EphA3 mutations are clustered in the kinase domain and extracellular 
domain (Figure 5.5A). Multiple sequence alignments indicate that the mutated residues 
are highly conserved through species (data not shown). To determine whether the 
mutations in EphA3 affect ligand-binding and/or kinase activity, we generated 5 mutants 
in the kinase domain (T660K, D678E, R728L, K761N and G766E) and 6 mutants in the 
extracellular domain (T166N, G187R, N379K, T393K, A435S and S449F). Three 
mutations identified in colorectal cancer (D806N, T37K and N85S) were included for 
comparison. Both phospho-tyrosine blots and kinase assays showed that R728L, G766E, 
and D806N mutations in the kinase domain had impaired activity relative to wild type 
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Figure 5.5. Ligand binding and kinase activity in EphA3 mutations.  
 
A. Schematic diagram of EphA3 mutations, including 8 mutations in extracellular 
domain and 6 mutations in tyrosine kinase domain. B. Wild-type EphA3 or EphA3 
bearing mutations in the extracellular domain was transfected into 293T cells. EphA3 
proteins were immunoprecipitated with ephrinA1-Fc, and western blotted by anti-EphA3 
and anti-pY to assess ligand-binding and tyrosine phosphorylation, respectively. C. Wild-
type EphA3 or EphA3 bearing mutations in the kinase domain was precipitated as above, 
followed by phospho-tyrosine blot or kinase assay. D. HA-tagged wildtype EphA3 was 
co-transfected with Myc-tagged mutant EphA3 into 293T cells in equal amount (1:1). 
Transfected EphA3 were pulled down by Myc-agarose and western blotted by anti-HA. 
Wild-type EphA3 receptors are able to form complex with mutant EphA3 proteins.
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Table 5. EphA3 mutations in lung and colon cancer 
 
Mutation frequency was calculated based on the percentage of patients containing 
mutated EphA3 or Eph receptors. PTK, protein tyrosine kinase domain; SAM, sterile 
alpha motif; FN3, fibronectin-type III repeats; CRR, Cysteine-rich region; LBD, ligand-
binding domain.
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EphA3 (Figure 5.5C). Most of the mutants in extracellular domain also exhibited 
decreased levels of kinase activity as well (Figure 5.5B). To test whether mutations in the 
extracellular domain affects ligand binding, wild-type or mutant EphA3 proteins were 
precipitated by ephrin-A1-Fc beads and blotted by anti-EphA3 antibodies. While most 
mutants were able to bind to ephrin-A1, G187R, a mutation located in the conserved 
ligand-binding domain, was unable to bind to ephrin ligands effectively (Figure 5.5C). 
These data suggest that most EphA3 somatic mutations identified in human cancer are 
loss-of-function mutations. These results, together with the fact that EphA3 gene is 
frequently deleted and its expression downregulated in NSCLC, indicate that EphA3 
functions as a tumor suppressor.  
 
Because most EphA3 mutations have decreased activity, and because the mutations were 
not accompanied by frame-shift or nonsense mutations, or loss of heterozygosity (LOH) 
(data not shown), EphA3 mutants (MUT) may act dominant negatively to suppress wild-
type EphA3 (WT) function in lung cancer. We hypothesize that the mutant EphA3 
molecules form heterodimers with wild type EphA3, resulting in a catalytically inactive 
complex. To test this possibility directly, HA-tagged wild-type EphA3 was co-transfected 
with Myc-tagged mutants and MUT:WT EphA3 dimers/multipmers were isolated by 
sequential immunoprecipitation using anti-HA and anti-Myc monoclonal antibodies. As 
shown in Figure 5.5D, HA-tagged WT EphA3 was able to bind to Myc-tagged mutants. 
Co-expression of wild-type and mutant EphA3 significantly inhibited receptor tyrosine 
phosphorylation and kinase activity (data not shown), suggesting that EphA3 mutations 
function dominant negatively to suppress wild-type EphA3 function. 
151 
 
 
Figure 5.6. Overexpression of EphA3 inhibits tumor growth in vivo.  
 
A. Cells overexpressing EphA3 were injected into nude mice subcutaneously. Cells 
carrying empty vector were injected contra-laterally in the same mouse as a control. 
Tumors were harvested three weeks after injection and tumor volume were measured. 
EphA3 overexpression in A549 or H1299 cells inhibits tumor growth. *, P < 0.001, 
paired t test. B. EphA3 mutants were introduced into H1299 cells and overexpression of 
the mutant proteins was confirmed by western blot analysis. C. H1299 cells expressing 
wild-type or mutated EphA3 were injected into the nude mice (n=10) subcutaneously. 
Tumors were harvested and measured three weeks after injection. EphA3 mutants did not 
inhibit tumor growth. *, P < 0.001, Student's t test. D. Tumors were harvested and 
photographed. E. Cell apoptosis in tumor sections were evaluated by cleaved-caspase3 
immunohistochemistry. Apoptosis index was calculated as numbers of caspase-3 positive 
cell/total numbers of cell.  Arrowheads indicate cleaved-caspase3 positive cells.
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Overexpression of EphA3 inhibits tumor growth in vivo 
Because most NSCLC cells express low to non-detectable levels of EphA3, we 
investigated the function of wild-type or mutant forms of EphA3 receptor by 
overexpression of these receptors in tumor cells. Expression of wild-type EphA3 in both 
A549 and H1299 cell lines significantly inhibited tumor growth in the xenograft animal 
model (Figure 5.6A). To determine whether EphA3 mutations are loss-of-function 
mutation in vivo, H1299 cells expressing wild-type or extracellular domain mutants 
G187R, T166N, S449, or kinase dead mutant G766E were injected into nude mice. 
Consistent with our in vitro data, EphA3 mutants did not affect tumor growth 
significantly in vivo (Figure 5.6B-D).  
 
To examine cellular changes within tumors, we analyzed cell proliferation and apoptosis 
in tissue section by staining for Ki67 and cleaved caspase 3, respectively. Quantitation of 
Ki67-positive nuclei revealed that there were no significant changes of cell proliferation 
between tumors expressing wild-type and mutant EphA3 (not shown). In contrast, 
apoptosis was increased approximately 3-fold in tumor expressing wild-type, but not 
mutant, EphA3 receptor (Figure 5.6E), consistent with the apoptotic-promoting role of 
EphA3 in vitro (Figure 5.4).   
 
EphA3 inhibits mTORC1 activity via activation of AMP kinase 
To gain mechanistic insight into EphA3's role in tumor suppression, we surveyed 
potential links between EphA3 and signaling molecules of known relevance to tumor 
growth and apoptosis. EphA3 overexpression had little or no effect on many key 
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molecules, including Akt, Erk, or Stat3. The one notable and consistent EphA3-induced 
alteration was inhibition of p70 ribosomal S6 kinase 1 (T389 phosphorylation) and S6 
(S235/236 phosphorylation) activities (Figure 5.7A&B). S6 kinase 1 is a major substrate 
of mammalian target of rapamycin complex 1 (mTORC1) and can also be phosphorylated 
by PDK1 [289]. As overexpression of EphA3 does not affect activities of PDK1, Akt, 
and Erk, these results suggest that EphA3 inhibits mTOR complex 1 activity. The 
molecular link of EphA3 to mTORC1 activation was reinforced by the fact that mutant 
EphA3 did not affect S6K1 T389 phosphorylation level (Figure 5.7C). mTORC1 
integrates three major signals to regulate many processes involved in cell growth, 
including growth factors, energy status, and amino acids [reviewed in [290-292]]. As 
EphA3 does not appear to affect mitogen-induced Akt or Erk activities (Figure 5.7A&B) 
or insulin or amino acid-induced S6K1 phosphorylation (data not shown), we 
investigated whether EphA3 regulates mTORC1 activity by energy status via AMP-
activated protein kinase (AMPK), a master sensor of intracellular energy status. As a first 
step, we measured intracellular ATP level. Cells expressing wild-type EphA3 have 
significantly lower ATP level than those expressing mutant EphA3 or vector control 
(Figure 5.7D). Consistent with low ATP level, phosphorylation of Thr172 of AMPK is 
higher in cells expressing wild-type EphA3, relative to cells with vector control (Figure 
5.7E). Inhibition of AMPK by either compound C or adenine 9-beta-d-arabinofuranoside 
(araA) abrogated EphA3-mediated suppression of activities of S6K1 and S6 (Figure 5.7F) 
and inhibited EphA3-mediated enhancement of apoptosis (Figure 5.7G). Taken together, 
these data suggest that EphA3 suppresses tumor growth by, at least in part, inhibition of 
mTORC1 via activation of AMPK.
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Figure 5.7. EphA3 inhibits mTORC1 activity by activation of AMP kinase.  
 
A and B. H1299 cells expressing EphA3 or vector control were serum starved and 
stimulated with either 10% of serum following a time course (A) or with increased 
percentage of serum (B). Phospho-S6, phospho-S6K1, phospho-Akt, and phospho-Erk 
levels were assessed by western blot analysis. Phospho-S6 and phospho-S6K1 were 
decreased in EphA3 expressing cells. C. EphA3 mutants fail to inhibit Phospho-S6 and 
phospho-S6K1 as determined by western blot anaysis. D. H1299 cells were stimulated 
with 10% FBS for 30 minutes and subjected to ATP measurements. Intracellular ATP 
concentration is lower in cells overexpressing wild-type, but not mutant, EphA3 in 
response to serum stimulation. *, p < 0.01, Student's t test. E. Phospho-AMPK levels 
were assessed by western blot analysis. The ratio of phospho-protein/total protein was 
determined by densitometry and expressed in arbitrary units. EphA3 expression resulted 
in higher phosphorylation of AMPK. F and G. Inhibition of AMPK by compound C 
(comp.C 10 µM) or adenine 9-beta-d-arabinofuranoside (araA, 1mM) abrogates EphA3-
mediated suppression of activities of S6K1 and S6 (F) and Trail-induced apoptosis (G). 
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Higher EphA3 levels are associated with lower responsiveness to rapamycin 
Although EphA3 expression is often reduced in NSCLC, some tumors do express various 
levels of EphA3 (Figure 5.3). To extrapolate our finding in cell lines to human lung 
cancer, we analyzed EphA3 and phospho-S6 expression in adjacent sections of two 
independent tissue microarray sets of human lung cancer specimens contains 104 tumor 
samples and 26 normal tissue controls. As shown in Figures 5.8A, normal tissue from 16 
individuals (62%) were positive for EphA3, whereas majority of the tumor samples were 
largely negative for EphA3 (71, 68%). In contrast, phospho-S6 was low or undetectable 
in normal samples but dramatically increased in lung cancer specimens and the increased 
pS6K1 is correlated with decreased EphA3 levels in tumors (p=0.03) (Figure 5.8A, Table 
6), suggesting that EphA3 also regulate mTORC1 activity in human lung cancer. 
 
Because wild-type EphA3 inhibits mTORC1 activity and mTOR inhibitors have been 
developed for cancer therapy, we investigated whether EphA3 level is associated with 
tumor cell sensitivity to mTOR inhibitors. We have identified 18 NSCLC lines that do 
not express significant levels of EphA3 and 12 NSCLC lines that express various amount 
of EphA3. NSCLC lines that do not express appreciable amount of EphA3 are associated 
with consistently higher levels of phospho-S6K1 and phospho-S6 (Figure 5.8B). When 
these cells were treated with mTOR inhibitor rapamycin, cells expressing EphA3 
(Figure5.8C, red bar) are more resistant to rapamycin than those lines that do not have 
significant amount of EphA3 (Figure 5.8C, grey bar) (p=0.03). Two EphA3 expressing 
cell lines, H1395 and H23, that are sensitive to rapamycin also carry LKB1 mutation, 
suggesting that LKB1 mutation upregulates mTORC1 activity, which render these cells 
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Figure 5.8. High EphA3 levels are associated with low pS6 and responsiveness to 
rapamycin in lung cancer.  
 
A. EphA3 and phospho-S6 expression levels in lung tumors and control normal tissues 
were determined by staining adjacent sections of two lung tumor tissue microarrays. 
EphA3 levels in tumors are negatively correlated with pS6 expression level 
(quantification see supplemental table 2). B. EphA3, phospho-S6K1, and phospho-S6 
levels were assessed by western blot analysis in a panel of 29 NSCLC lines. C. A panel 
of 29 lung cancer cell lines were treated with rapamycin (1µM) or vehicle control for 72 
hours and subjected to cell viability assay. Rapamycin resistance index was defined by 
luminescence unit of treatment group/luminescence unit of control group. Cells 
expressing EphA3 (red bar) are more resistant to rapamycin (P=0.03, right panel).
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Table 6. EphA3 and pS6 expression in lung tumor TMA 
 
Immunohistochemical staining for EphA3 and pS6 was scanned and analyzed using the 
Ariol® SL-50 platform. The samples were scored as positive or negative according to the 
percentage of positive color (brown) in the section, followed by visual verification to 
ensure positive/negative staining in tumor cells. Example images for scoring criteria were 
shown in supplemental figure 6. EphA3 expression in tumors is negatively correlated 
with pS6 expression (p=0.003). 
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sensitive to rapamycin. Together, these data indicated that higher EphA3 levels are 
associated with tumor cell resistance to rapamycin, suggesting that therapeutic 
intervention to diminish mTOR function may benefits patients with EphA3 deletion or 
mutation. 
 
EphA3-associated gene signatures predict clinical outcome 
 To determine the impact of EphA3 in lung cancer prognosis, we generated two 
independent EphA3-associated gene expression signatures in a training dataset [122], and 
queried EphA3 signatures in a large testing dataset containing 444 gene expression 
profiles and associated clinical outcome data [287]. EphA3 mutation signature (MutSig) 
was selected based on differentially expressed genes in patients carrying EphA3 
mutations relative to those bearing the wild-type gene. EphA3 co-expression signature 
(ExpSig) includes a cluster of genes with expression patterns co-regulated with EphA3 
defined by Pearson correlation coefficient.  In an unsupervised hierarchical clustering 
analysis, both MutSig and ExpSig grouped lung tumors into two distinct clusters (Figure 
5.9A&B, red and blue).  The two clusters defined by MuSig overlapped significantly with 
those defined by ExpSig (417 of 444 samples). Kaplan-Meier analysis was performed 
using overall survival as an endpoint, and the two clusters were significantly different in 
clinical outcome. These data indicate that EphA3 signatures are associated with patient 
prognosis in lung adenocarcinoma, supporting the clinical relevance of EphA3 function 
in human lung cancer. 
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Figure 5.9. EphA3-associated gene signatures predict patient survival. 
 
EphA3 mutation gene signature and EphA3 co-expression signatures were generated in a 
training dataset of Ding et al., and queried in a large testing dataset of Shedden et al. A. 
Hierarchical clustering of 444 clinically annotated human lung adenocarcinomas using 
two EphA3-associated gene signatures independently segregates tumors into two distinct 
clusters (blue, poor prognosis; red, good prognosis). B. Kaplan-Meier curves for the blue 
and red clusters of the hierarchical diagrams of A. The endpoint recorded for this dataset 
was death, measured in months.
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Discussion 
In this study, we used a systematic genome approach, combined with mutation analysis, 
to identify Eph receptors that play important roles in lung cancer.  We have provided 
genetic, functional, and mechanistic evidence of a tumor suppressor role for EphA3 in 
non-small cell lung cancer and have translated these observations to human clinical 
material.  Our results show that EphA3 functions as a tumor suppressor by regulating 
cellular apoptosis via AMPK- mTORC1 signaling pathway. 
 
EphA3 receptor tyrosine kinase as a tumor suppressor  
Malignant progression of solid tumors is a complex process that involves the activation 
of oncogenic signaling and downregulation of tumor suppressor pathways. Oncogenic 
conversion, amplification, or overexpression of proto-oncogenes, such as those encoding 
cell surface receptor tyrosine kinases (RTKs) like the EGF receptor family member 
ErbB2, are frequently observed in human cancers and contribute to malignancy.  EphA3 
is a member of the Eph receptor tyrosine kinase family.  However, both tumor promoting 
and tumor suppression functions have been assigned to Eph receptors.  As such, the 
discovery of EphA3 mutation at high frequency in human lung cancer indicates the 
clinical relevance but not the function of EphA3 receptor. Indeed, one mutation, K761N, 
is located in the kinase domain at a highly conserved position analogous to FGFR2 (K641) 
[293]. This mutation was predicted to be part of the "molecular brake" and functions as 
an activating mutation [122].  In addition, one recent report found EphA3 copy number 
gain in two NSCLC lines [286]. These studies implicate EphA3 as a possible "proto-
oncogene". Our observation, however, argue against the above possibility. First, a 
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detailed SNP analysis using datasets from both NSCLC cell lines and human lung cancer 
samples revealed chromosomal region containing EphA3 is frequently deleted (Figure 
5.1&5.2). Analysis of copy number of EphA3 in the same dataset as Sos et al revealed 
that EphA3 is deleted in 44 out of a total of 84 cell lines (below 1.87), compared to copy 
number gain (above 2.14) only in 20 cell lines (Figure 5.2C). Second, expression 
analyses by quantitative RT-PCR, western blot, and immunohistochemistry in both cell 
lines and tumor specimens showed reduced EphA3 expression in tumors, relative to 
normal tissues (Figure 5.3). Third, majority of EphA3 mutations lost kinase activity and 
exhibited reduced tyrosine phosphorylation status, whereas none of the mutations display 
increased activity (Figure 5.5). Finally, overexpression of wild-type EphA3, but not 
mutant, receptor in two NSCLC lines inhibited tumor growth in vivo (Figure 5.6). Taken 
together, these observations suggest that EphA3 receptor tyrosine kinase functions as a 
tumor suppressor in lung cancer. 
 
Role of EphA3 mutations in lung cancer 
Eph mutations that disrupt forward signaling by impairing ephrin binding or kinase 
activity have been discovered previously. For example, the EphA3 E53K mutation in the 
MeWo melanoma cell line abrogates ephrin binding [127], and the EphB2 G787R 
mutation found in colorectal cancer impairs kinase activity [128]. These data are 
consistent with our finding that majority of EphA3 mutations are loss-of-function 
mutations in lung cancer. It is interesting to note, however, that EphA3 mutations can 
form heterodimer/heteromultimer with wild-type receptor to inactivate wild-type EphA3 
(Figure 5.5E and F). This finding has clinical relevance, since EphA3 mutations in human 
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lung adenocarcinoma were neither accompanied by loss of heterozygosity, nor frame-
shift or nonsense mutations [data not shown, [122]], suggesting the possibility of EphA3 
mutation playing an active role in tumor initiation and/or progression in human cancer.   
 
In contrast to loss-of-function mutations in EphA3, gain-of-function mutation has been 
discovered in EphA2 receptor. Of particular interest is the R721Q activating mutation in 
EphA2 that is linked to cataract in human [294].  The R721 in EphA2 is corresponding to 
R728 in EphA3. However, R728L mutation in EphA3 resulted in loss of kinase activity 
(Figure 5.5C). Further investigation will be needed to determine whether the differences 
between glutamine and leucine in these mutations could account for the differences in 
kinase activity and phenotypic responses. 
 
Regulation of mTOR signaling by EphA3 
EphA3 receptor signaling was reported to mediate cell-cell repulsion in axonal guidance 
[295] and cell-matrix de-adhesion in tumor cells [281]. These biological responses appear 
to be mediated by EphA3 interacting adaptor Crk and RhoA GTPases [281]. The effect of 
EphA3 receptor on cell growth and survival has not been reported previously, although 
ephrin stimulation of EphA2 and EphA4 receptors inhibits cell growth via suppression of 
Erk1/2 activity in many normal and tumor cell types [34, 116]. Ligand-induced EphA2 
signaling has also been shown to suppress cell motility by inhibiting Akt phosphorylation 
in glioma and prostate cancer cells [35]. However, overexpression of EphA3 in NSCLC 
lines did not appear to affect Erk1/2 or Akt activities (Figure 5.7). The mechanism by 
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which EphA3 inhibits cancer cell viability appears to involve regulation of mTORC1-
S6K1 activity. 
 
S6K1 activity in tumors is primarily regulated by mTORC1 positively in response to 
mitogen and amino acid, and negatively in the presence of energy stress. Signals that 
inhibit the TSC2 tumor suppressor, and thus activating mTORC1, include PI3K-Akt and 
MAPK pathways that are often activated in many types of cancer. Indeed, a recent report 
showed that ephrin-induced growth cone collapse is mediated by inhibition of Erk 
activity and reduced inhibition of TSC2 by Erk, resulting in enhanced activity of 
mTORC1 and S6K1 [296]. The PI3K-Akt and MAPK pathways, however, do not appear 
to be regulated by EphA3.  Several observations support the notion that EphA3 regulates 
S6K1 activity through AMPK. First, intracellular ATP levels are significantly reduced in 
EphA3 expressing cells, suggesting EphA3 levels affect energy status in tumor cells 
(Figure 5.7D). Furthermore, phosphorylation of Thr172 of AMPK, an intracellular energy 
sensor, is higher in cells expressing wild-type EphA3, relative to cells with vector control 
(Figure 5.7E). Finally, inhibition of AMPK by compound C or araA abrogated EphA3-
induced suppression of S6K1 and apoptosis, providing a functional between EphA3 and 
AMPK (Figure 5.7F&G). In addition to EphA3, AMPK can also be activated by LKB1, a 
serine/threonine kinase that is frequently mutated in NSCLC [297-299]. Although further 
work will be required to gain a complete understanding of whether EphA3 activates 
AMPK directly or indirectly through modulation of LKB1, the fact that EphA3 
suppressed tumor growth in LKB1 mutation-bearing A549 cells suggest that EphA3 
action on AMPK is independent of LKB1. 
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Due to the importance of mTOR signaling in tumor cells, inhibitors of mTOR have been 
developed as anti-cancer agents and early clinical trials showed effectiveness of these 
inhibitors in several types of tumors [300]. However, not all patients respond to mTOR 
inhibitors, thus molecular markers need to be developed for pre-screen patient for 
treatment. Towards this end, our data showed that higher level of EphA3 in lung cancer is 
correlated with reduced cellular sensitivity to rapamycin in 35 NSCLC cell lines and 
lower S6K1 activity in both NSCLC lines and in 104 tumor samples, suggesting that 
EphA3 may be included in a panel of markers for tumor sensitivity to mTOR inhibitors. 
Further, these studies suggest that therapeutic intervention to diminish mTOR function 
will improve the survival of patients with EphA3 deletion or mutation. 
 
In summary, a combination of genomic and mutation analyses both in cell/animal model 
systems and in human tumor specimens revealed that EphA3 receptor tyrosine kinase 
functions as a tumor suppressor in lung cancer. Although our studies provide evidence 
that the kinase activity of EphA3 is required for its effect on cancer cell viability, future 
work is necessary to determine whether loss of other noncatalytic function will affect it 
tumor suppression function. Furthermore, because Eph receptor regulates communication 
between different cell types, the full impact of EphA3 mutations in vivo will require 
careful studies in inducible and tissue-specific transgenic tumor models. Finally, as 
another Eph family member, EphA2, appears to function in tumor promotion in NSCLC 
[101, 279], the discovery of EphA3 tumor suppressor function suggests that future 
therapeutic strategies targeting Eph receptors in cancer need to be directed at individual 
Eph molecule, rather than multiple or pan-Eph receptors.  Such therapeutic intervention 
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efforts will require studies to dissect the mechanisms of opposing role between EphA2 
and EphA3 in lung cancer. 
167 
 
CHAPTER VI 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Conclusions 
In the 20 years since the cloning of the first cDNA encoding an Eph receptor [301], 
EphA1, much progress has been made in characterizing the fundamental signaling 
mechanisms of Eph family, its biology and the pathological consequences of its 
deregulation [1, 25]. Notwithstanding these advances, a more complete understanding of 
Eph function and dysfunction in cancer is still to be achieved to make a significant 
impact on cancer therapy. These data in my thesis represent a step forward in exploring 
the remarkable multiplicity of Eph-ephrin signaling in tumor malignancy. We have now 
integrated genetically engineered mouse models with biochemical analyses in cell culture, 
and revealed that the role of one particular Eph receptor, EphA2, in breast tumor 
progression is dependent upon the oncogene/tumor suppressor context. More importantly, 
we showed the efficacy of a therapeutic antibody targeting EphA2 in vivo, suggesting that 
the mouse models are also useful for preclinical evaluation of new Eph-based therapies. 
In addition, EphA2 appears to serve as a predictor for prognosis and trastuzumab 
resistance in HER2 positive breast cancer, reflecting the intensive crosstalk between 
EphA2 and HER2. On the contrary, through an integrative approach by analyzing 
genome-wide profiling and examining biochemical properties of Eph mutations, we have 
identified another Eph receptor, EphA3, as a potent tumor suppressor in non-small cell 
lung cancer. Notably, EphA3 suppresses tumorigenicity in a kinase activity-dependent 
manner by regulating the mTOR signaling pathway. These seemingly paradoxical results 
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Figure 6.1. A working model of dual roles of Eph receptors. 
 
In normal cells, engagement of Eph receptors with ephrins on adjacent cells induces 
forward signaling, leading to inhibition of Ras-MAPK, PI3K-Akt and Abl-Crk pathways. 
In tumor cells, disruption of cell-cell junctions inhibits Eph receptor interaction with 
ephrins. In addition, some tumor cells have low ephrin levels. Elevated Eph receptors 
crosstalk with other receptor tyrosine kinases, which results in increased activity of Ras-
MAPK pathway and RhoA GTPase. 
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highlight the complexity of Eph functions and are consistent with the existing 
controversies in the field. Based on our studies and many others, we propose a working 
model in which the divergent roles reflect selective signaling pathways in Eph expressing 
cancer cells in different contexts (Figure 6.1). Generally, ligand-dependent Eph signaling 
is detrimental to cancer progression by inhibiting a variety of oncogenic cascades, such as 
Ras-MAPK, PI3K-Akt, Abl-Crk and mTOR-S6K pathways. On the other hand, non-
canonical Eph receptor activity independent of ligand stimulation can promote tumor 
development through interaction with other oncogenes, suggestive of altered signaling 
networks in this situation. Intriguingly, cancer cells have developed a variety of 
mechanisms, for example EphA3 gene mutation and deletion in lung adenocarcinoma, to 
minimize ligand-dependent Eph signaling, and/or to hijack high levels of Eph receptors, 
in the case of EphA2 in breast cancer, to maximize oncogenic signaling pathways. 
Together, these findings have provided genetic, genomic, functional and mechanistic 
evidence and uncovered the complex roles for Eph signaling in tumorigenesis. We are 
confident that the continued translation of knowledge emerging from the field will 
ultimately facilitate cancer diagnostics, prognostics and therapeutics. 
 
Future directions 
Our work has raised as many questions as it has answered. The divergent roles of Eph 
receptors in human cancers are only beginning to be explored, and we have the privilege 
to speculate the new avenues of discovery in the future. Here is a partial list of unlimited 
possibilities. 
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How does receptor endocytosis regulate Eph signaling? 
Previous studies have shown that EphB receptors are endocytosed after binding to 
ephrinB ligands [65, 66]. In this process, EphB receptors are initially activated, and 
induce Vav-Rac dependent cytoskeletal assembly that is required for internalization of 
the EphB–ephrinB complex [66, 169]. We have focused on EphA2 endocytosis, which 
has been explored as a means to reduce EphA2 levels and tumor malignancy. A negative 
regulatory loop via SHIP2 mediated Rac1 inhibition was identified to modulate EphA2 
trafficking. Therefore, once the EphA2 internalization is triggered, Rac1 activity seems to 
be precisely controlled by EphA2 itself through both positive and negative regulation, 
suggestive of the importance of this accurately concerted process. 
 
Several intriguing questions concern the role of receptor endocytosis in Eph signaling. Is 
it required for Eph signaling initiation, or just a way to terminate Eph signaling? Does 
Eph receptor continue to signal in cytoplasm, and if so, is the signaling different from 
that at the cell surface? The presence of phosphorylated EphB2 in intracellular vesicles 
suggests that EphB2 may continue to signal after endocytosis [65], as has also been found 
for other receptor tyrosine kinases such as the EGF receptor [302]. It remains to be 
determined whether EphA2 is also active in endocytic vesicles, and what the role of 
EphA2 endocytosis is in cancer. 
 
What are the specific signaling activities of different Eph receptors? 
There is a growing debate surrounding whether Eph receptors function as oncogene or 
tumor suppressor, as there is good evidence to support both roles. We proposed a 
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working model to reconcile the paradoxical effects of Eph signaling in malignancy. 
Under physiologic conditions, ephrin ligand interact with Eph receptors at cell-cell 
junctions, inhibiting the activation of Ras-Raf-MAPK, PI3K-Akt and Abl-Crk pathways, 
which is critical for development and tissue homeostasis, including the formation of 
tissue boundaries, assembly of intricate neuronal circuits and remodeling of blood vessels. 
However, tumor cells have developed a variety of mechanisms to prevent ligand-
dependent Eph signaling, such as disruption of cell junctions and differential expression 
of Eph receptors and ephrin ligands. Meanwhile, other oncogenes including EGFR family 
of receptor tyrosine kinases are able to transduce downstream signals by crosstalk with 
Eph receptors, presumably independent upon ephrin stimulation. Thus, ligand-dependent 
Eph receptor signaling functions in tumor suppression, whereas ligand-independent Eph 
receptor activities appear to promote tumor progression. 
 
Although our model is appropriate in most cases to decipher the complexities and 
paradoxes of Eph-ephrin signaling, there are several outliers which cannot be simply 
interpreted, suggestive of other potential mechanisms. For example, phosphorylation by 
Akt of a single serine (S897) in EphA2 appears to promote cancer cell migration and 
invasion, an effect that does not require, but is reversed by, ephrinA1 stimulation [35]. 
Thus, S897 of EphA2 serves as a binary switch to control cell motility, and it is 
conceivable that other Eph receptors may possess some types of molecular switch 
between agonistic and antagonistic. Interestingly, only EphA1 and EphA2 can be 
phosphorylated as substrates for Akt at this site, according to sequence conservation. 
Clearly, it is a distinct function in specific Eph members, and other Eph receptors may 
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have different mechanism for this switch. Further increasing complicacy, EphB2 
signaling regulates the expression of PI3K catalytic subunits, which control cell 
positioning in intestinal epithelium independent of EphB2 kinase activity. On the 
contrary, EphB2 kinase is necessary to convey proliferative signals through an Abl-cyclin 
D1 pathway. Therefore, EphB2 receptor simultaneously promotes cell proliferation but 
suppress invasive growth of intestinal adenomas, and these two pathways could be 
dissociated [84, 303]. 
 
Particularly, we observed completely opposite expression patterns of EphA3 and EphA2 
in non-small cell lung cancer. EphA3 is downregulated in cancer cells, while EphA2 is 
highly expressed which is consistent with previous reports. Our data indicate that EphA3 
inhibits cell survival by suppressing mTOR signaling pathway, and the inhibition is 
dependent on EphA3 kinase activity. On the other hand, EphA3 decreased cell migration 
is kinase-independent, uncoupling two separate EphA3 signaling pathways. It is possible 
that EphA2 does not exhibit same effects as EphA3 considering the high levels of EphA3 
in NSCLC. It would be interesting to find out the specific signaling partners of EphA3 
that regulates cell motility and apoptosis, and to determine the reasons that account for 
the discrepancies between EphA2 and EphA3 in lung cancer. 
 
Are EphA3 mutations in cancer drivers or passengers? 
Cancer genomes carry two biological classes of somatic mutations [124]. “Driver” 
mutations confer growth advantage on the cell in which they occur, are causally 
implicated in cancer development and have therefore been positively selected. 
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Conversely, “passenger” mutations have not been subject to selection. They were present 
in the cell that was the progenitor of the final clonal expansion of the cancer, are 
biologically neutral and do not confer growth advantage. Most somatic mutations in 
cancer cells are likely to be passenger mutations, and only a subset of genes carry driver 
mutations and therefore function as cancer genes. Apparently, it is important to 
distinguish driver from passenger mutations in order to yield further insights into the 
development of human cancer, and to provide new opportunities for molecular diagnosis 
and therapeutics. 
 
Our data suggest that most EphA3 mutations are loss-of-function mutations that impair 
EphA3 kinase activity and fail to inhibit tumor growth as wild-type EphA3 does. There 
are, however, mutants that are not associated with kinase inactivation, including 
mutations in the catalytic domain. These findings support the concept that acquired 
mutations in cancer may not contribute to malignant transformation and underscore the 
importance of functional studies to distinguish “driver” mutations underlying 
tumorigenesis from biologically neutral “passenger” alterations. More importantly, we 
found that EphA3 mutations can form heterodimers with wild-type receptor to inactivate 
wild-type EphA3, therefore obtain oncogenic properties. It remains to be determined 
whether mutated EphA3 could recruit specific effectors and activate alternative signaling 
pathways entirely different from wild-type EphA3. 
 
We are also aware that appropriate mice models are essential to accurately elucidate the 
function of EphA3 mutations. Although easier to interpret, the results of in vitro 
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approaches might be sensitive to experimental conditions and methods, whereas 
experiments in animal models yield more physiologically relevant information especially 
valuable for recapitulating human cancer. This is particularly important for understanding 
Eph-ephrin system, which extensively mediates cell-cell communication in physiological 
contexts. Additionally, the genetically engineered mouse models carrying EphA3 
deletion or mutation will enable us to answer many other open questions. Is EphA3 
mutation sufficient to generate de novo lung adenocarcinoma? How does EphA3 affect 
lung tumor initiation, progression and metastasis? What are the common and specific 
signaling networks downstream of wild-type versus mutated EphA3? What is the 
effective therapeutic strategy for cancers harboring the EphA3 mutation? Perhaps by 
using a combination of in vitro experiments and genetic tools, it will be possible to 
unravel the significance of EphA3 signaling in lung cancer. 
 
What is the role of ephrin reverse signaling in cancer cells? 
One unique feature of Eph-ephrin complexes is their ability to generate bidirectional 
signals that affect both the receptor-expressing and ligand-expressing cells. Our studies 
presented here have mainly focused on understanding the role of Eph forward signaling 
in tumor development. Ephrin ligands are also present in tumor cells, suggesting that 
ephrin reverse signaling may in some cases contribute to tumorigenicity as well. Similar 
to Eph forward signaling, both pro- and anti-tumorigenic functions have been attributed 
to ephrin reverse signaling. In colon cancer cells, ephrinB1 tyrosine phosphorylation 
disrupts binding of the ephrin with the scaffolding protein Par6, promoting the formation 
of tight junctions between cells [304]. In addition, ephrinA5 reverse signaling displays 
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tumor suppressive effect in glioma by down-regulating EGFR levels [305]. Other 
examples imply ephrin ligands function as a tumor promoter. In fibroblasts, ephrinA5 
reverse signaling activates the Fyn non-receptor tyrosine kinase, integrin-mediated cell 
adhesion and MAP kinases [29, 30]. Accordingly, ephrinA5 overexpression in murine 
fibroblasts can increase cell growth in soft agar, invasion and morphological 
transformation [306]. EphrinB reverse signaling has been reported to localize in lipid 
rafts, induce Rac1 activation and increase cancer cell migration and invasion [307-310]. 
 
It is not clear how ephrin reverse signaling is regulated in cancer cells. Both expression 
levels and selective signaling cascades could be involved in this regulation. Ephrin 
knockout mice and transgenic models, which abrogate reverse signaling but preserve 
forward signaling, will be instrumental for providing a detailed overview of the ephrin 
reverse signaling in cancer. Another interesting question is: how similar are ephrin 
reverse signaling and Eph forward signaling, and could they be functionally exchanged? 
An initial accomplishment has been achieved by applying a differential isotopic labeling 
technique to simultaneously and independently monitor signaling in two interacting 
populations of cells that express EphB2 and ephrinB1, respectively. Signaling networks 
were constructed, and the information processing by the two interacting cell types was 
modeled. This revealed that signaling between mixed EphB2- and ephrinB1-expressing 
cells is asymmetric and that the receptor forward and ligand reverse signaling use 
different tyrosine kinases and targets to process signals in most cases, but there are 
indeed shared modes of signal transduction. Unexpectedly, the intracellular tail of 
ephrinB1 also influences pTyr signaling in EphB2 positive cells, and soluble fusion 
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proteins containing the extracellular regions of ephrinB1 stimulate different signaling 
events compared with coculture [311]. Similar approaches should be applied into EphA-
ephrinA system to intertwine quantitative measurements of cell behavior and signaling 
dynamics. The integrative information available from these studies could be of general 
utility in comprehensively studying the role of Eph bidirectional signaling network in 
cancer and other pathological processes. 
 
Is whole-genome analysis a feasible approach to dissect Eph-ephrin in cancer? 
Cancer represents a special field of application for genomics, in which whole-genome 
analysis provides the opportunity for individualized diagnosis, prognosis and therapeutics. 
There are several reasons for this. First, the altered genome is the direct cause of cancer 
and precisely defines the tumor phenotype. Second, most cancer genomic alterations are 
somatic events, so that we can discern with confidence those changes specific to cancer 
relative to normal tissues. Third, genomic alterations are dynamic and progressive, 
related to disease stage, metastatic lesion and drug response. These connections have 
been largely uncovered with the rapid development of technologies. Therefore, the 
increasing sophistication of systems biology has made it possible that the complex 
interplay of events in cancer that activate and inactivate specific genes and pathways can 
now be deduced directly from deep genomic and transcriptomic analyses. Undoubtedly, 
these valuable information will make major contributions to the understanding of not 
only cancer in general, but also Eph-ephrin biology specifically. 
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Figure 6.2. Patterns of pathway deregulation and Eph-ephrin expression in human 
lung cancers. 
 
A. Hierarchical clustering of predictions of pathway deregulation in samples of human 
lung tumours. Prediction of Ras, PI3K, Myc, E2F3, β-catenin and Src pathway status for 
each tumour sample was independently determined using supervised binary regression 
analysis, as described in text. Red indicates high probability of pathway activation, with 
blue indicating a low probability. Patterns in the tumour pathway predictions were 
identified by hierarchical clustering, and separate clusters are indicated below. The 
expression of Eph receptors and ephrin ligands was plotted based on the clustering of 
signaling pathways. B. Kaplan-Meier survival analysis for lung cancer patients based on 
pathway clusters. Patient clusters with correlative pathway deregulation correspond to 
clusters comprising each independent survival curve. Overall survival was defined as 
death due to any cause. P=0.03, log-rand test.
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Bissell and colleagues used a three-dimensional culture model of non-malignant human 
mammary epithelial cells and developed a 22-gene signature, which accurately predicts 
breast cancer outcome across multiple datasets [100, 312]. Importantly, most individual 
genes in the 22-gene signature are significant predictors of patient survival, suggesting 
that these genes may be "master genes" with high predictive ability. The result supports 
the hypothesis that the 3D signature genes play important biological roles in breast cancer, 
and hence are potential targets for development of novel therapeutics. Interestingly, 
EphA2 is in the signature identified by this unbiased approach, which is consistent with 
our findings that EphA2 promotes tumorigenesis in breast cancer, at least under some 
circumstances. Another study combined nonsense-mediated RNA decay microarrays and 
array-based comparative genomic hybridization for the genome-wide identification of 
genes with biallelic inactivation involving nonsense mutations and loss of the wild-type 
allele. This approach, which identified previously unknown mutations in the EphB2 
receptor, again demonstrated the power of an integrated strategy for the genome-wide 
screening of cancer-related genes to explore the fundamental and discriminating 
properties of Eph receptors [313]. 
 
In our studies, by analyzing SNP array-based genetic maps with gene expression 
signatures, we applied an integrative approach to identify EphA3 receptor, which is often 
deleted and under-expressed, as a potent tumor suppressor in non-small cell lung cancer. 
Additionally, we generated two EphA3 gene signatures, one related to EphA3 mutation in 
lung adenocarcinoma, and the other one correlated with EphA3 expression. In an 
unsupervised analysis using an independent large cohort validation dataset, both 
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signatures were able to group tumors into two distinct main clusters, which are associated 
with patient overall survival. This genome-wide transcriptional analysis supports our 
hypothesis that EphA3 signaling pathway plays a major role in lung cancer progression. 
 
We sought to explore other possibilities for genomic analysis to be utilized in Eph-ephrin 
studies. Previous reports have shown that gene expression signatures can be identified 
which reflect the activation status of central oncogenic pathways [314-316]. These so-
called oncogenic pathway signatures can predict pathway deregulation in human tumors, 
and cluster tumors based on patterns of pathway signatures. This approach is very 
appealing since the categorization of patients could define prognosis in respective patient 
subsets, and also pathway deregulation provides an opportunity to guide the use of 
targeted therapeutics. We applied this technique in 572 lung adenocarcinomas to predict 
the activity of key pathways including Ras, PI3K, β-catenin, Myc, Src, and E2F3. 
Unsupervised hierarchical clustering was performed to identify patterns of pathway 
deregulation (Figure 6.2). This analysis stratified tumors into two groups, one of which 
exhibited worse survival than the other. It is also evident that the tumors predicted as 
exhibiting relatively high Ras activity are generally predicted at higher levels of β-catenin, 
Myc and Src activity. Conversely, the tumors with relatively elevated Ras activity 
showed relatively lower levels of PI3K pathway. When expression levels of Eph 
receptors and ephrin ligands were projected on the dendogram, they are associated with 
patterns of pathway deregulation as well as patient outcome. Specifically, lower Eph-
ephrin expression correlates with activated Ras, β-catenin, Myc and Src pathways, and 
poor prognosis. Notably, EphA3 is highly downregulated in the population of patients
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Figure 6.2. Patterns of the expression of angiogenic factors in human lung cancers. 
 
A. Hierarchical clustering of angiogenic factors in samples of human lung tumours. Red 
indicates high expression, with blue indicating a low expression. Separate clusters on two 
dimensions are indicated in color bars. B. Kaplan-Meier survival analysis for lung cancer 
patients based on clusters. Overall survival was defined as death due to any cause. 
P=0.002, log-rand test. 
182 
 
 
with poor survival, supporting our findings that EphA3 functions as a tumor suppressor in 
lung cancer. 
 
Such large, multi-site and well-performed gene expression studies can also help us to 
characterize the role of Eph-ephrin in tumor angiogenesis. We examined major classes of 
angiogenic factors expressed in tumor cells, including ephrins, VEGFs, PDGFs, 
angiopoietin, and Slits. Interestingly, these angiogenic modulators, which are grouped 
into three subsets, divided lung adenocarcinomas into three main clusters based on two-
dimensional hierarchical clustering. Cluster 1 and cluster 3 are distinguished by higher 
PDGFs, ephrinB, Slits, angiopoietin 1, and VEGFs, ephrinA, angiopoietin 2, respectively, 
while cluster 2 express lower levels of these angiogenic factors in general. These data 
suggest to us that lung tumors have distinctive patterns of angiogenic growth, and 
angiogenesis is related to cancer prognosis. Accordingly, ephrin ligands are not identical 
in regulating tumor angiogenesis, and may have interplays with other families of 
activators such as VEGFs and Slits. These information should help in the design of better 
anti-angiogenic therapies and to overcome drug resistance frequently observed in clinic. 
 
Concluding remarks 
The results we have reported herein make a significant step forward in understanding the 
role of Eph signaling in the regulation of cancer malignancy. Through integrating genetic, 
genomic, functional and mechanistic studies, we have been able to show that the 
distinctive characteristics of Eph signaling enable it to exhibit both pro- and anti-
tumorigenic effects. Canonical Eph signaling pathway, which is dependent on ephrin 
183 
 
stimulation, could suppress tumor progression by inhibiting crucial oncogenic events 
such as mTOR activity. On the other hand, non-canonical Eph signaling pathway, which 
is independent on ephrin stimulation, could promote tumorigenesis by coordinating with 
other oncogenes including HER2. We anticipate that important new insights into how 
tumors convert an inhibitory signal to a promoting one will emerge in the Eph field in the 
coming years. Such discoveries will become especially important when attempting to 
evaluate the effects of Eph-based therapies and establishing effective criteria for patient 
selection. 
 
It is noteworthy that our model dramatically simplifies the diversities of Eph receptors 
and ephrin ligands, and in addition, it does not consider the function of Eph-ephrin in 
tumor microenvironment. Many questions remain to be answered. What are the specific 
signaling activities of different Eph receptors? What is the role of ephrin reverse 
signaling in cancer cells? Why are some Eph receptors mutated more frequently than the 
others? How does cancer-related Eph mutation contribute to tumor biology? Another area 
of great interest is whether the Eph system has impact on tumor infiltrating immune cells, 
as well as cancer stem cells. With the emerging new technologies and accumulating 
knowledge of Eph-ephrin, it will be possible to better understand the complexities of the 
Eph family in cancer. 
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